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Abstract
The aim of this cross sectional study was to compare cardiopulmonary function in children 
with chronic lung disease of prematurity (CLD) with preterm and term-born controls. Whole- 
body plethysmography, alveolar diffusion capacity (DLco) and spirometry before and after 
cycle ergometry were assessed in 92 children: 29 with CLD, 33 preterm (<32 weeks 
gestation) and 30 term-born controls. They also underwent echocardiographic assessment of 
myocardial function and pulmonary arterial pressure while breathing room air and after 
breathing 15% and 12% oxygen for 20 minutes each.
Children with CLD had lower F E V i and FEF25-75 compared with preterm control (p<0.001) 
and term (p<0.001) groups and raised residual volume (p<0.01). DLco was significantly 
lower in the CLD (p<0.05) group. There were no differences in oxygen uptake and carbon 
dioxide output at maximum exercise between the groups but maximal voluntary ventilation 
and ventilatory reserve were significantly lower in the CLD group compared with the preterm 
(p<0.05) and term control groups (p<0.001). F E V i was reduced by 10.9% after exercise but 
increased by 15.1% after bronchodilator in the CLD group. Although those with CLD 
desaturated more than the control groups after the hypoxic challenge, surrogate markers of the 
pulmonary arterial pressure altered similarly in all three groups in response to hypoxia. 
Echocardiographic markers of the right ventricular function did not vary between groups at 
baseline or after the hypoxic challenge.
The findings of this thesis suggest that children with CLD continue to have airway 
abnormalities including reversible airway obstruction, air trapping and impaired gas transfer 
compared to term and preterm controls at 8-12 years of age. Although they had similar
1
exercise capacity to preterm and term control groups, this was at the expense of using greater 
proportion of their ventilatory reserve. At school age, they do not have evidence of 
myocardial dysfunction or subclinical pulmonary arterial hypertension.
(Word count: 300)
2
Chapter One: General Introduction
3
1.1 Development of the cardiopulmonary system
The association between fetal factors and the origin of complex adult diseases has been 
proposed by the epidemiologist David Barker (Barker 1989). Most of the current evidence 
from epidemiological studies that support Barker’s ‘fetal origin hypothesis’ points towards 
the relationship between low birth weight and environmental factors, with adult 
cardiovascular disease (Mi 2000; Eriksson 2001; Barker 2002). When infants are bom 
prematurely, their cardiovascular and pulmonary systems are still in the developmental stages, 
which may have important implications to the development of adult cardiopulmonary disease; 
yet our knowledge on association between premature birth and cardiopulmonary disease in 
later life is limited.
1.1.1 Lung g row th  an d  d ev e lo p m en t
Human lung growth starts as early as 3 weeks of embryonic life and undergoes several 
morphological stages that continue into postnatal life up to early adulthood. The stages of 
human lung growth are summarised in Table 1.1.
The pseudoglandular stage marks an important landmark in human lung growth. By 24 weeks 
of intrauterine life, surfactant protein is detectable, and thus, a possible platform for gas 
exchange is established. Further development of pneumocytes and division and enlargement 
of alveoli continue in the saccular and alveolar stages. Alveolar multiplication continues in 
the postnatal period at least up to 2-3 years and alveolar size and surface area increases until 
after adolescence (Kotecha 2000; Hislop 2002). In prematurely bom infants, lung growth is 
interrupted in the pseudoglandular or saccular stages, which has implications for infant 
respiratory and cardiovascular functions, in the short and long terms.
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Table 1.1 Stages of lung growth (Joshi and Kotecha 2007)
Stage Time Events
Embryonic 0-7 wks Formation of trachea, right and left main bronchi, and 
vasculogenesis around airway buds
Canalicular 7-17 wks Differentiation of epithelial cells, formation of 
pulmonary arteries and veins
Pseudoglandular 7-27 wks Formation of respiratory bronchioles, alveolar ducts and 
primitive alveoli, differentiation of type I and type II 
pneumocytes and formation of alveolar capillary barrier
Saccular 8-36 wks Increment in gas exchange areas, further differentiation 
of type I and type II cells
Alveolar 36 wks- 2 yrs 
Until 18-22 yrs
Septation and multiplication of alveoli 
Enlargement of terminal bronchioles and alveoli
Microvascular
maturation
Birth to 2-3 yrs Fusion of double alveolar capillary network into a single 
layer
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There are limited data on postnatal lung growth. Almost 40 years ago, Dunhill published data 
from morphometric studies on 10 children showing that these children had 20 million alveoli 
at birth which multiplied rapidly in the first few years of life but slowed down after 4 years of 
age and stopped at 8 years (Dunhill 1972). This was supported by other studies (Davies and 
Reid 1970, Thurlbeck and Angus 1975) albeit in small numbers of children. In 1982, 
Thurlbeck studied post-mortem lungs of 36 boys and 20 girls (aged 6 weeks to 14 years) 
dying as a result of trauma or after a short illness. The morphometric studies showed that 
there was rapid alveolar multiplication during the first 2 years of life. Alveolar dimentions 
and number of alveoli per unit area and volume did not change much during this period. 
There was minimal growth in the alveolar number after 2 years of age (Thurlbeck 1982) 
(Figure 1.1).
With recent advances on MRI imaging of lungs using hyperpolarized 3He (Ebert 1996, Peces- 
Barba 2003), it may be possible to quantify linear alveolar growth more precisely. Until 
longitudinal studies are carried out from birth onwards using these new technologies, our 
knowledge on postnatal human lung growth is limited. Based on current literature, it is 
assumed that alveolar hyperplasia is minimal after 8 years of age.
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Figure 1.1 Postnatal lung growth
boys
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Regression equations for lung volume against age plotted for boys and girls: Mean ±1 
standard error shown. VL = lung volume at a transpulmonary pressure of 25 cm formalin 
(Thurlbeck 1982)
7
1.1.2 D evelopm en t o f h e a rt an d  p u lm onary  v e s s e ls
The heart and corresponding major blood vessels develop between 3-8 weeks of gestational 
age. Unlike most other human organs, the fetal heart does not develop as a miniature adult 
heart. In fact, it develops as a tubular structure, which undergoes a series of morphological 
changes, to form the four chambers as well as the inflow and outflow tracts (Table 1.2).
Table 1.2 Development of cardiac structures (Koff 1993)
Neonatal structures Corresponding embryonic structures
Superior and inferior venae cavae Sinus venosus
Atria Dilation of heart tube
Septum Endocardial cushion
Left ventricle Dilation of heart tube
Right ventricle Bulbus cordis
Pulmonary and aortic arteries Truncus arteriosus
Pulmonary veins Outgrowth of posterior wall of left atrium
During early stages of lung development, the developing airways act as a template for 
pulmonary vascular development, and the pulmonary blood vessels form around the 
branching airway by vasculogenesis, the process by which blood vessels are formed by de 
novo production of endothelial cells (Hislop 2005). In later development, however, new 
pulmonary blood vessels are formed only from pre-existing blood vessels, the process known 
as angiogenesis. This physiological process takes place only as long as alveoli increase in size 
and number (Hislop 2005). During the postnatal period, the existing capillaries split to form 
new capillary meshes so that there is a double capillary network. Burri’s group has also 
described that, besides the multiplication and enlargement of airspaces, some important
microvascular changes occur in postnatal lung growth, which they termed as the stage of 
microvascular maturation (Burri 2006). Essentially, during this period, the double capillary 
network gradually merges as a single capillary layer. This is an extremely important event in 
postnatal lung growth, as angiogenesis and alveolization go hand in hand, and once the 
capillary network fuses into a single layer, new alveolar septa cannot be formed. This has now 
been postulated as the major cause of premature arrest of lung growth following postnatal 
steroid treatment in premature infants with chronic lung disease (Roth-Kleiner 2005).
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1.2 Cardiorespiratory adaptation at birth
There are some fundamental differences between fetal and postnatal pulmonary physiology 
and circulation. It is important to understand the mechanisms of fetal circulation and 
cardiorespiratory adaptation at birth, in order to understand the cardiorespiratory 
consequences of premature birth.
Fetal lungs are filled with fluid. The fluid secretion is maximal at mid-gestation and plays a 
vital role in lung growth and development. These fluid filled lungs do not contribute to 
oxygenation of blood in the foetus. Instead, the placenta acts as an organ of oxygenation. In 
intrauterine life, only 12-20% of total right ventricular output flows through the pulmonary 
circulation due to high pulmonary vascular resistance and high right atrial pressure. Besides, 
there are some key structures in the fetal circulation, which undergo acute changes after birth. 
In the fetal circulation, the ductus venosus and foramen ovale allow oxygenated blood to flow 
from the placenta to the left atrium and subsequently to the ascending aorta, to be distributed 
to the coronary and cerebral circulations. During labour, increasing levels of catecholamine 
decrease the production of lung liquid. After birth, the inflation of the lungs displaces the lung 
liquid from air sacs into perivascular space (Bland 1980). The majority of fluid is absorbed 
into pulmonary lymphatics and capillaries. Along with lung liquid absorption, the distension 
of lungs and increase in oxygen tension reduces the pulmonary vascular resistance, which in 
turn is associated with structural reorganization and thinning of the pulmonary vascular wall 
(Abman 1990; Lakshminrusimha and Steinhom 1999). This allows pulmonary vascular flow 
to increase by almost eightfold. At the same time, as the umbilical cord is clamped, venous 
return to the right atrium is reduced which leads to a drop in right atrial pressure and closure 
of the foramen ovale. In intrauterine life, pulmonary arterial pressure is equal to or more than 
the systemic arterial pressure. After birth, it rapidly falls to about 50% of that in the fetus,
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mediated by prostacyclin and endogenous nitric oxide (Leffler 1984; Fineman 1991). This 
drop in pulmonary arterial pressure initiates the closure of the ductus arteriosus. In the 
majority of healthy term infants, these steps of cardiorespiratory adaptation are complete by 
about 24 hours after birth.
In prematurely bom infants, postnatal cardiorespiratory adaptation does not occur as smoothly 
as in the majority of term bom infants. Pulmonary hypertension is a recognised complication 
of neonatal lung diseases, but the mechanisms for persistently high pulmonary vascular 
resistance in premature infants are not yet well understood (Goodman 1988; Mourani 2004; 
Danhaive 2005).
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1.3 Respiratory consequences of premature birth
A s ev iden t from  the stages o f  hum an lung grow th , p rem atu rely  born  infants have in terrupted  
lung  developm ent. V arious factors such  as m echanical ven tila tion , oxygen , infection , 
in flam m ation , nu trition  etc. affect th e ir postnata l lung g row th  (F igure  1.2).
F igure: 1.2 M odel o f  factors affec ting  lung grow th
Endocrine
PDA
RDS
Genetic
Infection
Nutrition
Barotrauma
Prematurity
Feto-maternal
Lung growth
Developmental
Oxygen toxicity
Prenatal
Postnatal
Other 
VGOR  
¥ Fluid 
overload
Pulmonary inflammatio
Top h a lf  show s prenatal factors th a t m ay be im portan t in norm al lung grow th; each  m ay cause 
in flam m ation , so affec ting  lung grow th . B ottom  h a lf  show s postnatal factors that m ay affect 
lung g row th  (K o techa 2000)
T hus, p reterm  birth  is associa ted  w ith  both antenatal and  postnatal risk factors that affec t lung  
g row th  and developm ent w hich  m ay lead to short term  and long term  resp ira tory  m orbid ity .
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In sections 1.3.1 and 1.3.2 I shall discuss respiratory distress syndrome and chronic lung 
disease, the two most important respiratory pathologies associated with premature birth.
1.3.1 R esp ira to ry  d is tre s s  sy n d ro m e
1.3.1.1 Introduction
Respiratory distress syndrome (RDS) is an acute respiratory illness caused by surfactant 
deficiency, primarily in prematurely bom infants. In the majority of affected infants, RDS is 
characterised by increased respiratory rate (>60breaths/ min), subcostal, intercostal or sternal 
recession, expiratory grunting, and cyanosis. Extremely premature infants (<26 weeks), 
however, may present with apnoea without any other associated respiratory signs. Premature 
birth is by far the most important factor contributing to development of RDS in infants. Male 
gender (M:F 1.7:1) and Caucasian race have also been strongly associated with this condition. 
Other predisposing factors related to development of RDS are, Caesarean section, birth 
hypoxia, maternal diabetes, hypothyroidism, genetic predisposition, twin pregnancy, 
hypothermia, malnutrition, intrauterine growth retardation, haemolytic disease of newborn 
and timing of cord clamping (Greenough 2005).
The incidence of RDS is known to be inversely proportional to the gestational age at birth. 
Data from previous studies have shown that the risk of RDS reduces from approximately 50% 
in infants bom less than 30 weeks of gestational age to only 2% in those bom at 35-36 weeks 
of gestational age (Rubaltelli 1998). Exposure to antenatal steroids (Ventolini 2008) and 
postnatal surfactant (Stoelhorst 2005) have been shown to significantly reduce the incidence 
of RDS. Despite these positive interventions, RDS is still a major cause of morbidity in 
preterm infants. As the incidence of preterm birth is ever increasing, and comprises about 5-
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7% of all live births in the developed world (Tucker 2005), further research into RDS and its 
consequences still remains an area that needs to be understood better.
1.3.1.2 Pathology
The basis of RDS is surfactant deficiency. Surfactant is a combination of phospholipids and 
proteins produced by type II pneumocytes, which spread as a layer of thin film at the air 
liquid interface of the alveolar surface and lowers its surface tension, thereby preventing 
alveolar collapse. Dipalmitoyl phosphatidyl choline or DPPC is the principal component of 
surfactant, which is responsible for reducing alveolar surface tension. As discussed in section 
1.1.1, differentiation of types I and II pneumocytes occur during 17-27 weeks of gestational 
age. Type II cells are detectable by 24 weeks of gestation. However, surfactant produced by 
type II cells at this stage is insufficient to adequately lower alveolar surface tension. 
Therefore, alveoli tend to collapse, particularly at end expiration, leading to poorly compliant 
lungs with atelectasis, and sometimes fluid filled lungs, which give rise to the ‘white out’ 
appearance in chest x-ray. Other radiological signs are small lungs and presence of air 
bronchograms.
Histologically, in lungs affected by RDS, the distended terminal and respiratory bronchioles 
are lined by hyaline membranes; giving its histological name ‘hyaline membrane disease’. 
The hyaline membranes are formed by coagulation of plasma proteins that leak onto the lung 
surface through damaged capillaries and epithelial cells, and fibrin exudates (Greenough
2005). After about 24 hours, the healing process begins, with appearance of inflammatory 
cells and macrophages. In uncomplicated RDS, the healing process is complete in the first 
few days after birth, and hyaline membranes disappear by the end of the first week. However,
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in extremely premature infants on mechanical ventilation, this process is markedly altered and 
delayed (Greenough 2005).
1.3.1.3 Effects of RDS on pulmonary function
The pulmonary function of infants with RDS depends upon the gestational age, type of 
ventilatory support and severity of RDS among other factors. By definition, the hallmark of 
RDS is non-compliant, stiff lungs. Pulmonary resistance in infants with RDS has been 
estimated to be 3-6 folds greater, compared with newborn infants without RDS. Studies have 
also shown that functional residual capacity is decreased in RDS. Although infants with RDS 
tend to achieve similar tidal volume as healthy term infants, almost 60-80% of this consists of 
dead space ventilation (Ainsworth 2005). To compensate for this, spontaneously breathing 
infants with RDS increase their respiratory rate. There is also evidence that prematurely bom 
infants with RDS tend to have poor pulmonary compliance and reduced functional residual 
capacity in the first month of life, which is not fully corrected by treatment with surfactant 
(Kawadia 1999). In some prematurely bom infants, this early structural and functional 
damage in the lungs may lead to chronic lung disease of prematurity, requiring prolonged 
oxygen dependency and/or ventilatory support.
1.3.2 N eonatal ch ro n ic  lung  d is e a s e
l.3.2.1 Introduction
In 1967 Northway introduced the term bronchopulmonary dysplasia (BPD), describing the 
pulmonary changes in the surviving population of prematurely bom infants with severe 
respiratory failure (Northway 1967). In current literature, the terms chronic lung disease and
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bronchopulmonary dysplasia are used interchangeably to describe chronic respiratory 
problems following premature birth. The National Institutes of Health workshop in 2001 
suggested that the term ‘Bronchopulmonary Dysplasia’ be used for prematurely bom infants 
who develop persistent respiratory problem, as this is a more specific terminology (Jobe and 
Bancalari 2001). However, in 2003 the American Thoracic Society (ATS) document on the 
‘Statement on the care of the child with chronic lung disease of infancy and childhood’ 
emphasized that the term bronchopulmonary dysplasia has certain histological and 
pathological implications that may not be present in all prematurely bom infants. More 
importantly, the long term management of children and adolescents with different forms of 
chronic lung disease of infancy are similar in principle. Therefore, the ATS document argued 
that it may be more appropriate to use the generic term chronic lung disease to describe the 
residual neonatal pulmonary problems in children and adolescents (ATS 2003).
Throughout this thesis, I have used the term chronic lung disease (CLD) to describe children 
who were bom <32 weeks of gestational age who were dependent on supplemental oxygen at 
36 weeks of corrected gestational age or discharge to home, whichever comes first.
The incidence of CLD has been reported to be as varied as 10-40% (Fanaroff 2007). This 
variation is probably contributed by lack of agreed diagnostic criteria; some using oxygen 
dependency at 28 days of life and others using oxygen dependency at 36 weeks of corrected 
gestational age for diagnosis of CLD (Bancalari 1979; Avery 1987; Shennan 1988). Shennan 
et al (Shennan 1988) made a case that the cut-off mark of oxygen dependency at 36 weeks of 
corrected gestational age predicts a more accurate incidence of CLD irrespective of the 
gestational age at birth. In 2001, the National Institute of Child Health and Human 
Development (NICHD)/ National Heart Lung and Blood Institute (NHLB)/ Office of rare
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diseases workshop on CLD agreed on diagnostic criteria for CLD (Jobe and Bancalari 2001) 
(Table 1.3). The NICHD also reported an incidence of CLD in 23% of prematurely bom 
infants, using the definition of oxygen dependency at 36 weeks of corrected gestational age in 
prematurely bom infants (Lemons 2001).
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Table 1.3 Diagnostic criteria for severity of CLD
Gestational age <32 weeks >32 weeks
TPA 36 wk PMA or discharge to home, >28 days but <56 days PNA or
whichever comes first discharge home, whichever is
first
Mild CLD Breathing room air at TPA Breathing room air at TPA
Moderate CLD Need for <30% oxygen at TPA Need for <30% oxygen at TPA
Severe CLD Need for >30% oxygen and/or Need for >30% oxygen and/or
positive pressure, (PPV or CPAP) positive pressure, (PPV or
CPAP)
(Jobe and Bancalari 2001)
TPA= Time point of assessment, PMA= Post menstrual age, PNA= Post natal age, PPV= 
Positive pressure ventilation, CPAP= Continuous positive airway pressure
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1.3.2.2 Risk Factors for the Development of CLD
Several antenatal and postnatal factors have been associated with the development of CLD. 
Antenatal inflammation and infections have been explored as potential causes in both animal 
models and in infants bom prematurely. In a sheep model, when chorioamnionitis was 
induced by injecting endotoxin, there were alveolar and microvascular changes in the fetal 
lung similar to CLD (Kramer 2008). Maternal preeclampsia (Hansen 2010) and 
chorioamnionitis (Watterberg 1996; Paul 2009) have been shown to increase the incidence of 
CLD in very low birth weight infants who are bom prematurely. Others have suggested that 
the exposure to antenatal inflammation is a risk for development of CLD only if the infant is 
exposed to postnatal infection (Van Marter 2002). Cytomegalovirus (Sawyer 1987) and 
Ureaplasma urealyticum (Cassell 1988) have also been suggested to be risk factors for CLD.
Oxygen toxicity and barotrauma are considered to be important postnatal causes of CLD. As 
premature infants have a poorly developed antioxidant system, they are at higher risk of 
oxygen free radical damage (Frank 1992). It has been clearly demonstrated in a piglet model 
that hyperoxia causes more significant physiological, inflammatory, and histological changes 
in the lungs than barotrauma alone (Davis 1991). The inverse relationship between 
hypocarbia and development of CLD has also been demonstrated in prematurely bom infants 
who were hypocarbic prior to receiving surfactant replacement therapy (Garland 1995). 
Barotrauma caused by high pressure ventilation is an important cause of pulmonary interstitial 
emphysema (Greenough 1984) which in turn may lead to neonatal CLD (Cochran 1994).
When Cunha et al studied a cohort of 86 infants with birth weight less than 1500g, they 
reported that apart from birth weight, gestational age and oxygen, the most important factors
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for development of CLD were prematurity, patent ductus arteriosus, high peak inspiratory 
pressure and fluid overload (Cunha 2005).
Although CLD is a disease of prematurely bom infants, lack of RDS does not prevent CLD. 
In fact, in one study, up to 5% of infants who developed CLD did not have any initial lung 
disease (Charafeddine 1999). Although antenatal corticosteroids have shown to be hugely 
beneficial in decreasing the incidence of RDS, this has not influenced the incidence of CLD, 
possibly as a result of increasing survival after extremely premature birth (Crowley 1995).
1.3.2.3 Pathogenesis and Pathophysiology of CLD
The population of infants, on whom Northway and his colleagues described CLD, were bom 
moderately premature and were exposed to high concentration of oxygen and aggressive 
mechanical ventilation, and none of them had received surfactant (Northway 1967). These 
infants had severe respiratory failure with prolonged healing process. The morphological 
changes in the radiograph were severe, and included pulmonary hyperinflation, emphysema, 
atelectasis and fibrosis. Histological characteristics of this classic CLD were epithelial 
squamous metaplasia and smooth muscle hypertrophy in the airways and in the pulmonary 
vasculature (Bancalari and Claure 2006). The post-mortem examinations of lung tissue in 
infants who died of CLD demonstrated normal or increased lung volumes, thin alveolar walls, 
and most importantly, less than normal total numbers of alveoli for post-natal and 
postconceptional age (Hislop and Haworth 1990).
With the introduction of antenatal steroids in the 1970s and surfactant replacement therapy in 
the early 1990s, along with improved mechanical ventilation, careful monitoring of oxygen
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therapy and improved nutritional care, the survival of extremely premature infants has 
improved, and the pathology of CLD has changed over the years. Unlike the ‘classic CLD’ or 
the ‘old CLD’ seen in the pre-surfactant era, the ‘new CLD’ of the post-surfactant era is seen 
in extremely premature infants, who may or may not have suffered from RDS. ‘New CLD’ 
seems to occur due to arrest of alveolar growth leading to enlarged airspaces with minimal 
alveolization (Jobe 1999; Coalson 2003), rather than the classic appearance of alternating 
sites of hyperinflation and fibrosis caused by oxidant injury or barotraumas seen in infants in 
the pre-surfactant years (Figure 1.3). The radiographic changes in the ‘new CLD’ are also 
different to what was observed classically. These infants seem to have small lungs with 
minimal alveolization. It has been demonstrated that antenatal exposure to steroids caused 
thinning of the alveolar wall, an increase in alveolar volume by 20% and a decrease in 
alveolar number by 30%, in fetal lambs (Willet 2000). This gives us the picture of pulmonary 
pathology in the prematurely bom children who have been exposed to antenatal steroids.
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Figure 1.3 H isto logical appearance o f ‘old* and ‘n ew ’ C L D
O ld  b ro n ch o p u lm o n a ry  d y sp las iaAtelectasis 
Alveolar obliteration
Focal septal fibrosis 
Scarring
Squamous metaplasia
Bronchiolar distortion
Mucosal inflammation 
and fibrosis
Emphysematous and 
bullous lesions
Disrupted and loosened 
alveolar attachm ents
Airway collapse
Vascular hypertensive 
changes
N ew  b ro n ch o p u lm o n a ry  d y sp las ia
Fewer alveolar 
attachm ents -
Airway collapse
Reduced airway caliber
Mild epithelial 
lesions
Mild penbronchial 
inflammation and fibrosis
Dysmorphic pulmonary 
microvascular network
Fewer, larger 
simplified alveoli
Reduced gas-exchange 
surface
(Baraldi 2007)
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1.3.3 Long term  resp ira to ry  o u tc o m e  of p rem atu rity
R esp ira to ry  co n seq u en ces o f  p rem a tu re  b irth  have  been  investiga ted  in in fan ts, p re-sch o o l and  
sch o o l-ag ed  ch ild ren , and in y o u n g  adults. T h e  s tud ies  in in fan ts have co n cen tra ted  m ostly  on 
the  inc idence o f  resp ira to ry  sym ptom s, low er resp ira to ry  tract in fec tion  such  as resp ira to ry  
syncy tia l v iru s  in fec tion , and  hosp ita l adm issions . R esearch  on  schoo l-aged  ch ild ren  and 
ad o lescen ts  has g iven  us som e in sigh t on  the  p u lm onary  function  in these  ch ild ren  in g rea ter 
deta il. H ow ever, m ost o f  these  stud ies  are  b ased  on ch ild ren  b o m  in the  p re -su rfac tan t era.
R e-hosp ita liza tion :
V arious stud ies have co n sis ten tly  show n th a t th e re  is an  increased  inc idence o f  hosp ita l 
ad m issio n s due  to  resp ira to ry  illness in p rem atu re  in fan ts w ith  C L D . In an  A m erican  co h o rt o f  
133 su rv iv in g  in fan ts o f  g es ta tio n a l age <32 w eeks and  I 2 l  hea lthy  term  con tro ls (b o rn  1985- 
1986), 36%  o f  p re te rm  in fan ts w ere  re -h o sp ita lized  in th e  first 2 y ears  o f  life co m p ared  to  
on ly  2 .5%  o f  te rm  infants. A m o n g  th e  p re te rm  in fan ts w ho  w ere  hosp ita lized , 45%  had  C L D  
co m p ared  to  25%  w ho d id  not have  C L D  (C u n n in g h am  19 9 1). In an o th er A m erican  study , ou t 
o f  125 su rv iv in g  ch ild ren  b o m  at 24-31 w eeks o f  gesta tiona l age, 53%  w ith  C L D  w ere  re ­
h o sp ita lized  w ith in  the  first 2 y ea rs  as o pposed  to  26%  o f  p re te rm  ch ild ren  w ith o u t C L D  
(G ro ss  1998). S im ilar resu lts have  a lso  been  sh o w n  by an  A u stra lian  g roup  w ho  fo llow ed  up 
78 in fan ts w ho w ere  d ischarged  hom e on h om e oxy g en  and 78 b irth  w eigh t m atched  in fan ts 
w ith o u t C L D . In th is study, the  overall rates o f  re-h o sp ita liza tio n  (58%  vs 35% ) and  
h o sp ita liza tio n  fo r resp ira to ry  illness (39%  vs 2 0% ) w ere  h igher in the C L D  g roup  in the  firs t 
y e a r  o f  life (C hye  and G ray  1995).
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In a  la rge  case con tro l study  ca rried  ou t in the  U SA , inc reased  risk  o f  h o sp ita liza tio n  for 
resp ira to ry  illness has been  reported  in 18-27 y e a r  o ld  adu lts  w ho  had  a  h istory  o f  low  b irth  
w eigh t. In th is study  invo lv ing  4 ,674  cases and  18,445 con tro ls , odds ratio  fo r h osp ita liza tion  
fo r resp ira to ry  illness w as 1.83 (9 5 %  C l 1.28 to  2 .62, p = 0 .0 0 1 ) fo r very  low  b irth  w eigh t 
(b irth  w eig h t < 1 ,500  g ram s) and  1.34 (9 5 %  C l 1.17 to  1.52, p< 0 .0 0 5 ) fo r m odera te  low  b irth  
w e ig h t (b irth  w eith  1,500 g ram s to  2 ,499  g ram s) sub jects. P rem atu re  b irth  and  p resen ce  o r 
ab sen c e  o f  C L D  w as no t co n sid ered  in th is  study  (W alte r 2009).
R esp ira to ry  sym ptom s:
T he fact th a t th e  inc idence  fo r re -h o sp ita liza tio n  due  to  resp ira to ry  illness is h igher in p re te rm  
ch ild ren  w ith  C L D  im plies th a t o n g o in g  resp ira to ry  sym ptom s m ust be  h igher in th is  g roup  o f  
in fan ts. A fou r y ea r  p ro sp ec tiv e  fo llow -up  o f  81 p rem atu re ly  born  ch ild ren  (m ed ian  
g es ta tio n a l age 29 w eeks) revealed  th a t 4 7 %  o f  ch ild ren  w ere  sym p to m atic  w ith  ch ron ic  
w heeze  and  co u g h  in th e  first y ea r  o f  life, 36%  in the  second  y ea r  and  33%  in the  th ird  and  
fou rth  y ea rs  (G reen o u g h  1996). G esta tio n a l age <28  w eeks, v en tila tio n  >5 days, supp lem en ta l 
o x y g en  > 1 0  days, fam ily  h isto ry  o f  a topy , and  p aren ta l sm o k in g  w ere  no ted  to  be im portan t 
p red ic to rs  o f  resp ira to ry  sym ptom s. In a  la rger study  w ith  492  in fan ts bo rn  b efo re  29 w eeks o f  
g es ta tional age, up  to  27%  w ere  sy m p to m atic  w ith  co u g h  and w h eeze  in the  first yea r. M ale 
sex , o x y g en  d ep en d en cy  at 36 w eek s o f  co rrec ted  gesta tiona l age, h av in g  o ld er sib lin g s under 
the age o f  five and  liv ing  in ren ta l acco m m o d atio n  w ere  reported  to  be risk  fac to rs for 
resp ira to ry  sy m p to m s at 6 and 12 m on ths o f  age (G reen o u g h  2005). P rem atu re  in fan ts w ho  
w h eeze  in the  firs t y ea r have a lso  been  asso c ia ted  w ith  abnorm al pu lm onary  function  te sts  
(B ro u g h to n  2007). N one o f  th ese  stud ies have  co m p ared  resp ira to ry  sym ptom s b e tw een  
p rem atu re ly  b o m  ch ild ren  w ith  and w ith o u t C L D .
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Whether or not the respiratory symptoms in preterm children persist as they grow older is not 
well understood, but there is evidence that prematurely bom children continue to have 
respiratory symptoms at school age. When respiratory symptoms over a period of 12 months 
were studied in 384, 8-year-old children who were bom with very low birth weight (<1500 
grams), the investigators noted that respiratory symptoms were twice as common in the study 
group compared to 154 term-born controls (Palta 2001). The investigators in this study also 
compared the respiratory symptoms in this group of preterm children (bom between 1988- 
1991), prior to the introduction of surfactant therapy, to 2 other groups of preterm children; 
those bom between 1989-1990 when surfactant was used only as a rescue therapy and 1990- 
1991 when surfactant became generally available. The investigators used a questionnaire from 
the International Study of Asthma and Allergies in Childhood (ISAAC) (Asher 1995). They 
concluded that with the advent of availability of surfactant, the prevalence of wheezing at 8 
years of age decreased from 50% to 16% among children with CLD (defined as use of 
supplemental oxygen at 25-35 days), but increase in wheezing at 8 years of age in those very 
low birth weight children who did not meet the criteria for CLD (Palta 2001). Another 
published data on the follow-up of the extremely premature children (<25 weeks, bom in 
1985) from the EPICure study cohort (Costeloe 2000) have shown that respiratory symptoms 
and medication use were more prevalent at 30 months and at 6 years, in the CLD population 
(n=180) compared to the non-CLD (n=56). They also concluded that need for hospitalization 
and medication use declined between 30 months and 6 years (Hennessy 2008). The authors 
found that discharge gestational age, exposure to passive smoking at home, maternal smoking 
in pregnancy, and CLD were risk factors for respiratory symptoms at 6 years of age.
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Pulmonary function tests:
Respiratory compliance and resistance have been reported to be abnormal (50% predicted) in 
infants during the acute phase of CLD, but these seemed to have improved during the first 
year of life with values reaching normal ranges by 2 years of age (Baraldi 1997). However, 
forced expiratory flow measured at the age of 2 years was abnormal in 70% of the children in 
this cohort. If prematurely bom infants wheeze, they tend to have evidence of gas trapping as 
opposed to those who are asymptomatic at 1 year of age (Broughton 2007). In the EPICure 
cohort which consisted of 236 infants bom at <25 weeks of gestational age (74%, CLD), peak 
expiratory flow was lower than in term bom classroom controls (mean adjusted difference 39 
1/min) at 6 years of age (Hennessy 2008). CLD defined as need for oxygen supplement at 36 
weeks of corrected gestational age was found to be the only independent predictor of peak 
flow.
Very low birth weight (<1000grams) and extremely preterm (<28 weeks) children have been 
shown to have compromised pulmonary function at school age (8-9 years) with lower forced 
expiratory volume at 1 second, FEVj (<75% predicted) in 20% of the index population 
compared to just 2% of term-bom controls. They also had higher residual volume (RV) and 
RV:TLC ratio (residual volume: total lung capacity) indicating air trapping (Doyle 2006). 
37% (out of 298) of the very low birth weight children in this study had CLD. FEVi was 
lower (<75% predicted in 27% with CLD V 15% without CLD), and RV as well as RV: TLC 
ratio were higher in the CLD population. The results from the Australian cohort of 52 preterm 
children with CLD and 62 preterm controls at 8 years of age are slightly different 
(Kulasekaran 2007). In this cohort, forced expiratory flow at 25-75% of vital capacity (FEF 25 -  
75) was the only respiratory parameter that was significantly lower in the CLD group 
compared to the preterm controls, which responded to bronchodilator therapy. There was no
26
evidence of increased air trapping or bronchial hyper-reactivity in the children with CLD 
compared with the preterm controls. None of the children in this study had received surfactant 
therapy. Data from 18 studies on children and young adults with CLD of prematurity (6-19 
years) have been extensively reviewed by Baraldi (Baraldi 2007). As shown in Figure 1.4, it 
is clear that even those children with CLD who receicved surfactant after birth tend to have 
lower FEVj later in life compared to the control population.
The evidence on the effect of surfactant therapy at birth on respiratory outcome at school age 
is varied. 38% (out of 298) of the preterm children in the study by Doyle et al had received 
surfactant therapy, and thus did not influence the respiratory outcome at 8 years of age (Doyle
2006). Similarly, 8 year follow-up on children who were recruited for a randomised control 
study of surfactant therapy revealed that there were no differences in FRC, forced expiratory 
flow (FEV,, FVC, FEF 25, FEF 50), PEF or airway resistance between those who received 
surfactant therapy and those who received placebo (Gappa 1999). 2/22 in the surfactant 
group, compared with 9/18 in the placebo group had developed CLD. Another follow-up 
study at school age (7-12 years), on children who were recruited in a randomised control trial 
for surfactant therapy gives a different perspective to the influence of surfactant therapy on 
long-term respiratory outcome. In this Finnish study which included 17 children who had 
received prophylactic surfactant at birth, 14 children who received surfactant as a rescue 
therapy and 9 children who received placebo, the recipients of the prophylactic surfactant 
therapy had better FVC and PEF than the placebo group (p<.05) but did not differ to those 
who received rescue surfactant. All the spirometric parameters were significantly lower in the 
11 preterm children who developed CLD (28%) than in those who did not develop CLD. 
None of the children in this study were exposed to antenatal steroids (Pelkonen 1998). 
Another Finnish study which reported lung function at 8 years of age in preterm children
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received surfactant therapy at birth, demonstrated lower FEVj, higher RV: TLC and higher 
airway resistance in the CLD group compared with the term controls (Korhonen 2004). The 
limitation of this study is that the investigators defined CLD as oxygen dependency at 28 days 
of life, and only 14 out of 34 children in the CLD group were oxygen dependent at 36 weeks 
of corrected gestational age. FEVj was lower in the 14 children who were oxygen dependent 
at 36 weeks compared to both the control groups.
The older population from the pre-surfactant era have had their lung function reported, in their 
early adulthood. At 18 years, 68% of 26 subjects (bom between 1964-1973) who had classic 
CLD, had evidence of airway obstruction; this was irreversible in 24% (Northway Jr 1990). 
Compared to the control population, the CLD group also had reductions in vital capacity and 
higher RV:TLC ratio. Similar results were also reported by another study on 42, 19-year old 
young adults who were bom at <32 weeks of gestational age and <1500 grams of birth weight 
(bom in 1983). Compared to 48 healthy term control subjects, the ex-preterm subjects had 
lower FEVj and lower diffusion capacities. This study also showed lower exercise capacity 
(lower maximum load), but normal peak oxygen consumption, ( V 02) in ex-preterm subjects 
(Vrijlandt 2006). In this study, the authors reported that none of these differences were 
statistically significant between preterm infants with and without CLD. This conclusion 
should be carefully interpreted, as only 9/42 preterm subjects in this study had CLD. 
Halvorsen et al (Halvorsen 2004) and Doyle et al (Doyle 2006) have also demonstrated lower 
FEVj in the ex- CLD population compared to term controls at 18-19 years of age. More 
recently published data on 60 ex- preterm subjects (7 with CLD) and 50 term-bom controls 
showed that at 21 years of age, the prematurely bom young adults still had excess respiratory 
symptoms but there was no significant difference in measured spirometry (Narang 2008).
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There are only limited studies with longitudinal data on preterm cohorts that give prospective 
evidence about the natural history of lung function in the survivors of CLD. In a study on 17 
survivors of CLD, 17 preterm controls and 34 healthy controls, the FEVi z- score was 
consistent in the CLD group at 2 years, 9 years and 15 years. Values for FEVi were 
significantly lower in the CLD group compared with the control groups at 9 and 15 years 
(Filippone 2009). In the study by Doyle et al (Doyle 2006), there was a larger fall in FEVi: 
FVC ratio in the subjects with CLD (n=29) than in preterm controls (n=129) between 8 and 
18 years of age (mean difference in FEVI: FVC -3.4%). On the other hand, Blayney et al 
reported improvement in FEVi by 10 years of age in 19 children (out of 32 who had CLD) 
who had FEVi <80% predicted at 7 years of age (Blayney 1991). In another study, 
Koumbourlis et al reported improvement in TLC and RV: TLC ratio over time (from 8 years 
to 15 years) suggesting resolution in gas trapping. FEVi and FEVi: FVC remained normal at 
both the phases but FEF at 25-75% of VC and at FEF at 75% of vital capacity remained low 
at both the phases (Koumbourlis 1996).
There are also limited data on diffusion capacity and exercise tests on school-aged children 
and young adults with history of CLD. Currently available literature on alveolar diffusion 
capacity and cardiopulmonary exercise on preterm subjects is summarized in Table 1.4 (a) 
and 1.4 (b) respectively.
Measurement of alveolar diffusion capacity (DLCo) is a method for indirectly assessing 
alveolar-capillary gas transfer. There is lack of consistency in the literature regarding 
information about the alveolar-capillary carbon monoxide diffusion in preterm infants. The 
only available data from school-aged children have shown lower DLco in children with CLD 
compared to the controls (Mitchell and Teague 1998). The investigators used the intrabreath
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technique rather than the more commonly used single breath method in this study. The 
EPICure study group recently reported lower diffusion capacity and lower peak oxygen 
consumption during exercise ( V02) in preterm children bom at <26 weeks gestation in the 
surfactant era (Welsh 2010). Balinotti and colleagues have reported significantly lower Dlco 
and the ratio of Dlco:alveolar volume in infancy in preterm infants with CLD compared to 
term controls suggesting impaired alveolar development (Balinotti 2010). Other studies for 
Dlco including those conducted in preterm bom children and young adults report variable 
results (Mitchell and Teague 1998; Vrijlandt 2006; Smith 2008; Narang 2009). Some studies 
in this older population showed lower DLCo values in preterm compared to term controls 
(Vrijlandt 2006; Narang 2009) but they suggested that the alveolar transfer factor was similar 
in preterm subjects with and without CLD. In the adult CLD population, Northway and 
colleagues demonstrated that although DLCo was statistically lower in the CLD group 
compared to the term controls, their alveolar diffusion capacity was >80% of the predicted 
value i.e. within normal limits (Northway Jr 1990).
Currently available data on cardio-pulmonary exercise tests in school-aged children (Jacob 
1997; Pianosi and Fisk 2000; Kriemler 2005; Welsh 2010) and young adults who were bom 
preterm are also inconsistent (Vrijlandt 2006; Narang 2009). Some studies have shown no 
differences in exercise capacity or peak VO2 between preterm and term groups (Jacob 1997; 
Kriemler 2005; Vrijlandt 2006; Narang 2009) whereas other studies have demonstrated 
reduced peakV02in the preterm subjects (Pianosi and Fisk 2000; Welsh 2010). These 
differences in the results may be due to variation in the study groups and also in the methods 
of cardiopulmonary exercise testing and, indeed, often do not differentiate between preterm 
infants with and without CLD.
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Thus, there is a lack of data on comparing lung function and exercise capacity between age 
and gender matched preterm children with and without CLD with those bom at term. 
Furthermore, the objective effect of exercise on airway function has not been reported nor has 
the effect of bronchodilator drugs after exercise been assessed in children with or without 
CLD. Finally, it is unclear which perinatal factors including gestational age, length of oxygen 
dependency or mechanical ventilation during infancy, influence important parameters such as 
Dlco, exercise tolerance and ventilatory capacity during exercise.
The pathogenesis and pathology of lung disease in prematurely bom children in recent years 
is different to those bom before the introduction of surfactant. Currently available literature is 
based on small cohorts of subjects and there is a lack of evidence based on comprehensive 
pulmonary function tests including exercise testing in a single cohort. Almost all pulmonary 
function studies on preterm children mix up preterm children with and without CLD. 
Therefore, it is unclear if pulmonary function abnormalities in ex-preterm children are due to 
prematurity per se or because of the chronic lung disease.
There is evidence from the older cohort that CLD of prematurity may be associated with 
early ‘ageing’ of lungs. CT scans on 21, 17-33 year old (median age 19) adults with a history 
of CLD revealed abnormal pulmonary CT in all the subjects with evidence of emphysema in 
84%. (Wong 2008). Although this is a small study, other studies have also shown similar 
results. Brostron et al studied 60 (28 with RDS, 32 with CLD) very low birth weight children 
at 1 month and at 6-8 years of age. 25/32 infants with CLD had abnormal chest x-ray at 1 
month of age. Only 26 of these children had high resolution computed tomography (HRCT) 
scan at 6-8 years of age. 19/26 had evidence of lung fibrosis, emphysema, bronchial wall 
thickening or linear opacities (Brostron 2010). Similarly, when HRCT was done on preterm
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(gestational age < 28 weeks) low birth weight (birth weight < 1000 grams) subjects who were 
10 years old (n=42) and a separate cohort of subjects who were 18 years old (n=32), 64 
subjects (86%) had minor abnormalities such as opacities and hypoattenuated areas. The 
authors have reported that neither age at examination nor birth cohort predicted the HRCT 
score. However, those who were oxygen dependent for >100 days after birth were noted to be 
at higher risk for CT abnormality (Aukland 2009). These results suggest that children who are 
bom prematurely and develop CLD are potentially at risk of developing chronic obstructive 
pulmonary disease (COPD) later in life.
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Figure 3. FEVX Values in Children, Adolescents, and Young Adults Who Were 
Born Prematurely and Had Bronchopulmonary Dysplasia, as Compared with 
Controls Born at Term.
Data (presented as means-2  SD) are from 18 studies, reported since 1990, 
in which survivors o f bronchopulmonary dysplasia who were 6 to 19 years 
o f age were compared with a reference population born at term. In all but 
two studies, the mean forced expiratory volume in 1 second (FEVX) was sig­
nificantly lower in the patients with bronchopulmonary dysplasia than in the 
healthy controls. Eighty percent of the predicted FEVX value is the accepted 
lower limit of the normal range. An asterisk indicates that the study was per­
formed after the introduction of surfactant therapy. The studies were conduct­
ed in the United States,2,15,35'37 Australia,22,24,38,39 Finland,21,40,41 Canada,42,43 
Italy,44,45 Norway,25 and the Netherlands.46 The numbers within the graph 
refer to the reference numbers of the studies.
(B ara ld i 2007)
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Table 1.4 (a): Summary of the literature review on alveolar diffusion capacity in prematurely bom children
Reference Participants (N) Age Method Results
(Balinotti 2010) CLD (39) 
Term (61)
12-14 months Single breath - DLCo adjusted for haemoglobin was lower in the CLD group
(p<0.01)
(Welsh 2010) Extremely preterm 
(38)
Term (38)
11 years Single breath -DLco was lower in the extremely preterm group compared to 
the term controls (p<0.001)
-CLD vs. non-CLD was not tested
(Mitchell and Teague 
1998)
CLD (10) 
Preterm control (10) 
Term (10)
7 years Intrabreath technique -Baseline DLCo was lower in CLD group.
(Vrijlandt 2006) CLD (9) 
Preterm control (42) 
Term (48)
19 years Single breath -Preterm subjects had lower DLCo compared to term controls 
but there were no differences between those with and without 
CLD
(Narang 2009) CLD (57) 
Term (50)
21 years He dilution mixed 
expired gas analysis
-Reduced DLCo and Qpeff at baseline in ex-preterm subjects 
which normalised during exercise and reduced again after 
recovery.
(Northway Jr 1990) CLD (26) 
Preterm control (26) 
Term (53)
Adult Single breath - DLco >80% predicted for patients and controls.
-CLD vs. Term p <0.05
-CLD vs. preterm control (not significant)
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Table 1.4 (b): Summary of the literature review on cardiopulmonary exercise test in prematurely bom children
Reference Participants (N) Age Method Results
(Welsh 2010) Extremely preterm (38) 
Term (38)
11 years Cycle ergometry -Peak V02 was lower in the extreme preterm compared to term 
-CLD vs. non-CLD not tested
(Bader 1987) CLD (10) 
Term (8)
7-14 years Treadmill - No difference in peak VO: between CLD and term groups.
(Baraldi 1991) Preterm (15) 
[None had CLD] 
Term (26)
7-12 years Treadmill -No difference in peak VO: between preterm and term groups
(Jacob 1997) CLD (15) 
Preterm control (15) 
Term (13)
9-12 years Cycle ergometry - No difference in peak V02 between groups
(Pianosi and Fisk 
2000)
CLD (17) 
Preterm control (15) 
Term (15)
8-9 years Cycle ergometry - Preterms with and without CLD had lower V02 compared to the 
terms (p<0.05)
(Kriemler 2005) CLD (17) 
Preterm control (14) 
Term (24)
5-7 years Cycle ergometry - No difference in peak V02 between groups
(Vrijlandt 2005) CLD (9) 
Preterm control (32) 
Term (48)
19 years 
(mean age)
Cycle ergometry - No difference in peak V02 between preterm and term groups 
-Work load was 15% lower in preterm group (p<0.0001)
(Smith 2008) CLD (37) 
Preterm control (89) 
Term (34)
10 years 
(mean age)
-6 minute walk 
- 20 meters shuttle 
run
- Peak V02 was lower in the preterm group compared to the term
- Difference between CLD and preterm controls was not tested
- No difference in 6 minute walk distance
- Mean completed shuttle stage in the preterm control group was 
50% lower than that of the Term group
(Narang 2009) CLD (7) 
Preterm control (53) 
Term (50)
21 years 
(mean age)
Cycle ergometry - No difference in peak V02 between term and preterm groups
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Whether or not the short term respiratory morbidilty and the long term abnormalities in 
pulmonary function in prematurely bom children with CLD are due to prematurity per se or 
due to the pathology of CLD is difficult to disentangle. As shown in Figure 1.2, there are 
various antenatal factors that affect lung growth, and if a baby is bom prematurely, lung 
growth is interrupted. This alone may be a major risk factor for long term respiratory 
morbidity. In a large American population consisting of 233,844 deliveries (bom in 2002 to 
2008), when late preterms (34 to 38 weeks) were compared to term bom infants (>38 weeks), 
incidence of RDS was 10.5% in the late preterms vs 0.3% in the term population (Hibbard 
2010). This suggests that even in late preterms who may or may not have developed CLD, 
respiratory morbidity in infancy is higher than in the term-born population. However, 
postnatal interventions such as mechanical ventilation and oxygen inhalation also contribute 
to lung inflammation. Factors such as low birth weight and postnatal nutrition may also have 
a role in long term respiratory outcome. When spirometry was performed on 8-9 year old 
children who were appropriate or gestational age at birth (n=3,462) and those who had 
intrauterine growth retardation (n=576), FEVi was significantly lower in those with 
intrauterine growth retardation (Kotecha 2010). This study did not include prematurely bom 
children. Current literature on respiratory outcome of CLD do not differentiate if the 
respiratory consequences are due to prematurity alone or due to the pathology of CLD. 
Prematurity, CLD and IUGR are intermingled in most of the literature. The question still 
remains that if preterm infants do not develop CLD, would they still have abnormal lung 
function in later life?
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1.4 Cardiac consequences of premature birth
Although primary airway disease following premature birth is more obvious, premature 
infants with RDS and CLD are also at high risk of cardiovascular sequelae, particularly 
pulmonary arterial hypertension (PAH).
1.4.1 P u lm o n ary  v a sc u la r  c h a n g e s  in RDS a n d  CLD
Premature arrest of lung development and subsequent exposure to hypoxia has important 
effects on infant haemodynamics during the transitional period. These infants are more likely 
to have persistent fetal circulation leading to increased pulmonary arterial pressure in the early 
postnatal period. Hislop and Haworth have also demonstrated that those infants who died of 
RDS or subsequent CLD had significant structural abnormalities in their pulmonary 
vasculature irrespective of whether or not they had clinical or pathological features of cor 
pulmonale (Hislop and Haworth 1990). In infants who died within the first 3 months, while 
still being supported by mechanical ventilation, the muscularity of the pulmonary vascular 
wall was similar to that seen in the normal fetus. This was less evident in those who had 
recovered from initial RDS and did not have clinical cor pulmonale. However, in those who 
died of cor pulmonale, the muscularity of the pulmonary vessels was considerably increased. 
All infants who died of CLD, with or without cor pulmonale, had increased adventitial 
thickness. These structural changes in the pulmonary vasculature cause narrowing of the 
vessels and also compromise their compliance, thereby contributing to high pulmonary 
vascular resistance. These findings clearly demonstrate the importance of the assessment of 
pulmonary arterial pressure and right ventricular function in premature infants with CLD.
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1.5 Body composition in prematurely bom children
Prematurely bom infants are known to have impaired growth in early infancy (Huysman 
2003; Cooke and Griffin 2009). Although the mechanisms underlying growth failure in 
infants with CLD are poorly understood, this has been speculated to be due to increased work 
of breathing (Kurzner 1988), infection and a different body composition (Huysman 2003).
Cooke et al studied 149 preterm infants (<34 weeks of gestational age, <1750 grams at birth) 
at discharge from hospital (Cooke and Griffin 2009). The researchers reported that fat free 
mass measured by dual-x-ray-absorptiometry (DXA) was significantly less in preterm infants 
than in the reference infants at the same weight or gestational age. Global fat mass was greater 
in the same group of preterm infants compared to the control population. The authors 
concluded that the impaired linear growth and fat free mass in preterm infant may be because 
dietary protein needs were not met before discharge.
In a study by Fewtrell et al (Fewtrell 2004) when 497 prematurely bom children (<37 weeks 
of gestational age) and 95 term-born children were studied at 8-12 years of age, the 
researchers noted that those bom prematurely had significantly lower fat mass index (FMI) 
measured by DXA compared with the term-born controls but fat free mass index (FFMI) was 
not different between the two groups. There was no association between birth weight, 
gestational age, or neonatal diet and FMI or FFMI at 8-12 years of age.
Body composition has also been measured in prematurely bom children with CLD. Bott et al 
studied 71 children, aged 4-8 years, with CLD of prematurity (Bott 2006). The researchers did 
not compare the results with preterm or term-born controls. Instead, this study was designed 
to compare FMI and FFMI measured using anthropometry, dual x-ray-absorptiometry (DXA)
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and bioelectrical impedance analysis (BIA). The authors concluded that both BIA and 
anthropometry gave good agreement with DXA to evaluate fat mass and fat free mass but 
BIA overestimated fat mass (mean difference: 0.34 kg±2.06) and underestimated fat free mass 
(mean difference: -1.24 kg±3.32).
In prematurely bom young adults aged 19 years (n=403, <32 weeks of gestational age), 
weight gain before 32 weeks of corrected gestational age was positively associated with adult 
body size but not with body composition and fat distribution (Euser 2005). Whether body 
composition of prematurely bom children with CLD varies from those who do not develop 
CLD is not clear.
1.5.1 V alidation  o f b io e lec trica l im p e d a n c e  fo r m e a su re m e n t o f b o d y  
c o m p o s itio n  in ch ild ren
Dual-x-ray-absorptiometry (DXA) is a reference criterion for measurement of body 
composition. The drawbacks of this method are that this is a time-consuming and expensive 
method that requires an expert technician and sophisticated equipment. DXA also involves 
fadiation, albeit a negligible dose of 0.001 milli Sievert (Radiological Society of North 
America. http://www.radiolozvinfo.orz/en/safetv/index) Bioelectrical impedance (BIA) is a 
more user-friendly and an easily accessible method for measuring nutritional status. BIA is 
based on the principle that the electrical conductivity through body fluid is much greater in fat 
free mass than in fat mass because fat free mass contains all body fluids and electrolytes 
(Sung 2001).
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BIA has been validated in a large study on 1139 girls and 1243 boys, aged 7-16 years (Sung 
2001). The 95% limits of agreement between BIA and DXA methods were considered to be 
acceptable (-3.3 kg to -0.5 for fat mass in kg and -3.9 to 0.6 for % body fat). Bott et al studied 
71 children, aged 4-8 years, with CLD of prematurity (Bott 2006). The investigators 
compared fat mass and fat free mass measured using anthropometry, BIA and DXA. The 
results showed that BIA overestimated fat mass (mean difference: 0.34 kg, SD: 2.06) and 
underestimated fat free mass (mean difference: -1.24 kg, SD: 3.32) compared to that 
measured by DXA in children with CLD. The researchers did not, however, adjust fat mass or 
fat free mass to body size. As a result, it is also not clear from this study whether the 
reproducibility for fat mass and fat free mass measured by BIA compared with DXA is 
different in children with CLD compared with the term-born population. A previous study has 
suggested that in an undernourished population, body composition data correlate less with a 
reference method like DXA (Wells 1999). In a more recent study on 69, 8 year old children, 
the same group of researchers have suggested that body composition data should be 
normalised to height rather than weight (Wells and Cole 2002).
BIA is simple and quick to use in clinical settings. Although BIA may not be as accurate as 
DXA in measuring body composition in undernourished children, this is a useful method for 
cross-sectional and longitudinal studies because of its simplicity and acceptable validity. It 
has been shown to have a relatively good agreement with DXA.
1.5.2 R elationsh ip  betw een  body  co m p o sitio n  and  resp ira to ry  func tion
In adult studies, abnormality in body composition, especially depletion of fat free mass has 
been associated with increased mortality and lower maximal exercise performance in patients
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with chronic obstructive pulmonary disease (COPD) (Andreassen and Vestbo 2003). Low fat 
free mass and low body mass index have been found to predict a higher mortality even in 
those with a predominantly early stage COPD (Vestbo 2006). It has been demonstrated that 
patients with COPD have less fat free mass index and that this may be associated with normal 
body mass index (17/33 COPD patients had low FFMI but normal BMI) (Bolton 2004). In 
another study, higher lean-to-fat mass ratio was shown to be associated with a greater distance 
walked in 6 minutes in adults with COPD (Eisner 2007). FFMI has also been shown to be 
significantly associated with percentage of predicted FEVi and FEVi :F VC ratio in adults with 
clinically stable COPD (Ischaki 2007).
The influence of body composition on respiratory muscle and lung function has been 
established in adults (Ionescu 1998; Enright 2007) with cystic fibrosis. Loss of fat free mass 
has particularly been associated with loss of diaphragmatic muscle mass and loss of 
inspiratory muscle work capacity (Enright 2007). In children with cystic fibrosis appropriate 
weight gain has been associated with better FEVi (Zemel 2000; Peterson 2003). These studies 
have not explored the individual roles of fat mass and fat free mass on lung function.
Bott et al have reported that in children with CLD undemutrition does not correlate with 
pulmonary status at childhood (4-8 years), but is associated with nutritional status before the 
age of 2 years (Bott 2006). The authors also noted that although children with CLD had lower 
fat mass, resting energy expenditure adjusted for weight and fat free mass was similar in those 
with CLD and the control population (Bott 2006). There is lack of information on how 
different components of body composition vary between prematurely bom children with CLD 
and the control population and whether this has any correlation with different aspects of lung 
function.
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1.5.3 R elationsh ip  betw een  body  co m p o sitio n  an d  c a rd io v a sc u la r  
function
The relationship between body weight and cardiovascular disease has been explored in 
numerous studies in the past. Low birth weight has been related to increased cardiovascular 
morbidity and mortality later in life (Barker 1994; Lurbe 2001; Lackland 2003). The 
association between low birth weight and elevated blood pressure later on life has been 
extensively studied on the population in the Bogalusa Heart Study (Mzayek 2007). On the 
other hand, a high body mass index in children has been associated with various 
cardiovascular risk factors, atherosclerosis and mortality in adulthood (Berenson 1998; Reilly 
2003; Bjorge 2008).
There is a gap of knowledge in the current literature on the relationship of different 
components of the body mass index and cardiovascular risk factors in children. As high body 
mass index can reflect increase in either fat mass or fat free mass, it would be useful to 
understand the relationship between specific components of body composition with 
physiological and biochemical indices of cardiovascular disease. Furthermore, it is not clear if 
altered body composition is related to subclinical myocardial dysfunction. Understanding the 
basis of these relationships can help in the holistic management of prematurely bom children, 
particularly those with CLD, who may be at high risk of developing cardiopulmonary disease 
later in life.
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1.6 Assessment of pulmonary arterial pressure by 
echocardiography
The technical challenges in the assessment of pulmonary arterial pressure (PAP) and RV 
function in infants and children cannot be overstated. Although the reference criterion for 
diagnosis of pulmonary arterial hypertension (PAH) is right heart catheterization, this is an 
invasive procedure, which is highly impractical and unethical, particularly for diagnosis of 
subclinical disease in small infants and children. Therefore, over the last two decades, non- 
invasive echocardiographic features have been explored extensively for diagnosis of PAH.
1.6.1 P u lsed  D oppler m e th o d s
Pulmonary arterial hypertension (PAH) is defined as mean PAP >20 mm Hg at rest, or >30 
mm Hg during exercise. Commonly used equations for assessment of PAP by Doppler 
echocardiography are,
1. Systolic PAP = 4 x (Tricuspid regurgitation peak velocity)2 + right atrial pressure (Hatle 
1981)
2. Mean PAP = 79 -  0.45 (Pulmonary arterial acceleration time, AT) (Dabestani 1987)
3. Diastolic PAP = 4 * (Pulmonary regurgitation end diastolic velocity) 2 + right atrial 
pressure (Masuyama 1986)
1.6.1.1 Tricuspid regurgitation peak velocity
The assessment of peak systolic pressure across the tricuspid valve using tricuspid 
regurgitation (TR) peak velocity is perhaps the most widely used echocardiographic
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parameter for direct assessment of systolic PAP. In this method, maximum peak velocity of 
blood flow through tricuspid valve is measured by continuous wave Doppler ultrasound 
(Figure 4.7) and right ventricular to right atrial pressure gradient is calculated by applying the 
modified Bernoulli equation (AP=4V2). RV pressure is calculated by adding estimated right 
atrial pressure to the calculated pressure. The right atrial pressure can be estimated by the 
degree of collapse of the inferior vena cava on inspiration (Kircher 1990). In the absence of 
RV outflow tract obstruction RV systolic pressure should be equal to the PAP.
This method has been validated both in adults, and in children. When a measurable TR jet is 
visible, this has been demonstrated to be highly accurate in diagnosis of PAH in adults and 
correlated well with catheterization measurements (r=0.97) (Skjaerpe and Hatle 1986). It has 
also been shown to be accurate and reproducible in infants with congenital heart disease 
(r=0.95) (Skinner 1993). The problem however is, that a TR jet was detectable only in 47% of 
patients with chronic obstructive airway disease (COPD) with only 30% patients having good 
quality TR jet in one study (Tramarin 1991). Similarly, in young children <2 years with 
chronic lung disease of various aetiology, TR jet could be detected in only 63% of patients 
and TR velocity could diagnose presence of PAH in 79% of patients, but could correctly 
estimate PAP in only 47%. 58% of children (7/12) who did not have measurable TR jet were 
diagnosed to have PAH by subsequent catheterization (Mourani 2008). Thus, although in the 
presence of a measurable TR jet velocity, the presence of PAH can be diagnosed with fairly 
good accuracy, its absence does not exclude PAH.
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1.6.1.2 Pulmonary regurgitation end diastolic velocity
Continuous-wave or pulse-wave Doppler echocardiography can be used to measure 
pulmonary regurgitation flow velocity (Figure 4.8), to estimate PAP by modified Bernoulli 
equation. This method has also been validated in a small study of 21 patients with PAH and 
24 controls without PAH (Masuyama 1986). The Doppler determined pressure gradient at end 
diastole correlated well with catheter measurements (r=0.94) in this study. However, 
measurable PR velocity was visible in only half of the controls and 78% of patients with 
PAH.
1.6.1.3 RV outflow systolic time intervals
RV systolic time intervals are probably the most extensively studied surrogate markers of 
PAH. In this method, the forward flow through the pulmonary artery is visualized by pulse- 
wave Doppler ultrasound. Acceleration time (AT) is measured from the onset of ejection to 
the time of peak flow velocity, and ejection time is measured from the onset to the end of 
systolic flow velocity (Figure 4.9) The advantage of this method is that unlike the TR and PR 
jets, pulmonary flow can invariably be measured in all patients, irrespective of age and 
presence or absence of PAH.
The negative linear correlation with mean PAP in adult population has been demonstrated in 
various studies (Matsuda 1986; Dabestani 1987).
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Table 1.5 Sensitivity and specificity of acceleration time (AT) for detecting pulmonary 
arterial hypertension (PAP >20 mm Hg)
Doppler index Sensitivity Specificity
AT <120 ms 91% 63%
AT <110 ms 87% 88%
AT <100 ms 78% 100%
(Dabestani 1987)
In the study by Dabestani et at (Dabestani 1987), all patients with pulmonary systolic flow 
acceleration time (PA AT) <75 ms had severe PAH (PAP of at least 40 mm Hg). There was 
significant correlation between PA AT and mean PAP (r=0.84, p<0.001). In this study, the 
use of acceleration time to ejection time ratio (AT: ET) did not improve the correlation with 
mean pulmonary arterial pressure. All patients in this study had heart rate (HR) <110 beats 
per minute. The high specificity of PA AT for diagnosis of PAH does not hold true unless the 
heart rate is 60-100 beats per minute. This caveat needs to be taken into account when using 
PA AT as a surrogate marker of PAH in infants and children. Reassuringly, when AT was 
corrected for heart rate by dividing AT by square root of R-R interval, significant inverse 
correlation with ATc (r = -0.78) and AT/ETc (r=0.87) was noted in children aged 4 days to 16 
years (Akiba 1988).
AT:ET ratio has been used to study changes in PAP in preterm infants during the acute phase 
of RDS (Evans and Archer 1991), during recovery (Evans and Archer 1991), and in infants 
with CLD of prematurity (Fitzgerald 1994; Subhedar and Shaw 2000). In one of these studies, 
using AT:ET ratio of >0.35 as normal and <0.31 as definitely low, 24% of infants with CLD 
were suggested to have raised PAP (Fitzgerald 1994). The evidence of lower AT:ET ratio in
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preterm infants with RDS compared to controls is evident in all these studies. However, this 
measurement has been reported to have considerable intraobserver variability in preterm 
infants (Subhedar and Shaw 1996). The coefficient of repeatability for measurement of 
AT:ET ratio was only 25.4% in this study. The PA AT measurement also depends upon the 
sampling site, possibly due to varying angle of incidence to pulmonary arterial flow and also 
sample volume of pulsed Doppler (Panidis 1986).
In summary, pulmonary systolic flow acceleration time (PA AT) is a specific, but not a 
sensitive index of PAP.
1.6.2 T issu e  D oppler m e th o d s / M yocardial velocity  im aging
1.6.2.1 Right ventricular relaxation time 'IVRT'
Myocardial pulsed Doppler imaging of the tricuspid annulus can be used to measure RV 
relaxation time ‘IVRT (Figure 4.11)’. In adults, IVRT correlates well (r=0.74 to 0.87) with 
simultaneously measured PAP by RV catheterization (Dambrauskaite 2005; Brechot 2008). 
RV relaxation time was longer in patients with PAH, compared to those who did not have 
PAH. RV relaxation time ‘IVRT’ <40 ms has been shown to exclude PAH with 100% 
negative predictive value (Brechot 2008). Although prolonged IVRT is suggestive of elevated 
PAP, this cannot confirm the diagnosis of PAH by itself. At present, there is a lack of normal 
values and validation of this technique in infants and children.
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1.6.2.2 RV lateral wall peak systolic strain
Strain is the percent magnitude of myocardial deformation during cardiac cycle. Systolic 
strain is percent shortening of myocardium in a defined region of interest, during systole 
(Figure 4.14). RV systolic strain has been explored as a promising new technique for 
diagnosis of PAH. When used as a surrogate marker of PAH, RV systolic strain had 
significant inverse correlation with PAP (r= -0.67; p<0.001) and pulmonary vascular 
resistance (r=0.6; p<0.001) (Rajagopalan 2008). In another large study on adults, when 111 
patients with PAH and 35 patients with normal PAP had tissue Doppler myocardial imaging 
and cardiac catheterization, RV systolic strain < -20% was shown to predict PAP>40 mm Hg 
with a sensitivity of 60% and specificity of 87% (Lopez-Candales 2008). In this study, RV 
dyssynchrony measured by delayed time to peak strain between the ventricular septum and 
RV lateral wall of >25 ms was demonstrated as a good predictor of systolic PAP>40 mm Hg 
with sensitivity of 78% and a specificity of 80%. In view of these promising results in adult 
studies, it is possible that RV systolic strain may be a useful surrogate marker for diagnosis of 
PAH in infants and children as well. Strain and strain rate imaging has been proved to be 
feasible and reliable in infants (Nestaas 2007). This has not yet been validated for diagnosis of 
PAH in infants or children. Nevertheless, normal values for RV strain have been described in 
children, albeit in a wide age range of 1.1-18 years (Kutty 2008). The mean RV basal strain in 
this study for 30 normal children was, -18.9± 4.7%. Thus, the cut-off value of strain < -20% 
cannot be blindly applied in children for diagnosis of PAH.
48
1.6.3 E ch o card io g rap h ic  ev id en ce  o f pu lm onary  arteria l h y p e rten sio n  in 
resp ira to ry  d is tre s s  sy n d ro m e  an d  ch ro n ic  lung d is e a s e  o f prem aturity
Evans and Archer have used pulmonary acceleration time to ejection time ratio (AT: ET) for 
indirect assessment of PAP in 57 preterm infants (38 infants with RDS) at different time 
periods during the acute phase of RDS (Evans and Archer 1991). In this study, AT:ET ratio 
did not differ in preterm infants with and without RDS during the first 6 hours after birth, but 
the ratio was significantly different by 73 to 96 hours. The mean AT: ET ratio did not show 
significant correlation with gestation, birth weight, maximum supplemental oxygen, or the 
length of acute phase of illness. Importantly, the investigators noted that the AT: ET varied 
considerably among infants with RDS, and also depending upon the sampling site. The same 
group of investigators followed up 37 infants with RDS, during recovery phase of the illness. 
12/37 premature infants in this study continued to have low AT: ET ratio at discharge, despite 
having no clinical signs of respiratory illness. The infants in this group had lower gestational 
age at birth, lower birth weight, and had required longer duration of additional oxygen 
compared to the groups in which the ratio returned to normal at discharge (Evans and Archer 
1991). Following this, a study involving preterm infants who developed CLD (oxygen 
dependency at 28 days) has also demonstrated that 24% of infants with CLD, who had no 
clinical evidence of PAH, had low AT: ET ratio (<0.31), suggesting raised PAP. In a more 
recent study involving 248 examinations on 54 infants with CLD and 44 healthy preterm 
controls who were bom between 1995 and 1997, the AT: ET ratio was significantly lower in 
the preterm CLD group compared to preterm controls (0.31 vs 0.37) (Subhedar and Shaw 
2000). All infants in this study, who had required mechanical ventilation, had been treated 
with 2 doses of surfactant, 12 hours apart. The infants had longitudinal echocardiographic 
studies from 36 weeks of corrected gestational age till 40-52 weeks of corrected age. This 
longitudinal study showed that in infants with CLD, the AT: ET ratio was significantly
independently associated with age and inversely correlated with duration of supplemental 
oxygen treatment. Thus, although PAP falls with increasing age in the premature infants, 
there is evidence that some infants with CLD may have persistent subclinical PAH, even in 
the post-surfactant era. Whether this subclinical PAH seen in infants with RDS and CLD 
persist later in life, is yet to be seen.
In adults with chronic obstructive airway disease, left ventricular function has also been found 
to be compromised (Acikel 2010; Sabit 2010) and left ventricular diastolic function has been 
found to be closely related to the level of pulmonary hypertension (Acikel 2010). This has not 
yet been tested in children with CLD of prematurity.
In most of the studies assessing PAP in infants with RDS or CLD, the investigators have used 
blood Doppler echocardiography for indirect assessment of PAP. Tissue Doppler or 
myocardial velocity imaging methods have not yet been applied in prematurely bom infants 
and children for diagnosis of PAH.
1.7 Cardio-Respiratory Effects of Hypoxia
1.7.1 Hypoxic e ffec ts  o f a ltitude
The atmosphere consists primarily of nitrogen (78%) and oxygen (21%). This percentage of 
inspired oxygen remains constant at different altitudes. What varies is the atmospheric 
pressure. As the altitude increases, the atmospheric pressure decreases, which results in the 
reduction of the driving pressure for gas exchange in the lungs i.e. reduction in the inspired 
alveolar and arterial partial pressure of oxygen (Dalton’s Law).
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Atmospheric pressure is the pressure at any point of the earth’s atmosphere and is determined 
by hydrostatic pressure caused by the weight of air above the point of measurement. At sea 
level, the weight of air above us is normally lOOkPa. Atmospheric pressure is calculated as the 
sum of the partial pressure of the constituent gases (oxygen and nitrogen) and the partial 
pressure of water vapour (6.3kPa at 37°C). As oxygen is 21% dry air, the inspired oxygen 
pressure at sea level is 0.21*( 100-6.3) =19.6kPa (Peacock 1998). As we ascend, the air 
becomes less dense resulting in hypobaric hypoxia and is effectively equivalent to breathing 
oxygen at lower concentration.
The accessibility of commercial flights means that more and more people are travelling by 
long distance air flights. Similarly, visits to high altitude ski resorts or hiking in the mountains 
are becoming increasingly popular. Some of the ski resorts in Europe and North America are 
less than 2,438m (8,000ft) high. Others are higher than 8,000ft. The highest ski resort in 
North America is 3,962m (13,000ft) in Colorado, and in Europe, it is 3,794m (12,450ft). 
Destinations such as the Everest base camp (5,500m) and Tibet (3,658m), which were once 
considered remote, are now relatively easily accessible. The impact of this fast pace, 
adventurous life means that increasingly more people are exposed to altitude related hypoxia 
and its consequences.
1.7.1.1 Air flight and altitude
Commercial aircrafts generally cruise at altitudes of 9,000 to 12,000m (30,000 to 40,000ft) 
above sea level, where atmospheric partial pressure of oxygen, PO2 is <5kPa. This level of 
oxygen would normally cause lethal alveolar hypoxia. To reduce the hypoxic effect of
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altitude, aircraft cabins are pressurised to an altitude of 1,500-2,400m (5,000-8,000ft) above 
sea level, giving atmospheric pressure of about 75kPa and an atmospheric PO2 15-17kPa. This 
is equivalent to breathing 15-17% oxygen at sea level (Samuels 2004; Bossley and Balfour- 
Lynn 2007). In emergency, if the aircraft has to cruise above this altitude, oxygen masks are 
automatically deployed to all the passengers. For practical and commercial reasons, it is not 
possible to pressurise aircrafts to sea level. Maintaining aircraft at a sea level pressure would 
reduce the energy available for other aircraft systems, increase fuel consumption and reduce 
the working life of the aluminium airframes (Samuels 2004).
The current code of US Federal Aviation Regulations specifies that the air flight cabins and 
compartments should be pressurised to not more than 2,438m (8,000ft) at the maximum 
operating altitude of the aeroplanes under normal operating conditions (Anonymous 1986). 
One important fact to be noted with this regulation is that, it is practically not possible to 
always adhere to this limit and also, that the cabin altitude does not remain constant during 
the flight. This has been demonstrated when cabin pressures were directly measured in 
commercial aircraft flights (Cottrell 1988; Kelly 2007).
1.7.1.2 Flight hvnoxia in adults and children
With the growing number of passengers flying with pre existing cardiorespiratory conditions, 
insight into the hypoxic effects of flight and its possible consequence has become an area of 
intense scrutiny. When oxygen saturation (SaC>2) was monitored in 84 passengers (aged 1-78 
years) during short and long haul flights, the average change in oxygen saturation was noted 
to be from 97% (93-100%) at ground level to 93% (85-98%) at cruising altitude (Humphreys
2005). In this study, the authors presented the results from long and short haul flights together
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and did not present the data from adults and children separately. Lee and his colleagues have 
also carried out a similar study on 80 healthy, 0-15 year old children, on a long distance flight 
from Honolulu to Taipei, lasting 8-10 hours. In this study, the mean oxygen saturation 
declined from a mean sea level SaC>2 of 98.5% (± 1.2) to 95.7% (± 1.7) after 3 hours and 
94.4% (± 1.8) after 7 hours of flight (Lee 2002). It is now well established that most children 
and adults experience some degree of oxygen desaturation in long haul flights. This degree of 
hypoxia may not be clinically significant in a well, asymptomatic passenger. On the other 
hand, passengers with pre-existing cardiopulmonary conditions with chronic mild hypoxemia 
may develop exaggerated hypoxemia during commercial airline flights or in any other high 
altitude conditions. There is no strong evidence at present to argue for or against this 
hypothesis.
1.7.1.3 British Thoracic Society guidelines
With the growing concerns regarding patients with respiratory conditions embarking on 
commercial flights and lack of clear guidance for recommendation of oxygen for these 
passengers, there was clearly a need for consistent, practical, and comprehensive advice. To 
meet this demand, in 2002, British Thoracic Society Standards of Care Committee provided 
recommendations for respiratory physicians, for those passengers who travel by commercial 
aircraft and have predisposing lung disease (Coker 2002). In summary, the 2002 BTS 
guidelines for children recommended that,
• It is prudent to wait for 1 week after birth before allowing infants to fly to ensure the infant 
is healthy
• If the infant has had any neonatal respiratory problems, the proposed journey should be 
discussed with a paediatrician and a hypoxic challenge test considered
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• For oxygen-dependent children including ex-premature infants with chronic lung disease 
where flying is imperative, oxygen requirements should be titrated in a body box as 
follows:
The infant, receiving oxygen via nasal cannula is placed in the body box in the company of a 
parent or a carer, and SaC>2 monitored. The air in the body box is then diluted to 15% oxygen 
with nitrogen for 20 minutes. Any fall in SaC>2 can be restored to the original value by titration 
of the flow of oxygen through the nasal cannula. This flow of oxygen should then be supplied 
during the flight.
For adults with respiratory disease, the BTS guidelines suggest that those with sea level SaC>2 
of 92-95% should undergo hypoxic challenge with 15% oxygen for 20 minutes, while those 
with SaC>2 <92% at sea level should receive in-flight oxygen. For those undergoing hypoxic 
challenge, the guidelines recommend that if either the SaC>2 during the challenge falls <85% 
or post-test PaC>2 is <6.6, in-flight oxygen (2 1/min) should be advised. However, the 2004 
update of these guidelines suggested that in-flight oxygen should be recommended if SaC>2 
falls <90% during the hypoxic challenge (instead of <85%). Thus, the cut off value of 
SaC>2<90% during hypoxic challenge for in-flight oxygen requirement is an arbitrary 
consensus view rather than evidence based.
1.7.2 Pre-flight hypoxia te s t
Since the publication of the BTS guidelines for passengers with lung disease, there have been 
prospective as well as retrospective studies on pre-flight hypoxia challenge tests. In the 
paediatric age group, the pre-flight hypoxia tests have been mainly concentrated on preterm
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infants (Buchdahl 2004; Udomittipong 2006; Hall 2007; Martin 2008) and children with 
cystic fibrosis (Oades 1994).
Buchdahl and colleagues used 15% oxygen delivered in a body box to test 20 infants (8, 
CLD). 6/8 infants with CLD had baseline SaC>2 of >95% but overall 8/20 children dropped 
their SaC>2 to <90% during the hypoxic challenge (Buchdahl 2004). In a retrospective review 
of infants who had pre-flight hypoxic challenge test by Udomittipong et al (Udomittipong
2006), 14% oxygen had been delivered using face masks. 32/47 infants in the study had CLD. 
All had baseline SaC>2 >95% but 23/32 infants with CLD dropped their SaC>2 to <85% during 
the hypoxic challenge. In a larger study by Martin et al (Martin 2008), 69 children who had 
pre-flight hypoxic challenge test using 14% oxygen were reviewed. In this study, 14/23 
children with CLD (<2 year old) desaturated to <90% whereas 6/23 children with CLD (>2 
year old) dropped their oxygen saturation to <85%. Interestingly, 12/24 healthy children (<2 
year old) also desaturated to <90% and 1/24 healthy child (> 2 year old) desaturated to <85%.
It is interesting that SaC>2 in room air was not predictable of the response to hypoxic challenge 
in any of the above studies. More importantly, in the study by Martin et al (Martin 2008), 
when SaC>2< 90% was considered as a failure to pass a hypoxic challenge as suggested by 
2004 BTS guidelines, 50% of healthy infants failed hypoxic challenge. SaC>2 <85% seems a 
more reasonable cut-off according to this study.
1.7.2.1 Hvpobaric hvooxia V normobaric hypoxia
Hypobaric hypoxic chambers can simulate aircraft cabin pressure and partial pressure of 
oxygen (PaC>2) and would be an ideal method of carrying out pre-flight hypoxic challenge.
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However, hypobaric hypoxic chambers are not readily available. Alternatively, hypoxic 
challenge can be carried out by diluting the oxygen concentration in a body box as suggested 
in the 2002 BTS guidelines or by letting the child breathe reduced concentration of oxygen 
via a face mask or nasal cannula. Both these methods would create normobaric hypoxia as 
opposed to hypobaric hypoxia encountered in an aircraft or at high altitude.
To assess the validity of a normobaric hypoxia inhalation test compared with actual in-flight 
responses, Kelly et al (Kelly 2006) studied 15 healthy adults, who underwent pre-flight 
normobaric hypoxia inhalation testing by inhaling 15% oxygen, and compared the SaC>2 
results with actual in-flight SaC>2 results. They noted that although there was no difference 
between the final normobaric hypoxia inhalation test SaC>2 (92±2) and mean in-flight SaC>2 
(92±2), there was a significant difference between the lowest normobaric hypoxia inhalation 
test SaC>2 (90±2%) and the lowest in-flight SaC>2 (88±2%). Reassuringly, a study on adult 
patients with Chronic Obstructive Airway Disease (COPD), comparing Pa02 at 15% 
hypobaric hypoxia inhalation test and 2,438m (8,000ft) hypobaric chamber has shown that the 
Pa02 relationship was comparable (Dillard 1995). Another validation of normobaric hypoxia 
testing has been carried out on 7 children aged 2-51 months in Perth, Australia (Hall 2007). 
These children were exposed to 14% oxygen at high flow rate of 15 1/min via a mask for 20 
minutes. 2 separate periods of 30 seconds of quiet breathing were recorded and inhaled 
oxygen concentration for each inspiration was calculated. It was noted that the median 
concentration of inhaled oxygen was 13.5% (SD 0.2%). Therefore, use of normobaric hypoxia 
inhalation test seems to be a good method to simulate hypobaric hypoxia.
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1.7.3 Hypoxic pulm onary  v a so c o n s tr ic tio n
Hypoxic pulmonary vasoconstriction is an adaptive mechanism whereby blood is shunted 
from segments of poorly perfused segments of the lung to the well perfused segments, thereby 
optimizing the ventilation-perfusion match and thus reducing shunt function. This also results 
in optimal systemic delivery of oxygen in patients with focal lung disease such as pneumonia 
and atelectasis (Thomas and Garrett 1982; Brimioulle 1996). However, with global hypoxic 
conditions such as in high altitude hypobaric hypoxia or sleep apnoea, hypoxic pulmonary 
vasoconstriction results in constriction of pulmonary arteries throughout the pulmonary 
circulation resulting in increased pulmonary vascular resistance (Moudgil 2005). Bindsler and 
his colleagues observed that during anaesthesia, hypoxic pulmonary vasoconstriction 
increased pulmonary vascular resistance by 50% to 300%, and that the response to hypoxia 
starts within minutes of exposure and peaks within 15 minutes (Bindslev 1985). Similarly, 
inhalation of 12.5% oxygen at sea level has been shown to decrease systemic PaC>2 to below 
50 Torr and increase pulmonary vascular resistance by 100% -150% in normal adult 
volunteers (Naeije 1987). Interestingly, it is the alveolar oxygen tension that determines the 
hypoxic pulmonary vasoconstriction and not the blood PaC>2 As long as the alveolar oxygen 
tension is maintained above 60 Torr, there seems to be little hypoxic pulmonary 
vasoconstriction even when blood PaC>2 is reduced to 10 Torr (Marshall and Marshall 1983). 
To combat the hypoxic pulmonary vasoconstriction, hypoxia also results in hyperventilation 
and respiratory alkalosis (Bindslev 1985). All these effects of hypoxia are modulated by 
pulmonary vascular endothelium and the mechanisms surrounding this complex process, 
including the Redox Theory and the role of K+ and Ca++ channels have been extensively 
reviewed by Moudgil et al (Moudgil 2005).
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1.7.4 E ffects o f a c u te  hypoxia  on  ch ild ren  with n eo n ata l hypoxic 
pu lm onary  arteria l h y p e rten sio n
Epidemiological studies have clearly suggested that adverse events in utero may lead to 
cardiovascular and metabolic diseases in adulthood (Barker 1994; Barker 2001). With regards 
to hypoxic pulmonary arterial hypertension, although there is enough evidence that localized 
or generalized pulmonary hypoxia leads to hypoxic pulmonary vasoconstriction, there is little 
evidence to prove that hypoxia in perinatal period leads to susceptibility for hypoxic 
pulmonary arterial hypertension (PAH) in adulthood. Animal studies on rats have 
demonstrated that exposure to hypoxia in the first few days of life induces transient 
pulmonary arterial hypertension and predisposes to augmented pulmonary arterial 
hypertension in response to hypoxia in adulthood (Hakim and Mortola 1990; Hampl and 
Herget 1990).
In the only relevant human study in this field, Claudio Sartori and his team tested this 
hypothesis on 15 adults (mean age 21 years), who had transient hypoxic pulmonary 
hypertension in the first week of life (Sartori 1999). These volunteers had their systolic 
pulmonary arterial pressure (PAP) measured by echocardiography at sea level with hypoxic 
breathing (12% oxygen for 20 minutes), and then at a high altitude research laboratory at 
4,559m (4,600m ~ inhalation of 12% oxygen at sea level). They also had their PAP measured 
after inhalation of nitric oxide at high altitude. The results were compared with that of 10 
healthy volunteers who were bom at full term and had normal perinatal period. The results 
showed that at sea level, PAP between the two groups was similar but 24-36 hours after 
arrival at 4559m, the mean increase in PAP in the group who had neonatal pulmonary 
hypertension was significantly higher compared to the control group (p<0.01). In this 
experiment, the decrease in PAP after inhalation of nitric oxide at high altitude was also
significantly higher in the neonatal pulmonary hypertension group compared to the control 
group.
We know from post mortem studies that infants who died from neonatal chronic lung disease 
showed thickening of pulmonary vascular smooth muscle (Bush 1990; Margraf 1991). Similar 
findings were also noted on those infants who died from pulmonary hypertension (Haworth 
1988; Stenmark 1988). Whether this early life pathology persists in children who survive 
neonatal chronic lung disease is not known. If it does, it could predispose to exaggerated 
vasoconstrictor response to acute hypoxia. Specifically, in light of the observations made by 
Sartori et al in the above study, it seems prudent that we look for evidence of pulmonary 
arterial hypertension in response to acute hypoxia in the surviving children with chronic lung 
disease of prematurity.
In summary, fetal lung growth and the development of pulmonary vasculature are closely 
related to each other. Pulmonary function studies on ex-preterm children suggest that they 
continue to have evidence of airway obstruction and impaired alveolar diffusion as they grow 
older, but most studies do not differentiate whether this impaired pulmonary function is due to 
prematurity per se or due to CLD. Besides, current literature on exercise capacity in children 
with CLD is not consistent. It is also not clear if these children have exercise induced 
bronchospasm and whether the CLD related airway obstruction is reversible. Premature birth 
is also associated with abnormal pulmonary vascular development. There is some evidence 
that prematurely bom infants who develop CLD have thickened pulmonary arterial smooth 
muscle and develop pulmonary arterial hypertension. Whether this early life pathology 
persists as these children grow older is not clear. It is also not known if children with CLD of 
prematurity are at risk of developing subclinical right ventricular dysfunction and pulmonary
59
arterial hypertension secondary to impaired lung function, especially if they are exposed to 
hypoxic conditions.
As lung function and cardiovascular function have both been generally related to nutritional 
status, it would also be useful to learn if children with CLD have a different body composition 
compared to the control population and whether there is any relationship between body 
composition and cardio-respiratory function in children.
1.8 Hypothesis and study aims
1.8.1 H ypo thesis
I hypothesized that prematurely bom children who had chronic lung disease in infancy would 
have:
1(a) Impaired pulmonary function at rest and after exercise
1(b) Reduced exercise capacity compared to both preterm and term controls
1(c) Greater exercise induced bronchoconstriction
1(d) Greater response to bronchodilator administered after exercise.
Children who had chronic lung disease in infancy would also have:
2(a) Subclinical right ventricular dysfunction
2(b) Evidence of raised pulmonary arterial pressure after exposure to acute hypoxia 
2(c) Subclinical left ventricular dysfunction
compared with preterm and term-born controls.
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1.8.2 Specific  a im s 
Primary aims:
1(a) To assess pulmonary function at rest in children with CLD and in term and preterm 
control subjects, using spirometry, single breath test for alveolar carbon monoxide diffusion 
capacity and whole body plethysmography for static lung volumes
1(b) To measure spirometry after cardiopulmonary exercise test to assess exercise induced 
bronchospasm in children with CLD and in control subjects
1(c) To assess exercise duration and exercise load, oxygen consumption, carbon dioxide 
production, maximum voluntary ventilation and ventilatory reserve at maximum exercise in 
those with CLD compared with preterm and term-born control subjects
1(d) To test response to inhalation of bronchodilator agent in children with CLD compared 
with the control subjects, to assess the presence of reversible airway disease
2(a) To assess baseline right and left ventricular function in children with CLD compared
with term and preterm control subjects, using physiological, biochemical and 
echocardiographic markers
2(b) To assess right ventricular function and evidence of subclinical pulmonary arterial 
hypertension in response to acute hypoxia in children with CLD compared to healthy term 
and preterm controls, by using pulsed-wave Doppler and tissue-Doppler echocardiography.
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Secondary aims to generate hypothesis for future studies:
1(a) To assess body composition using bioelectrical impedance in children with CLD and 
compare it with preterm and term-born control population.
1(b) To assess subclinical relationships between body composition and indices of 
pulmonary function and cardiovascular function.
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Chapter Two: Pulmonary Function Study
63
2.1 Introduction
Survivors of chronic lung disease of prematurity (CLD) have increased respiratory morbidity 
(Greenough 1996; Greenough 2005), increased hospitalization (Cunningham 1991; Chye and 
Gray 1995; Gross 1998) and poor lung function during infancy and early childhood (Baraldi 
1997; Hennessy 2008). Increased respiratory morbidity is thought to be related to limited 
ventilatory capacity in infancy but it is unclear if this improves with age. Children with CLD 
have evidence of airway obstruction (Fawke 2010; Doyle 2006; Hennessy 2008), bronchial 
hyper-reactivity (Bader 1987; Korhonen 2004) and air trapping (Doyle 2006) compared with 
term-born controls at school age and in early adulthood (Northway Jr 1990). Preterm children 
without CLD have also been demonstrated to have lung function abnormalities in early 
adulthood (Hakulinen 1996; Vrijlandt 2006). Recent studies have reported lower diffusion 
capacity (D lco) in preterm infants (Balinotti 2010) and children (Welsh 2010) suggesting 
impaired alveolar development in preterm children bom in the surfactant era. As described in 
section 1.3.3 currently available data on Dlco (Mitchell and Teague 1998; Vrijlandt 2006; 
Smith 2008; Narang 2009) and cardiopulmonary exercise test (Jacob 1997; Pianosi and Fisk 
2000; Kriemler 2005; Vrijlandt 2006; Narang 2009; Welsh 2010) in prematurely bom 
children and young adults are inconsistent.
Currently available data on lung function in preterm children do not differentiate those with 
and without CLD. There is also lack of information on the objective effect of exercise on 
airway function and the effect of bronchodilator drugs after exercise in children with or 
without CLD in infancy.
I hypothesized that children who had CLD in infancy would (a) have impaired pulmonary 
function at rest and after exercise; (b) have reduced exercise capacity compared to both
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preterm and term controls; (c) have greater exercise induced bronchoconstriction; and (d) 
have greater response to bronchodilator administered after exercise. Finally, I modelled the 
data to assess which perinatal factors may influence D lco, exercise tolerance and ventilatory 
capacity.
2 .2  Methods
2.2.1 R ecru itm en t o f th e  su b je c ts
Inclusion criteria:
1. 8-12 year old children, who were bom at <32 weeks of gestational age and who were
oxygen dependent at either 36 weeks of corrected gestational age or at discharge to
home, were included in the preterm CLD group.
2. 8-12 year old children, who were bom at <32 weeks of gestational age and who did not 
require oxygen at 36 weeks of corrected gestation age, were included in the preterm 
control group.
3. 8-12 year old children, who were bom at >37 weeks of gestational age, were included in 
the term control group.
Exclusion criteria:
1. Children with congenital structural cardiac defect
2. Children with congenital structural respiratory tract defect
3. Children with any neuromuscular disease that could compromise cardiac or lung 
function
4. Children with severe neurodevelopmental impairment who would not be able to comply
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with the research protocol 
Temporary exclusion criteria:
1. Recent respiratory tract infections, i.e. within last 3 weeks
2. Hospital admission within the last 6 weeks for any reason 
These children were invited to attend at a later date.
Recruitment of prematurely born children:
Prematurely bom children were recruited from Cardiff and Vale NHS trust and Gwent 
Healthcare NHS trust.
1. Cardiff and Vale NHS Trust
Two sources were used to identify children from Cardiff and Vale NHS trusts: Neonatal Unit 
Database at University Hospital of Wales, and Neonatal Outreach Team Register for all 
children who were followed up by Neonatal Outreach Team once they are discharged from 
the Neonatal Unit at University Hospital of Wales and Llandough Hospital.
204 children who were bom at <32 weeks gestational age between January 1996 to December 
1999, and cared for at the Neonatal Unit at University Hospital of Wales were identified by a 
Consultant Neonatologist (Dr Drayton) from the patient database which is maintained by the 
Neonatal Unit. A further 101 children who were bom at <32 weeks of gestational age at 
University Hospital of Wales or Llandough Hospital between January 1996 and December 
2001, who were followed up by the Neonatal Outreach Nursing Team were identified from 
the Neonatal Outreach Team register.
66
From the computer database, each child’s name, date of birth, gestational age at birth, 
duration of oxygen dependency was identified. The deceased children were identified from 
the hospital ‘Patient Management System- PMS’ programme.
Out of the 305 children (91 children with CLD, 214 children without CLD) who were 
identified, 31 (10%) children were excluded for the following reasons;
• 9 children were deceased (7 CLD, 2 without CLD)
• 7 had been diagnosed with congenital structural cardiac defects: 2 Pulmonary stenosis, 2 
atrial septal defect and ventricular septal defect, 1 Pulmonary atresia and 2 cardiomyopathy 
(1 CLD, 6 without CLD)
• 15 children resided outside South Wales
General practitioners for the remaining 274 children were contacted by telephone to ensure 
that the children are alive, and to confirm their home addresses prior to sending out the 
letters to the parents inviting the children to participate in the study.
• The current General Practitioner could not be located for 117/274 (43%) children.
Letters (Appendix C) were sent out by a Consultant Neonatologist (Dr M Drayton), to the 
parents of the remaining 157 children inviting the children to participate in the study, along 
with the information sheets for the parents (Appendix D) and for the children (Appendix 
E), and reply letter with a self addressed return envelope.
• 53/157 (34%) (25 CLD, 28 without CLD) children and parents agreed to participate in the 
study
• 16/157 (14%) (6 CLD, 10 without CLD) children/ parents declined to participate
• 87/157 (56%) parents did not reply
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2. Gwent Healthcare NHS Trust
In order to obtain the desired number of prematurely bom children to maintain the power of 
the study, 8 children (5 CLD, 3 without CLD) were recruited from Royal Gwent Hospital. 
Children who were bom at <32 weeks of gestational age, who were admitted in the Special 
Care Baby Unit at the Royal Gwent Hospital were identified from the admission register. 
Letters of invitation was sent out by a Consultant Neonatologist (Dr S Sen) at Royal Gwent 
Hospital to the parents of 23 children (10 CLD, 13 without CLD) out of which 5 did not agree 
to participate, 9 agreed to participate and were recruited. The others did not reply.
Recruitment of subjects for the term control group:
Four different sources were used to recruit term-born healthy children for the control 
population of the study.
1. Siblings/ friends of the participants in the preterm groups
All the parents of the prematurely bom children who agreed for their children to participate in 
the study were asked if the child had a term-born sibling or friend between the ages of 8-12 
who may want to participate in the study as a term control.
• 4 children in the term control group are siblings of children in the preterm groups
• 1 child in the term control group is a friend of a child in the preterm control group
2. Children who attended General Paediatric and Orthoptic Clinics at University 
Hospital of Wales
A research nurse (A Russell) attended the General Paediatric Clinics and Orthoptic Clinics at 
the University Hospital of Wales twice a week to identify children who were suitable for the
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study. If the parents of these children were interested in the study, they were given the 
information pack for the study, which included information sheets for the parents, information 
sheets for the children and reply letter with a self-addressed envelope.
• 8 children in the term control group were recruited from the clinics.
3. Children of Staff working in University Hospital of Wales and Cardiff University
Flyers were posted on various notice boards in the University Hospital of Wales and Cardiff 
University buildings at Heath site, inviting children between the ages of 8-12 years to 
participate in the study.
• 10 children in the term control group are the children of the staff from the University 
Hospital of Wales or Cardiff University, or the children of their friends and colleagues
4. Schools in Cardiff
Electronic flyers were distributed to nine Primary and Secondary schools in Cardiff who 
agreed to post the flyer in their school websites.
• 7 parents responded to the flyer, out of which 5 participated in the study
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Figure 2.1. Flow chart showing recruitment of prematurely bom children
60 attended for the cardiac tests62 attended for the pulmonary 
Amction tests
32S children identified
20 (11%) declined
9 were deceased 
117, unable to trace
22 were excluded
87 (49%) did not respond
179 invited ta paxiici-  ^
pate
62 (354b)agxeed ta partici­
pate
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2.2.2 H istory an d  general exam ination
For the prematurely bom infants, their neonatal history including exposure to antenatal and 
postnatal steroids, surfactant therapy, gestational age at birth, birth weight, treatment with 
oxygen and mechanical ventilation, age and weight at discharge were all obtained from the 
hospital case notes and/or hand-held neonatal records. The birth weight and gestational age at 
birth for the term-born controls were obtained from the hand-held neonatal records. Case 
notes for 2 preterm children could not be traced.
The parents of all the participants completed a history proforma that included questions 
regarding family history of parental smoking, atopy, respiratory and cardiac conditions as 
well as the child’s history of atopy, asthma, respiratory and cardiac conditions and self 
assessment of physical activity. The proforma for the medical history is in Appendix B.
2.2.3 P hysio log ical m e asu re m e n ts
Height and weight were measured using a Stadiometer and a balance scale (Weylux, Model 
424, UK). Blood pressure, pulse rate and oxygen saturation were measured using a Dynamap 
Procare monitor (GE Healthcare, UK). The children had 10-15 minutes rest prior to the 
measurement of these parameters.
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2.2.4 Urinary co tin ine
A 10-20 ml urine sample was obtained in a sterile container. The urine sample was 
immediately divided into 3 individual containers and stored at -80° centigrade.
The samples were analysed in batches of 44. The urine samples were defrosted in the water 
bath at 36° centigrade before being analysed. The samples were tested for ‘Urinary Cotinine’, 
using Urine Cotinine Enzyme Immunoassay (Cozart EIA Cotinine Urine Kit, M155U1). Each 
sample was tested in duplicate using the following method;
• 10 pL of sample was added to each well
• 100 pL of Cotinine Enzyme was added into each well
• The 96 well plate with sample and enzyme was incubated at room temperature for 30 
minutes
• The plate was washed four times with 300 pL of Wash Buffer
• 100 pL of Substrate Solution was added to each well and incubated for 30 minutes at room 
temperature
• 100 pL of STOP Solution was added to each well
• The absorbance was measured at 450 nm immediately
Urinary cotinine level was measured in 85 (92%) children to assess level of exposure to 
smoking. 6 children did not provide the urine sample.
2.2.5 Pulm onary  function  te s ts
The ‘Pulmonary function tests’ were carried out in the ‘Physiological Assessment Suite’ at 
Glyntaff Campus, University of Glamorgan in Pontypridd. The study comprised of
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• Baseline spirometry
• Measurement of alveolar diffusion capacity of carbon monoxide using a single breath 
helium dilution test
• Measurement of static lung volumes using whole body plethysmography
• Exercise test using bicycle ergometry
• Post exercise spirometry
• Reversibility test with inhaled p2 agonist (Salbutamol)
2.2.5.1 Spirometry 
Baseline spirometry
Prior to the spirometry tests, I explained and demonstrated the forced expiratory methods to 
the children. The children had the opportunity to practice the manoeuvre using an animated 
programme (Flow screen, Viasys Healthcare Gmbh, Hoechberg, Germany) until they were 
comfortable with it and I was satisfied with the child’s technique.
Baseline spirometry was carried out in a whole body plethysmograph (Mastersceen, Jaeger, 
Germany) (Figure 2.2). All the equipments were calibrated using the manufacturer’s (Jaeger) 
instructions each morning after adjustment for ambient conditions. Volume and measures of 
flow rate were calibrated using a certificated 3 litre syringe, and gas concentrations set against 
certificated cylinders of known concentration. The equipment was serviced before the study 
began by the manufacturers.
The test was carried out with the child in sitting position and with nose clip in place and the 
body box door kept open. The subjects were instructed to place their lips around the
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mouthpiece of the pneumotachometer so that the air did not leak around the mouthpiece when 
breathing. They were then instructed to take the deepest breath possible and blow out as hard 
and as fast as they could for as long as possible. The absolute values for FEVi, FVC, FEF 25-75 
and PEF along with % predicted values based on age, gender, and heights were calculated. 
Each child performed at least three to five spirometric tests and at least three reproducible 
manoeuvres as per the European Respiratory Society, ERS recommendations (Miller 2005). 
The reproducibility was assessed by visually observing the flow volume curves and also by 
ensuring that the differences in the FVC and FEVi between the manoeuvres were within 5%.
Post-exercise spirometry
Following the exercise test on bicycle ergometry as described in section 2.2.5.4, the children 
underwent a series of spirometry tests at 5 minutes, 10 minutes, 15 minutes, 30 minutes and 
40 minutes after the exercise was stopped at peak V 02. At each stage, they performed at least 
three spirometric manoeuvres with at least two reproducible and acceptable tests.
Reversibility test
Inhaled bronchodilator (Salbutamol) was delivered as 4 doses of 100 microgram puffs using a 
paediatric aerochamber with a mask (Figure 2.5). The children were asked to take 10 normal 
breaths through the aerochamber in between the puffs. Spirometry was repeated soon after 
inhalation of the last dose of Salbutamol and after 15 minutes, to test for evidence of 
reversible airway disease. Reversibility was defined as improvement in FEVi of >10% after 
bronchodilator therapy (Quanjer 1993).
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2.2.5.2 Carbon monoxide diffusion capacity
A single breath method for measuring the diffusion capacity of lungs has been most widely 
used and validated. Both the ERS and the ATS documents for recommendations for a 
standard technique for measuring DLco (Cramer 1993; ATS 1995) propose the use of single 
breath method for this purpose. Therefore, I used the single breath method to study the 
alveolar diffusing capacity of lungs in the subjects in my study.
MS-PFT analyzer unit (Jaeger, Germany) was used to measure DLco in this study (Figure 
2.3). The participants were seated in a comfortable chair in upright position. A nose clip was 
used in all participants. After 4-5 tidal breaths, the participants were instructed to expire to 
residual volume (RV) followed by deep inspiration to total lung capacity (TLC). As soon as 
they reached the maximal inspiration, they were asked to hold the breath at TLC for 10 
seconds. The countdown was visible on the screen for the benefit of both the participant and 
the investigator. The children then continued expiration and tidal breathing until the analyser 
signalled the end of test.
All subjects were trained prior to the actual tests using the ‘training mode’ to avoid inhalation 
of carbon monoxide during the training period. The tests were started only when the subject 
and I were both satisfied with the technique. At least three consecutive tests were performed 
on all subjects with 4 minutes of interval between the manoeuvres to allow carbon monoxide 
to wash out and to avoid the carbon monoxide back-pressure due to formation of 
carboxyhaemoglobin. For the same reason, the tests were not repeated more than 5 times. The 
subjects were seated during the intervals in between the manoeuvres.
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2.2.5.3 Static lung volumes
Static lung volumes were measured by whole body plethysmography method using a body 
box (Jaeger Masterscreen Plethysmograph, Jaeger, Hoechberg, Germany). The tests were 
explained to the child in detail including the fact that the door of the body box would be 
closed. The child was then seated in the chair inside the body box and the height adjusted so 
that the child’s neck was not hyperextended or flexed while breathing through the mouth 
piece. The child was then instructed on how to breathe through the mouthpiece, and to breathe 
against the shutter when the shutter is closed. This manoeuvre was demonstrated by asking 
the child to breathe through one end of the mouthpiece while briefly closing the other end by 
hand to replicate shutter closure. Once the child and I were both satisfied that the child had 
understood the procedure, the door of the body box was closed. After 1-2 minutes of waiting 
time to maintain the temperature equilibrium inside the body box, the child was then asked to 
breathe normally at the rate of 15-20 breaths per minute. Once tidal volume breaths were 
maintained, specific airway resistances (SReff) and effective resistance (Reff) measurements 
were performed with at least 5 consecutive loops established. Immediately after the SReff 
measurements, the shutter was closed and the child was instructed to breathe in and out 
against the shutter to measure FRC. This was repeated at least 3 times to obtain at least 2 
satisfactory tests. After the final occlusion, the child was asked to inspire maximally, followed 
by maximal expiration and then full inspiration to measure vital capacity (VC), total lung 
capacity (TLC) and residual volume (RV). The door of the body box was closed and the nose 
clip was used throughout the test.
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2.2.5 A  Cardiopulmonary exercise testing
Maximal exercise capacity was measured using an incremental symptom limited bicycle 
ergometer test using electrically braked cycle ergometer (Jaeger, Germany) by a fellow 
researcher, T Powell and me (Figure 2.4). Pedalling was started on an unloaded cycle, and 
then every 3 minutes thereafter the load was incremented by 30W until volitional exhaustion 
or until the heart rate reached 80-90% of the predicted maximum (220-age in years). Pedalling 
cadence was held at approximately 60 rpm. Children were verbally encouraged to cycle as 
long as possible. Heart rate was monitored throughout the exercise test using a telemetric 
monitor (Polar t31, Polar Electro Inc, UK). The mouth-piece was connected to a computerised 
O2/CO2 breath-by-breath analysis system (Jaeger MS-CPX, Germany). The test was 
considered to be acceptable if at least 2 of the following 4 criteria were met;
• Maximum heart rate >80% of predicted maximum
• Respiratory exchange ratio> 1
• VO 2 Plateau was reached
• Volitional exhaustion as assessed by Borg’s scale
Peak oxygen uptake at peak exercise (V 0 2), carbon dioxide output (V C 02) and minute 
ventilation (VE) were calculated as a mean from the final 15 seconds of exercise. Maximum 
voluntary ventilation (MVV) was calculated as baseline FEVi x 35 (Stein 2003). Ventilatory 
reserve (VR) was calculated as (1 -  peak VE/MVV) x 100% (Medoff 1998).
77
Figure 2.2 Photograph o f  a child performing a spirometry test
A child  inside the body-box  perfo rm ing  a sp irom etry  test 
(A w ritten parental consent and the assen t from  the child  w as obtained for the publication  o f  
th is im age)
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Figure 2.3 Photograph o f  a child performing a ‘single breath test’
A child  perform ing a ‘S ingle-breath  te s t’ fo r m easurem ent o f  alveo lar diffusion capacity  
(A w ritten parental consent and the assen t from  the child  w as ob tained for the publication  o f  
th is im age)
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Figure 2.4 Photograph o f  a child perform ing a ‘cardiopulmonary exercise test’
A child perform ing ‘ca rd iopu lm onary  exercise te s t’ using a b icycle ergom eter.
(A w ritten parental consen t and the assen t from  the child  w as obtained for the publication  o f  
this im age)
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Figure 2.5 Photograph o f  a child  having bronchodilator medication using a spacer device
S albu tam ol adm inistered  using a  spacer device 
(A  w ritten  parental consen t an d  the assen t from  the child  w as ob ta ined  for the publication  o f  
th is im age)
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2.2.6 S ta tis tica l m e th o d s
2.2.6.1 Sample size
I aimed to study 90 subjects (30 CLD, 30 preterm controls and 30 term controls) to give 80% 
power and p<0.05 to detect 30% difference in FEVi between preterm children with CLD and 
term-born controls.
2.2.6.2 Statistical analysis of data
Data are given as mean ± standard deviation, SD. Differences between groups were tested by 
ANOVA with Tukey’s posthoc analyses. Multiple linear regression modelling used 
haemoglobin corrected DLco, total exercise time and ventilatory reserve as dependent 
variables and perinatal factors including gestational age, oxygen duration in the neonatal 
period and days of mechanical ventilation as explanatory variables and adjustments were 
made for age, gender and height or body mass index (BMI) as appropriate. p<0.05 was 
considered significant. SPSS 16.0 (SPSS Inc., Chicago, IL) was used to perform analyses.
2.2.7 E thical approval
‘South East Wales Regional Ethical Committees’ gave ethical approval for this study on 10 
October 2007. (Reference: 07/WSE03/77)
Written informed consent from parents (Appendix F) and assent from children (Appendix G) 
were obtained prior to the study.
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2.3 Results
2.3.1 B ase line  c h a ra c te r is tic s
I studied 92 children, 29 CLD, 33 preterm control and 30 term-born controls with one CLD 
re-classified into the preterm control group after detailed review of the patient’s neonatal 
records. Characteristics of the population studied are given in Table 2.1 and reported 
symptoms in Table 2.2. As expected, the CLD group was significantly more immature and 
had a lower mean birth weight than the preterm or term groups. They also received 
mechanical ventilation and oxygen therapy for longer. All infants in the CLD group had 
received exogenous surfactant compared to 45% in the preterm group and none in the term 
group. The weight at the time of lung function was significantly lower in the CLD group 
compared to the preterm and term groups but height and body mass index (BMI) were not 
statistically different between the groups.
Doctor diagnosed asthma and exercise-induced wheeze were reported more frequently in the 
CLD group compared to the preterm and term groups (Table 2.2). Whilst reporting of dry 
cough at night and current asthma treatment were greater in the CLD group, this difference 
did not reach statistical significance. Self-reported physical activity was significantly less in 
the CLD group compared to the other two groups.
Parents also reported the respiratory symptoms of the children by completing a questionnaire. 
39% (24/62) of prematurely bom children had been diagnosed with asthma at some stage in 
life. The prevalence was similar in preterm children with or without CLD (45% vs. 33%), but 
only 4/30 (13%) of the term bom children had ever been diagnosed with asthma. Similarly, 
42% (26/62) of preterm children had parents and/or siblings with asthma whereas family
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history of asthma was reported in only 11% (3/30) term-born children. None of the term-born 
children were symptomatic within the 12 months prior to the study, whereas 31% (9/29) of 
children with CLD and 28% (9/33) of preterm children without CLD were symptomatic with 
some form of chronic respiratory symptom, and 10(6,  CLD and 4, preterm control) of them 
continued to use inhalers for asthma. Significantly more parents of the prematurely bom 
children were reported to be smokers (41% CLD, 47% preterm control) compared to the term- 
born controls (11%).
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Table 2.1. General characteristics of the subjects (Pulmonary function study)
Parameters CLD
(n=29)
Preterm control 
group 
(n=33)
Term group 
(n=30)
p-value
Demographics
Male gender 17 (59%) 15 (46%) 15 (50%)
Gestation (weeks) 27.3 (2.1) 30.0 (2.0) 39.8(1.5) §,§§
Birth weight (kg) 1.1 (0.4) 1.5 (0.4) 3.4 (0.5) §,§§
Age (years) 10.2(1.4) 10.3(1.1) 10.5(1.5)
Height (cm) 137.1 (9.6) 140.9 (9.0) 143.2(11.0)
Weight (kg) 32.1 (8.2) 37.3 (10.9) 39.6(13.7) tt
Basal metabolic index (kg m'2) 16.3 (3.2) 17.6 (3.8) 17.9 (4.6)
Antenatal and postnatal 
respiratory status
Antenatal steroids 24 (83%) 20 (61%) None
Postnatal steroids 9 (32%) 1 (3%) None t
Surfactant 29 (100%) 15 (45%) None §
Supplemental oxygen (days)* 84 (30-410) 4(0-61) None §
Assisted ventilation (days) * 28 (5-80) 3(0-50) None §
Results are expressed in Mean (SD) unless otherwise specified, *Median (range),
5 p<0.001 (CLD vs. preterm control),§§ p<0.001 (CLD vs. term),tf p <0.05 (CLD vs. term), 
* p<0.01 (CLD vs. preterm control)
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Table 2.2. Prevalence of parent reported respiratory symptoms and measured urine cotinine 
levels
CLD
(n=29)
Preterm control 
group
(n=33)
Term group 
(n=30)
p value
Asthma ever (Doctor diagnosed) 13 (45%) 11 (33%) 4(13%) t
Current asthma on treatment 
(Past 12 months)
3 (10%) 4 (12%) Nil
Exercised induced wheeze 
(Past 12 months)
5(18%) 2 (6%) Nil t
Dry cough at night (Past 12 months) 9(31%) 9 (28%) 1 (4%)
Eczema ever 7 (24%) 12 (36%) 9 (32%)
Eczema (Past 12 months) 4(14%) 6(19%) 4(14%)
Family history of asthma 11 (38%) 12 (36%) 9 (32%)
Family history of eczema 10 (35%) 12 (36%) 11 (39%)
Family history of hay fever 9(31%) 18 (55%) 16 (57%)
Parental smoking 11 (41%) 15 (47%) 3(11%) t
Self-reported physical activity 
per week (hours)*
2.0 (0-24) 3.0 (0-10) 3.5 (0-24) tt
Urine cotinine (ng/ml)* 11.3 (7.6-74) 19.6 (0-186.8) 12.3 (0-104.2)
Results are expressed in Count (%) or Mean (SD) unless stated otherwise. * Median (Range) 
+ Pearson’s Chi square significance p<0.05, * Pearson’s Chi square significance p<0.01, 
**p<0.05 (CLD vs. preterm control, CLD vs. term)
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2.3.2 Urinary cotinine
Mean urinary cotinine levels were 22.6, 38.7 and 19.6 nanograms/ml in the CLD, preterm 
control and term control groups respectively. Urinary cotinine is considered to be ‘not 
detected’ if the level is <10 nanograms/ml. Levels of 10-14 nanograms/ml is considered to 
signify low exposure, 15-40 nanograms/ml as moderate exposure and >40 nanograms/ml as 
heavy exposure to tobacco smoking. Taking this into account, the level of exposure to tobacco 
smoking in different groups are summarised in table 2.3
Table 2.3. Levels of exposure to tobacco smoking
Cotinine not 
detected
Low
exposure to
tobacco
smoke
Moderate 
exposure to 
tobacco 
smoke
High
exposure to
tobacco
smoke
CLD 8 (28%) 14 (48%) 2 (7%) 5 (17%)
Preterm control 7 (22%) 4(13%) 14 (44%) 7 (22%)
Term control 8 (30%) 11 (41%) 4(15%) 4(15%)
The mean difference of urinary cotinine levels were not statistically different between the 
groups although when split into different categories, more children in the preterm control 
group seem to have been exposed to moderate level of exposure to tobacco smoking than the 
other two groups.
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2.3.3 Pulmonary function tests
2.3.3.1 Spirometry
All reported results from the forced spirometry manoeuvre are the best out of 3 reproducible 
measurements. The measurements were considered to be reproducible if they were within 5% 
of each other. The best measurements for FEV i, FVC, FEF25-75 and PEF are reported, 
although they may be from different tests.
All 92 participants were able to perform the manoeuvre for baseline spirometry with at least 3 
reproducible and acceptable measurements. As some of the children were unable to perform 
the exercise test successfully as mentioned in section 2.3.3.4, there are some missing data for 
the post-exercise spirometry series.
The results of the baseline spirometry are summarised in Table 2.4. Baseline FEV i, FEF25.75 
and PEF were significantly lower in the CLD group when compared to the preterm and term 
control groups. Although the preterm control group had lower values, they were not 
statistically different from the term group. 13 (45%), 6 (18%) and 1 (3%) respectively from 
the CLD, preterm control and term groups had a predicted FEVi of <80%.
Following maximal exercise, FEVi decreased from baseline by 10.6% (95% Cl 6.6 to 14.7%, 
p<0.012) in the CLD group compared to 7.4% (4.1 -  10.6%, p=ns) and 6.9% (3.5 -  10.4%, 
p=ns) decrease in the preterm control and term control groups (Figure 2.6) respectively. After 
bronchodilator was given 45-60 minutes after exercise, post-exercise FEVi improved by 
15.1% (95% Cl 10.9 -  19.3%, p<0.001) in the CLD group and by 8.5% (4.4 -  12.6%, p=ns) 
and 5.6% (2.4 -  8.7%, p=ns) in the preterm control and term groups (Figure 2.6). After 
bronchodilator therapy, FEVi remained lower in CLD children when compared to preterm
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(-6.2%, 95% Cl -16.2 to 3.8%, p=ns) and term (-9.9%, -19.6 to -0.2%, p=0.043) groups.
FVC did not alter with bronchodilator therapy in the CLD group whereas it decreased in the 
control groups but remained >90% predicted in both the preterm and the term control groups.
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Table 2.4 Results for the baseline spirometry
CLD
(n=29)
Preterm control
(n=33)
Term
(n=30)
p value 
(ANOVA)
FEV,
Measured (L) 
% Predicted
1.5 (0.37) 
81.9(12.6)
1.8 (0.44) 
92.0(14.2)
2.1 (0.47) 
97.5(11.6) <0.001*’§§
FVC
Measured (L) 
% Predicted
2.2 (0.51) 
98.9(1.1)
2.3 (0.47) 
100.8(11.3)
2.5 (0.60) 
102.0 (2.8) 0.600
FEF 25-75
Measured (L) 
% Predicted
1.2 (0.44) 
49.2(16.1)
1.8 (0.85) 
69.2 (24.6)
2.1 (0.64) 
80.0(17.1) <0.001*’§§
PEF
Measured (Lmiri1) 
% Predicted
2.9 (0.98) 
71.6(19.5)
3.6(1.1) 
82.2(17.5)
4.2 (1.1) 
90.8(16.7) <0.001§§
Results are expressed in Mean (SD).
* p <0.01 (CLD vs. preterm control),§§ p<0.001 (CLD vs. term control),
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Table 2.5 Spirometiy after exercise and bronchodilator therapy
Post-exercise Post-bronchodilator
Variables Groups Baseline 5 minutes 10 minutes 15 minutes 30 minutes 40 minutes 0 minutes 15 minutes
FEVI (%) CLD
PT
Term
81.9(12.6)
92.0(14.1)
97.5(11.7)
79.3(14.1)
88.7(16.4)
95.5(12.9)
77.4(14.1)
87.5(17.3)
95.4(13.6)
78.8(14.1)
90.4(14.3)
95.6(12.1)
76.6(14.6)
88.2(15.7)
94.7(12.9)
78.0(13.0)
89.3(16.1)
94.8(12.8)
84.4(11.7)
89.7(17.3)
96.7(12.4)
85.8(11.5)
92.1 (17.1)
97.1 (13.8)
FVC (%) CLD
PT
Term
98.9(11.1)
100.8(11.3)
102.0(12.8)
94.4(12.4)
98.6(12.8)
100.9(13.4)
92.6(11.9) 
98.3 (12.8) 
100.0(13.1)
94.8(10.9)
99.0(11.9)
99.5(14.3)
92.2(14.1)
97.0(12.6)
99.8(12.5)
92.7(11.5)
97.4(14.7)
99.3(13.5)
93.6(12.4)
97.5(11.8)
99.6(12.6)
94.0(15.6)
97.3(11.4)
99.2(11.6)
PEF (%) CLD
PT
Term
71.6(19.5) 
82.2(17.5) 
90.8 (16.7)
68.7(17.5) 
81.5(19.6) 
89.1 (19.2)
68.0(17.6)
80.6(19.8)
91.5(18.0)
71.4(18.8)
80.4(19.70
91.9(17.0)
73.3 (20.6) 
85.6 (22.3) 
91.5(18.9)
76.1 (20.2)
85.1 (23.7) 
88.9 (23.6)
80.1 (21.1) 
85.1 (23.9) 
92.7 (20.5)
84.2 (20.1) 
89.7 (24.4) 
92.0 (23.4)
FEF 25-75 
(%)
CLD
PT
Term
49.2(16.2) 
69.2 (24.6) 
80.0(17.1)
50.4 (22.2) 
67.0 (26.9) 
75.6 (21.7)
48.5(19.7) 
65.8 (25.1) 
78.8(19.3)
48.1 (19.0) 
68.7 (26.0) 
76.7(16.3)
49.2 (21.3) 
67.7 (28.3) 
76.5(18.1)
49.3 (20.1) 
70.2 (28.2) 
77.8 (20.7)
61.1 (23.4) 
72.0 (28.0) 
83.6 (20.5)
64.5 (22.8)
77.9 (28.1)
85.9 (24.2)
Results are expressed in Mean (SD) for % predicted values
Figure 2.6 Percent predicted FEVi at baseline, after exercise and 15 minutes after 
bronchodilator therapy
100
90
80
70
Baseline Lowest Post 15 Minutes
Exercise
After exercise, FEVi decreased by 10.6% in the CLD group compared with 7.4% in the preterm 
and 6.9% in the term control groups. FEVi increased by 15.1% in the CLD group from the post­
exercise FEVi but the increases of 8.5% and 5.6% were not significant in the preterm and term 
groups after bronchodilator therapy. * p<0.12 and p<0.001 in the CLD group between the 
baseline and post-exercise FEVi and between the post-bronchodilator FEVi and post-exercise 
FEVi respectively.
Symbols: chronic lung disease, CLD (o ) ,  preterm controls (•), term controls ( )
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2.3.3.2 Carbon monoxide diffusion capacity
Out of the 92 children who were recruited for the study, ‘Single breath test’ was performed on 
87 children. The test could not be performed on 5 subjects due to equipment failure. Out of 
the 87 children who performed the ‘Single breath test’, 3 did not meet the acceptability 
criteria. Therefore, 84 children successfully completed the test.
The test was repeated a minimum of 3 times and a maximum of 5 times to document at least 2 
acceptable measurements. Following the ATS guidelines, the average of the two most 
acceptable tests that meet the reproducibility requirement of ± 10% of the average DLCO are 
reported.
64 out of 92 subjects (70%) had their haemoglobin concentration measured using a finger 
prick method and analysed by a blood gas analyser (ABL 735, Radiometer, Copenhagen). The 
average haemoglobin was 13.8 (12.4 - 15.3) for CLD group, 13.6 (11.4 - 15.2) for the preterm 
control group and 13.1 (11.9 - 14.3) for the term control group. The average haemoglobin for 
each group of subjects was used to complete the missing data on 30% of the subjects who did 
not consent for the blood test. DLco was adjusted for haemoglobin using the equation 
recommended by the American Thoracic Society (ATS 1995); haemoglobin adjusted DLCO= 
observed DLCO (9.38 + haemoglobin)/1.7 * haemoglobin.
Haemoglobin adjusted D lco was significantly different between the groups [p<0.05 between 
CLD, 4.8 (95% Cl, 4.5 to 5.2) mmol/min/kPa and preterm control group, 5.5 (95% Cl, 5.1 to 
5.6) mmol/min/kPa, and p<0.05 between CLD and term group: 5.5 (95% Cl, 5.1 to 6.0) 
mmol/min/kPa]. However, predicted haemoglobin adjusted Dlco was significantly decreased 
in the CLD children compared to the preterm group but not the term group. Thus, I used 
linear regression modelling to assess which factors including perinatal ones may have affected
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haemoglobin adjusted Dlco- Unsurprisingly, height (p<0.001), age (p=0.002) and gender 
(p=0.001) were significantly associated with a lower D lco as was duration of oxygen 
dependency (p<0.05) after adjustment for age, gender and height but not gestational age.
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Table 2.6 Results of the ‘Single breath test’ for alveolar diffusion capacity
CLD
(n=26)
Preterm control 
(n=32)
Term
(n=26)
p-value
(ANOVA)
DLco (mmoI-'min^kPa)
Measured 
% predicted
4.9 ±0.81 
89.1 ± 10.8
5.5 ± 0.97 
96.3 ± 10.6
5.5 ± 1.2 
92.8 ± 12.7 0.059
DLco adjusted for Hb 
(mmol-lmm'lkPa)
Measured 
% predicted
4.8 ±0.81 
88.0 ± 10.7
5.5 ± 1.0 
95.9 ± 11.3
5.5 ± 1.2
93.5 ± 12.1 0.033f
KCO
Measured 
% predicted
1.8 ±0.26 
75.4 ± 11.4
2.1 ±0.25
90.1 ± 13.6
2.0 ± 0.36 
89.3 ±15.8 <0.001§§§
KCO adjusted for Hb
Measured 
% predicted
1.8 ±0.27 
74.6 ±11.9
2.1 ±0.26 
89.7 ± 13.9
2.0 ± 0.35
90.0 ± 15.5 <0.001§§§
VA(L)
Measured 
% predicted
2.8 ±0.51 
115.4 ± 17.3
2.7 ± 0.45 
106.5 ± 16.1
2.8 ± 0.75 
105.3 ± 17.5 0.064
Results are presented as Mean (SD)
* p<0.05 (CLD vs. preterm control)
5p<0.001 (CLD vs. preterm control),§§ pO.OOl (CLD vs. term)
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Figure 2.7 Bar diagram  show ing  differences in the percent predicted  D Lco corrected for 
haem oglobin, betw een groups.
D ata are presented as m ean %  predicted  values and the error bars represent SD
Figure 2.8 Bar d iagram  show ing differences in the percent p redicted  K C O  corrected  for 
haem oglobin, betw een groups.
* 120 -
p < .0 0 15  100
D ata are presented as m ean % predicted  values and the  error bars represent SD
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2.3.3.3 Static lung volumes
The resistance measurements are presented as a mean of 3-5 acceptable measurements. The 
measurements were included only if they were within ± 10% of the mean. Similarly, the 
reported lung volumes are also the mean of 2-3 acceptable measurements that are within ± 
10% of the mean. The vital capacity (VC) manoeuvre was performed only once at the end of 
the test.
All 92 children who participated in this study underwent the whole body plethysmography 
test. Out of them, 1 child from the CLD group and 1 child from the term control group were 
unable to perform the manoeuvre correctly. Therefore, the following results are from the 
remaining 90 participants. FRCne, which was measured using ‘Single breath He test’ while 
measuring the DLco, could be performed on only 87 children. Out of these, only 84 children 
were able to perform the manoeuvre satisfactorily.
Children with CLD had a significantly higher specific airway resistance (SReff) than the 
children in the preterm control group (mean difference 61%, 95% Cl 10% to 111%, p=0.014) 
and the children in the term control group (mean difference 104%, 95% Cl 52% to 156%,
p<0.001).
Functional residual capacity measured by plethysmography (FRCpieth) and by single breath 
test (FRCHe) was higher in the children with CLD compared to both the control groups. The 
difference in FRCpieth between the CLD and preterm control group was 21% (95% Cl 5% to 
37%, p=0.005), and that between the CLD and the term group was 27% (95% Cl 11% to 
43%, p<0.001). Similarly, the difference in the FRCne between the CLD and the preterm 
control group was 21% (95% Cl 11% to 43%, p=0.015), and that between the CLD and the 
term control group was 24% (95% Cl, 6% to 42%, p=0.006).
97
Residual volume (RV) was higher in the children with CLD compared to both the control 
groups. RV was 28% higher in the children with CLD compared to the preterm control group 
(95% Cl 4% to 53%, p = 0.020) and 35% higher than the term control group (95% Cl 9% to 
60%, p=0.005). Total lung capacity (TLC) and vital capacity (VC) were similar in all three 
groups of children, but RV: TLC ratio was significantly higher in the CLD group compared to 
the term control group (mean difference 0.08, 95% Cl 0.02 to 0.13, p=0.002).
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Table 2.7 Results of the static lung volumes measured by body plethysmography
CLD 
(n=28 )
Preterm control 
(n=33 )
Term 
(n=29 )
p value 
(ANOVA)
SReff (kPa.sec) Measured 
% predicted
1.4 (0.56) 
253.4(103.1)
1.0 (0.45) 
192.6 (85.7)
0.78 (0.28) 
149.4 (52.6) 0.001*’§§
Reff (kPa.sec.L1) Measured 
% predicted
0.69 (0.27) 
243.3 (93.2)
0.58 (0.31) 
210.5(121.7)
0.45 (0.17) 
171.0 (63.3) 0.021ft
FRC pieth (L) Measured 
% predicted
1.8(0.54) 
120.6 (38.7)
1.6 (0.31) 
99.4(16.0)
1.5 (0.37) 
93.8(18.3) <0.001*’§§
FRC He (L) Measured 
% predicted
1.6 (0.40) 
114.6 (32.9)
1.4 (0.41) 
93.9 (25.9)
1.4 (0.49) 
90.5 (21.9) 0.004*’**
FRC pieth: FRC He
Measured 
% predicted
1.2 (0.49) 
1.1 (0.47)
1.3 (0.72) 
1.2 (0.67)
1.2 (0.49) 
1.1 (0.48)
0.787
0.743
RV (L) Measured 
% predicted
1.1 (0.43) 
131.6 (55.6)
0.86 (0.31) 
103.2 (32.4)
0.83 (0.26) 
96.9 (29.7) 0.004*’**
TLC (L) Measured 
% predicted
3.1 (0.72) 
104.9 (20.9)
2.9 (0.56) 
96.7 (14.9)
3.1 (0.68) 
99.0 (12.0) 0.144
RV:TLC
Measured 0.34 (0.09) 0.29 (0.09) 0.27 (0.07) 0.003**
VC (L) Measured 
% predicted
2.0 (0.45) 
89.9(12.3)
2.1 (0.41)
92.1 (12.7)
2.3 (0.55) 
94.7 (13.4) 0.362
Results are presented as mean (SD),
* p<0.05 (CLD vs. preterm control),+t p<0.05 (CLD vs. term)
* p<0.01 (CLD vs. preterm control), ** p<0.01 (CLD vs. term),§§ pO.OOl (CLD vs. term)
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2.3.3.4 Cardiopulmonary exercise tests
Out of the 92 children who attended for the pulmonary function tests, 4 children (2 CLD, 1 
preterm controls, 1 term) were too short for cycle ergometry test. 8 children (3 CLD, 3 
preterm controls and 2 term controls) did not meet the study criteria and were therefore 
excluded. Further 2 children (1 preterm control, 1 term) were unable to do the 
cardiopulmonary exercise test, CPET due to equipment failure and 2 children from the 
preterm control group missed the cardiopulmonary exercise test for other reasons (1 was 
temporarily on crutches and 1 missed the test due to time constraint). Thus, there are missing 
data for 16 children (5 CLD, 7 preterm controls and 4 term).
The results for the cardiopulmonary exercise tests are shown in Table 2.8. Baseline heart rate, 
respiratory rate and oxygen saturations were similar between the groups. Peak V 0 2, VC02 
and VE were similar in the three groups. Duration of exercise was decreased in the CLD group 
but failed to reach statistical significance (p=0.085). Since a range of obstructive lung disease 
was observed in the CLD and preterm groups, I used linear regression modelling to assess if 
length of exercise was affected by perinatal factors. After adjusting for age, height and 
gender, only length of oxygen dependency was significantly associated with exercise 
duration. Maximum voluntary ventilation (MVV) and ventilatory reserve (VR) were both 
markedly decreased in the CLD group when compared to the preterm and term control groups 
(Figure 2.9A) with the latter being 25.8% (95% Cl: 19.7 to 31.9) compared to 37.5% (32.2 to 
42.8) in the preterm control and 43.7% (38.6 to 48.7) in the term control groups. Linear 
regression modelling was used to assess if the VR was associated with any perinatal factors 
including gestational age at birth, length of oxygen dependency and length of mechanical 
ventilation after correction for age, gender and height. VR was significantly associated with 
haemoglobin adjusted Dlco and gestational age after correction for age, gender and height.
The relationships between VR and gestational age and Dlco are shown in Figure 2.9B and
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2.9C. VR was also closely correlated to maximum respiratory rate after maximal exercise, 
peak V 02 and with load per Kg at maximum exercise.
1 0 1
Table 2.8 Results of the ‘cardiopulmonary exercise test’
Variable CLD
(n=24)
Preterm control 
(n=26)
Term
(n=26)
p value 
ANOVA
Baseline oxygen saturation (%) 99.1 (0.98) 99.5 (0.71) 99.2 (0.91) 0.178
Baseline respiratory rate 
(per minute)
25.3 (7.2) 27.4 (6.5) 25.6 (5.9) 0.412
Maximum respiratory rate 
(per minute)
53.8(11.3) 52.5(11.9) 48.1 (11.6) 0.189
Baseline heart rate 
(per minute)
80.5(10.9) 77.5(13.1) 77.9(10.5) 0.553
Maximum heart rate 
(per minute\)
175.3 (9.1) 178.7(8.9) 171.4(15.9) 0.090
Exercise duration (seconds) 554(100) 614(133) 625(120) 0.085
Load (Watts) 78.8(17.3) 84.4 (23.1) 83.2 (20.9) 0.421
VOz max (ml.kg.min'1) 35.4 (5.7) 34.9 (7.2) 31.1 (8.3) 0.073
VC02 max (ml.kg.min1) 37.2 (7.3) 36.9 (9.2) 32.6 (9.9) 0.125
RER 1.04 (0.06) 1.05 (0.09) 1.07 (0.06) 0.232
Peak VE (L min'1) 40.7 (7.8) 41.0 (8.6) 40.9 (8.2) 0.991
M W  (L min'1) 54.1(12.9) 64.7(15.5) 72.0(16.3) <0.001T,§§
VR (L min -1) 25.8 (14.4) 37.5(13.2) 43.7(12.6) <0.0011’
Borg’s scale 16.2 (3.6) 14.6 (4.0) 15.6 (2.6) 0.311
Results are expressed in mean (SD)
+ p<0.05 (CLD vs. preterm control),§§ p<0.001 (CLD vs. term control), 
* p< 0.01 (CLD vs. preterm control)
1 0 2
Figure 2.9 Scatter plot show ing ventilatory reserve in different groups and its relationship 
w ith gestational age and alveolar d iffusion capacity
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(A) M ean ±  95%  confidence intervals for ventilatory reserve (V R ) are show n for subjects 
with chronic lung disease, preterm  group and term  controls. p<0.01 (C LD  vs. preterm  control) 
and p<0.001 (CLD  vs. term ). Relationships are show n betw een ventilatory reserve and (B) 
gestational age (r2=0.45, p<0.001) and (C )  haem oglobin adjusted D l Co  (r2=0.49, p<0.001). 
Symbols: chronic lung disease, CLD  (o ), preterm  ( • ) ,  term  controls ( )
103
Figure 2.10 Scatter plot showing relationship between ventilatory reserve and maximum
respiratory rate during exercise, maximum load and peak VO2
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Figure 2.11 A proposed model showing relationships between ventilatory reserve, alveolar
diffusion capacity and exercise duration with other lung function parameters and possible
influences o f  perinatal factors
O, duration
Load Kg
Exercise
Time
FEV. Age
Venti atory 
Reserve
VE >
HeightHeight
DLco.
Age
Gestational
Age CLD Gender
0 2 durationCLD
A bbreviations: CLD  =  chronic lung disease, F E V i=  forced expiratory volum e in 1 second, 
VE =  m inute ventilation, O 2 duration =  duration o f  oxygen dependency in infancy.
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2.4 Discussion
In this study I have comprehensively studied each child with and without CLD of infancy for 
their symptoms, lung function, exercise capacity as well as effect of exercise and 
bronchodilator on airway obstruction. I also assessed the possible effects of perinatal factors 
on Dlco, ability to exercise and on ventilatory reserve. I report increased diagnosis of asthma 
and marked airway obstruction in children with CLD; decreased self-reported physical 
activity and decreased markers of large and small airway function. Air-trapping was still 
evident at 8-12 years of age. Furthermore, Dlco was decreased and although peakvo2 was 
similar between the groups; this was at the expense of the children who had CLD in infancy 
using much greater ventilatory reserve (VR). VR was related closely to D l c o ,  maximum 
respiratory rate during exercise and with peak vo 2. Most interestingly, perinatal factors seem 
to affect several parameters either directly or indirectly: oxygen duration in infancy seem to 
have an effect on D l c o  and on duration of exercise whilst gestational age appeared to affect 
ventilatory reserve (Figure 2.11).
Children bom preterm are known to have higher incidence of respiratory illness during 
infancy and early childhood. In my study group, 45% of the CLD group and 33% in the 
preterm group had been diagnosed with asthma in the past compared to only 4% in the term 
group. By 8-12 years of age, only 10% of children with CLD and 12% children born preterm 
but none in the term group were on medication for asthma. However, the prevalence of 
respiratory symptoms associated with asthma such as exercise-induced wheeze and night 
cough were still higher in the CLD population compared to the term controls (31% vs. 4%); 
this is likely to reflect small airway obstruction as shown by spirometry in this group of 
children.
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41% of parents in the CLD group and 47% parents in the preterm group admitted to smoking 
regularly, in comparison to only 11% of parents in the term group. However, there was no 
statistically significant difference in the urine cotinine levels in the subjects between groups 
and no correlation was noted between the urine cotinine level and the percent predicted FEVi. 
Thus, it is unlikely that passive smoking may have influenced differences in the lung function 
between children in the different groups in this study. Our lung spirometry data for the CLD 
group, in which children had received surfactant as an infant, was similar to that reported in 
the pre-surfactant era (Bader 1987; Northway Jr 1990; Gross 1998; Smith 2008) showing 
FEVi and F E F 2 5 - 7 5  at the lower end of normal at 81.9% of predicted values. I am unable to 
explain why FVC decreased with bronchodilator in the control group but FVC remained 
within normal range in this group at rest, after exercise and after bronchodilation. Therefore, 
this is unlikely to be of clinical consequence. RV and RV as a proportion of TLC both were 
increased in the CLD group suggesting on-going airway trapping even for 8-12 years of age. 
It is unclear why the term group had low predicted values for F E F 2 5 - 7 5  at 80% but the relative 
differences with the CLD group were significantly different. The primary aim of this study 
was not to measure the airway resistance. However, I have reported these results as they were 
available as a part of the whole body plethysmography. The methodology I used for the whole 
body plethysmography is not the optimal way of measuring airway resistance and this is 
reflected in the wide variation in the results including high airway resistance in the control 
population as well. Therefore, this data should be interpreted with caution.
In this study, haemoglobin corrected D l c o  was lower in the CLD group compared to both the 
preterm and term groups but predicted values were lower in the CLD compared to the preterm 
group but not the term infants. I, therefore, used linear regression modelling to assess which 
perinatal factors, after adjustment for age, gender and height may be important in its value 
and noted that duration of oxygen adversely affected its value. This is perhaps not surprising
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as oxygen therapy is likely to affect the gas exchange apparatus. My data is in keeping with 
the results from infants studied by Balinotti’s group (Balinotti 2010), the 8-year-old ex­
preterm subjects in the EPICure cohort (Welsh 2010) and 19-year-old cohort from the Dutch 
study (Vrijlandt 2006). Thus, there is evidence of limitation in alveolar-capillary gas 
exchange in the ex-preterm children with CLD. Narang and colleagues have measured Dlco 
combined with effective pulmonary blood flow ( QPEFF) at rest and during exercise in preterm 
bom young adults from the pre-surfactant era (Narang 2009). The investigators demonstrated 
that Dlco was reduced in the preterm group compared to the control population; this 
normalised during exercise. The investigators suggested that the rise of Dlco during exercise 
maybe a mechanical consequence of increased QPEFF and not a true increase.
For the exercise tests, the peak vo 2 was lower in the CLD but the differences to the preterm 
and term groups was not significant (p=0.073). Similarly, peak vC02and peak vEdid not 
differ between the groups. However, there were significant differences in the self-reported 
hours of physical activity per week between the CLD and control groups. I thus, modelled the 
data to assess which perinatal factors may affect duration of cycle ergometry and noted that 
duration of neonatal oxygen therapy and Dlco were important factors after correction for age, 
gender and height. In view of the explicit airway obstruction of both the large and small 
airways in the CLD group, and a drop of 11% in FEVi after exercise, the variously reported 
studies’ (Mitchell and Teague 1998; Vrijlandt 2006; Smith 2008; Narang 2009) failure to 
show limitation of exercise capacity in this group is perhaps surprising. Most interestingly, 
however, I noted that both M W  and ventilatory capacity were markedly decreased in the 
CLD group with intermediate values noted in the preterm group compared to the term 
controls. Thus the CLD and preterm groups were able to exercise similarly to the term infants 
but at the expense of using greater proportion of their ventilatory reserve capacity. Clearly VR
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at maximum exercise is dependent on peak VE and FEVi by definition but after correction for 
age, height and gender, Dlco and gestational age were both significantly associated with VR 
at maximum exercise.
Taken together these data appear to demonstrate that several perinatal factors affect Dlco, 
duration of exercise and VR. In particular, duration of oxygen or CLD affected D lco  and 
duration of exercise; and gestational age and CLD appear to affect VR. Using these data, I 
have proposed the model shown in Figure 2.11 showing the effects of perinatal factors on 
important elements that may affect exercise capacity in children who had CLD in infancy.
During this study, we also assessed both the effect of maximum exercise on FEVi and the 
response to bronchodilator after 45 minutes of rest after exercise. I noted a drop in FEVi of 
11% after exercise in the CLD group but <10% in the two control groups. After exercise, the 
response to bronchodilator was greater in the CLD group suggesting under-diagnosed 
exercise induced bronchoconstriction which clearly is an area that needs further study and 
intervention if confirmed by other studies. If >30% prematurely bom children smoke when 
they are young aduts as reported by previous studies (Doyle 2006, Halvorsen 2004), the 
increased rate of decline of FEVi due to smoking may make CLD a major risk factor for 
chronic obstructive pulmonary disease in these patients (Baraldi 2007, Figure 2.12).
In conclusion, 8-12 year old children with CLD in infancy have on-going pulmonary 
abnormalities including a greater incidence of doctor diagnosed asthma, exercise induced 
bronchoconstriction and a greater response to bronchodilation than do preterm or term 
controls. Furthermore, these children have on-going airflow limitations and also abnormalities 
of gas exchange. Although they reached similar exercise load to control children, this was at 
the expense of using greater ventilatory reserve. Finally, several perinatal factors including
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gestational age and oxygen duration seem to  have a direct effect on several param eters o f  lung 
function.
Figure 2.12 Theoretical m odel o f  changes in F EV I in survivors o f  C LD  and healthy subjects 
according to age
Maximal Level o f  FEVj (%)
100 Healthy subjects
Survivors o f broncho­
pulmonary dysplasia
Lung immaturity
Prolonged oxygen supplementation 
Mechanical ventilation 
Infections
Patent ductus arteriosus I
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Figure 4. Theoretical Model o f C hanges in FEVX in Survivors o f Bronchopulm onary Dysplasia and Healthy Subjects 
According to  Age.
Theoretical curves are shown for th e  forced expiratory volume in 1 second (FEVJ in healthy su b jec ts  and survivors 
o f bronchopulm onary dysplasia. Survivors o f bronchopulm onary dysplasia may have variable airflow  lim itation from  
the  first years o f life, with little evidence o f “catch-up" growth in lung function. In som e o f th e se  p a tien ts, FEVi does 
not reach the normal maximal value in early adulthood, and the phase o f declining FEVi values s ta r ts  from a s u b s ta n ­
tially reduced maximal value. W hether the  rate o f decline with advancing age will parallel th a t am ong healthy persons 
or will be accelerated is not known. The dashed  lines represen t the  potential effect o f sm oking on  the  ra te  o f  decline 
o f FEV^n susceptible subjects. Values for FEVj in th e  first 3 years o f life are extrapolated from  m easu rem e n ts  o f 
maximal flow a t functional residual capacity. A dapted from Fletcher and Peto.61
(Baraldi 2007)
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Limitations
Recruitment
The prematurely bom subjects in this study were traced from the contact details of the 
children at the time of their birth and their current hospital records. As it would have been 
insensitive to contact the parents of these children without ensuring that their child is alive 
and well, I did not contact any child/ parent for whom the current General Practitioner could 
not be traced. Thus, I was unable to trace 117/328 (36%) of the preterm children who were 
originally identified. 49% of those contacted (87/179) i.e. 27% (87/328) of the initially 
identified population did not respond to the ‘letter of invitation’ (Figure 2.1). Only one letter 
was sent to the parents/ guardians inviting the children to take part in the study, as advised by 
the ethics committee. The reasons for non-response for these children are unknown. Both the 
above caveats may have caused unintentional and unavoidable selection bias.
Sample size
Power calculations for this study were done to assess evidence of increment in pulmonary 
arterial pressure in response to acute hypoxia. The power calculation for the pulmonary 
function study was post-hoc. This is one of the limitations of the study.
Pulmonary function study
As the pulmonary function studies and the cardiovascular studies were conducted in separate 
sites, the subjects were invited to attend for the pulmonary function study and the 
cardiovascular study on separate days. This meant that all aspects of the pulmonary function 
tests had to be accommodated on a single sitting and therefore, the study protocol had to be 
compromised in the following aspects:
• Ideally, a multiple breath test to study FRC He in order to assess FRC pie*: FRC He would 
have been extremely useful to assess evidence of air trapping in children with CLD.
I l l
However, the study was designed to perform a ‘single breath test’ to assess alveolar 
diffusion capacity. Due to the time constraint it was not practical to perform both the single 
breath and the multiple breath tests on the same day.
• Similarly, it would have been ideal to assess exercise induced bronchoconstriction and the 
reversibility test on separate occasions. As both these tests had to be performed on the 
same day, I have presented the findings as ‘change in FEVi from baseline to after exercise’ 
as a measure of exercise induced bronchoconstriction and ‘increase in FEVi from its 
lowest point after exercise to 15 minutes after Salbutamol inhalation’ as a measure of 
response to bronchodilator.
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Chapter Three: Reproducibility of Myocardial Velocity and 
Deformation Imaging
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3.1 Introduction
Historically, it has not been easy to quantify right ventricular function using non-invasive 
methods such as 2-D and Doppler echocardiography. In recent years, myocardial velocity 
imaging (MVI) or tissue Doppler imaging (TDI) has been validated and widely used in the 
adult population for diagnosis of left ventricular (LV) and right ventricular (RV) dysfunction. 
MVI is an echocardiographic technique which directly measures the velocities of myocardial 
motion during systole and diastole. This has been suggested as a potentially useful diagnostic 
tool for quantitative assessment of myocardial function in infants (Mori 2004) and children as 
well (Kapusta 2000; Mori 2000). Certain tissue Doppler parameters such as RV relaxation 
time ‘IVRT’ (Dambrauskaite 2005; Lindqvist 2006; Brechot 2008) and RV systolic strain 
(Dambrauskaite 2007; Lopez-Candales 2008; Rajagopalan 2008) have been validated as 
useful markers for estimation of pulmonary arterial pressure in adults. Regional myocardial 
strain has also been shown to be feasible in healthy term infants (Nestaas 2007; Pena 2009).
The feasibility and reproducibility for off-line tissue Doppler measurements in adults has been 
extensively studied by the MYDISE study group (Fraser 2003). This has not yet been tested 
or validated in prematurely bom infants or children. Limited data on children have suggested 
that reproducibility for measurement of myocardial velocities in children are acceptable (intra 
and interobserver variability <10%) (Pauliks 2005) but there is lack of data on reproducibility 
of parameters such as isovolumic acceleration (IVA), deformation index, strain and 
isovolumic relaxation time ‘IVRT’ in children. In adult studies, coefficient of variation for 
parameters such as relaxation time was >10% (Lindqvist 2006) and for IVA >20% 
(Margulescu 2010). Thus, understanding the feasibility and reproducibility for these 
echocardiographic parameters was vital prior to using these methods for assessment of 
myocardial function in children with CLD for this thesis. I had the opportunity to study the
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reproducibility of myocardial velocity and deformation imaging in great detail with a separate 
ongoing research on the neonatal population, which I shall describe in this chapter.
In this study, I assessed the intra and interobserver variability for off-line analysis of 
longitudinal systolic and diastolic myocardial velocities, myocardial strain, annular 
displacements, and isovolumic acceleration compared with conventional blood pool Doppler 
parameters such as mitral inflow velocities and pulmonary arterial acceleration time.
3.2 Methods
Feasibility and reproducibility of myocardial velocity and deformation indices was 
established using infants who were recruited for a separate study on ‘myocardial velocity 
imaging in term and preterm infants’. Thirty healthy term infants (>38 weeks of gestational 
age) and 25 preterm infants (<34 weeks of gestational age) were recruited from the post-natal 
wards and the Special Care Baby Unit of University Hospital of Wales. Written informed 
consent was obtained from parents prior to recruitment. The South East Wales Regional 
Ethics Committee gave ethical approval for this study.
All infants had their first scan within the first 72 h after birth. The infants were screened for 
congenital cardiac defects and those with structural cardiac defects were excluded from the 
study, with the exception of patent ductus arteriosus. A second scan was performed a month 
later. Images were acquired using a commercially available system (Vivid 7, GE Vingmed 
Ultrasound AS, Horten, Norway) with a 7.0 or 5.0 MHz transducer.
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We selected a random sample of 16 studies for the reproducibility study, by drawing lots: 8 
out of 30 studies from term infants and 8 out of 25 studies from preterm infants. The results 
presented for the reproducibility of echocardiaographic indices are from these 16 scans.
In order to establish the reproducibility of myocardial velocity and strain indices, myocardial 
velocity loops acquired from 16 infants were analysed by four observers including myself (S 
Joshi, research fellow, JM Edwards, research sonographer, DG Wilson, consultant paediatric 
cardiologist and JK Wong, paediatric cardiology staff grade) for interobserver variability, and 
re-analysed after 6 months by myself for intraobserver variability. Images were analysed 
using commercially available EchoPAC software. Observers were blinded to the clinical 
status of the infants.
Intra and interobserver variability were assessed for thirteen parameters including 4 blood 
Doppler parameters: LV VTI (Figure 4.4 B), mitral E and A velocities (Figure 4.5), and 
pulmonaiy arterial AT (Figure 4.9) and 9 tissue Doppler parameters from LV and RV images: 
annular displacement (Figure 4.13), myocardial systolic, early and late diastolic velocities 
(Figure 4.12), RV relaxation time (Figure 4.11), QRS to peak systolic time interval (Figure 
4.12), isovolumic acceleration (Figure 4.12), myocardial systolic strain at the apical and the 
basal segments (Figure 4.14). All parameters were measured in 3 beats and averaged, except 
if the signal from an individual beat was too noisy to be analysed in which case 1 - 2  beats 
were measured. The details of the methods and results of this study have been published in 
the paper, ‘Reproducibility of myocardial velocity and deformation imaging in term and 
preterm infants’ (Appendix H2). The methodologies for off-line analysis of the individual 
parameters are described in section 4.2.3.5.
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The echocardiographic equipment used for acquiring the images, the equipment used for post­
processing of the tissue Doppler images and the methodology used for acquisition and 
measurement of echocardiographic indices were similar to that for the study carried out on 8- 
12 year old children studied for this thesis (Chapter 4).
Statistical methods
The sample size of 16 scans observed by four observers for the interobserver reproducibility 
gave 48 degrees of freedom [number of studies * (number of observers-1)], and the power to 
demonstrate differences with 95% confidence intervals estimated at 0.4 x standard deviation 
(SD).
Intra and interobserver reproducibility were reported as coefficients of variation (CVs, in %), 
calculated using the formula: CV = (SD/arithmetic mean of measurements) x 100, where SD 
is the standard deviation of residuals (measurement 1 - measurement 2). As there were four 
observers, there were six pairs of data for comparison (each derived from repeated analysis of 
the 16 patients); the interobserver reproducibility of each variable is therefore expressed as a 
pooled CV, which is the mean value of the six comparisons. Intraobserver variability is also 
presented as CV for each variable.
3.3 Results
Feasibility
Most pulsed and tissue Doppler parameters could be measured in 90% of neonates. A single 
diastolic velocity at the mitral valve was noted in 5% (1 infant), and using tissue Doppler in
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31% (5 infants) at the LV, 20% (3 infants) at the RV, and 12% (2 infants) at the septum. In 
these cases, a single diastolic velocity was measured and noted as early diastolic velocity (E 
or Ve’). The fusion of early and late diastolic velocities may be due to rapid heart rates in 
infants. Missing values for the myocardial velocity occurred because a segment could not be 
imaged or because the traces were of the poor quality. The feasibility for measuring LV apical 
strain was only 75%.
Reproducibility
The mean values for all parameters, and the results of coefficients of variation (CV) for both 
intra- and interobserver variability, are summarized in Table 3.1.
Indices for assessment of LV function
Mitral annular early diastolic velocity by pulsed tissue Doppler (Ve’) had reproducibility of 7 
-13% (intraobserver) and 9% (interobserver). Intra- and interobserver variability for LV 
myocardial systolic and diastolic velocities as well as annular displacements, obtained by 
processing stored digital loops, were between 10 and 15% except for the diastolic velocity 
(Va) (20% interobserver). More advanced parameters such as QRS to Vs time interval (T q _ v s)  
and LV strain had intraobserver CVs of 15%, but interobserver reproducibility for these 
parameters was sub-optimal at CVs 35%. LV IVA was not reproducible (CVs 30-60%).
In comparison, blood Doppler parameters such as LV velocity time integral and mitral inflow 
Doppler had CVs of 3-6% for both intra- and interobserver variability.
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Indices for assessment of RV function
Intraobserver CVs for the RV indices were generally higher compared with the corresponding 
LV indices. Intra and interobserver CVs for the RV myocardial systolic and diastolic 
velocities, annular displacement, and QRS to Vs time interval (Tq.vs), were between 15 -19% 
and 18 -24%, respectively. IVA was poorly reproducible in the RV, with CV of 40%.
Indices for assessment of pulmonary arterial pressure
Pulmonary arterial acceleration time, which has been traditionally used to estimate pulmonaiy 
arterial pressure, had CV of 12- 15%. Tissue Doppler parameters that are relatively new 
methods of indirect estimation of pulmonary arterial pressure were less reproducible. CV for 
tricuspid annular IVRT was 16% (intraobserver) and 25% (interobserver), and that for RV 
basal strain was 19% (intraobserver) and 25-37% (interobserver).
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Table 3.1 Reproducibility of echocardiographic indices
Intraobserver variability 
CV%
Interobserver variability 
CV%, pooled mean (SD)
VTI (cm) 3.6 6.0 (1.9)
Mitral E (m s'1) 2.5 2.8 (0.4)
Mitral A ((m s'1) 5.5 4.5 (0.8)
PA AT (ms) 11.9 15.2(2.9)
Displacement (mm)
LV Ds’ 6.2 12.2 (3.4)
RV Ds’ 12.8 18.2 (4.6)
Mitral annular velocity (cm s ' )
Lateral Ve’ 12.6 9.4 (4.2)
Medial Ve’ 6.9 9.2 (3.9)
Myocardial velocity (cm s ' ) 
LV
Vs (bl) 9.8 14.3(1.8)
Ve (bl) 11.1 13.5(1.9)
Va (bl) 9.9 20.3 (4.7)
RV
Vs (bl) 17.7 18.3 (4.5)
Ve (bl) 15.0 23.3 (8.4)
Va (bl) 18.5 24.1 (7.8)
Timing (ms)
RV relaxation time ‘IVRT’ 16.1 27.0 (8.8)
T q-Vs
LV 13.3 34.6(18.3)
RV 9.4 22.2(12.3)
Isovolumic acceleration (ms")
LV 62.5 46.7 (7.6)
RV 29.3 60.3(13.3)
Strain (%) 
LV
Ssbl 14.0 43.0(13.9)
Ssal 17.1 36.9(15.7)
RV
Ssbl 19.0 37.1 (11.5)
Ssal 23.9 25.3 (1.9)
SD, standard deviation; CV, coefficient of variation; VTI, left ventricular outflow tract
velocity time integral; PA AT, pulmonary arterial acceleration time; LV, left ventricle; RV, 
right ventricle; Ve’, annular early diastolic velocity; Vs, myocardial systolic velocity; Ve, 
myocardial early diastolic velocity; Va, myocardial diastolic velocity during atrial 
contraction; IVRT, right ventricular isovolumic relaxation time; T q .Vs, QRS to Vs time 
interval; Ss, systolic strain; bl, basal segment of lateral wall; al, apical segment of lateral wall; 
bs, basal segment of septal wall; ms, mid-septal segment.
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3.4 Discussion
Feasibility of tissue Doppler in infants
Due to RV dominance in newborn infants, the acquisition of images from the LV, without 
missing the apex and while retaining a narrow sector of the image and thus a high frame rate, 
was a challenge. This accounts for the fact that LV apical strain had the most missing values 
(37%). The other tissue Doppler parameters measured in this study were not similarly affected 
as they were all measured either at the annulus or in the basal segments.
Reproducibility of off-line analysis of tissue Donnler measurements
As anticipated, pulsed Doppler recordings of blood flow were more reproducible than 
myocardial velocities. The reproducibility for measuring the acceleration time of pulmonary 
arterial flow in this study was better than previously published data in infants by Subhedar 
and Shaw (Subhedar and Shaw 1996) (intraobserver CV 12 vs. 25%).
The lateral mitral annular early diastolic velocity in this study had interobserver variability of 
9% which is comparable to that reported in an adult study (CV 9- 17%) (Vinereanu 1999). 
Although there is evidence that the relaxation time 'IVRT' of the tricuspid annulus is a useful 
parameter for excluding pulmonary hypertension in adults (Brechot 2008), the interobserver 
reproducibility for this index in infants was sub-optimal (CV 27%), compared with 12-13% in 
adults (Dambrauskaite 2005; Lindqvist 2006). Intraobserver variability was better at CV 16%. 
When Pauliks et al. addressed myocardial velocities in children undergoing closure of an 
atrial septal defect (Pauliks 2005), the CVs for systolic (Vs) and diastolic (Ve) velocities 
were, 10% for both intra- and interobserver variability, while CVs for diastolic velocity (Va) 
were higher (21.5% intra- and 15% interobserver) (Pauliks 2005). In infants, I found that the 
reproducibility of measuring myocardial velocity was more variable in the RV (15-18% intra-
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and 18-24% interobserver variability) than in the septum and the lateral wall of the LV (CV, 
15%). In adults with LV dyssynchrony, variability for measuring myocardial systolic 
velocities (Vs) has been as much as 18-56% (Mandysova 2008). There are limited data on the 
reproducibility of deformation indices or IVA in infants and children. Weidemann et 
al.(Weidemann 2002) measured radial and longitudinal strain and stain rate in 33 healthy 
children aged 4-16 years. They reported intraobserver variability of 11% and interobserver 
variability of 15%; these data are pooled CVs for LV, RV, and septal strain. In my study, 
when measuring longitudinal peak systolic strain, variation between lowest and highest CVs 
varied in the LV (14-17%) and RV (19-23%). Pena et al.(Pena 2009) have reported a 
reproducibility of longitudinal peak systolic strain in infants of only 1.2%, but this is 
misleading as the figure given is a Bland-Altman difference presented as percentage, and not 
the CV between observers. One of the major difficulties faced when measuring myocardial 
strain in infants is the small size of the heart. I used a computation length of 10 mm, as 
previously recommended (Nestaas 2007). Using smaller distances increased noise and 
reduced reproducibility. The strain length of 10 mm was therefore necessary, but in small 
hearts means that it becomes difficult to position the sample volume accurately to avoid 
influences from surrounding structures such as the atrium. IVA has been validated as a useful, 
load-independent index for assessing myocardial contractility in animal models (Vogel 2002). 
It has also been used to assess myocardial contractility in children after surgical closure of 
atrial septal defect where the variability reported by Pauliks et al. (Pauliks 2005) 
(intraobserver 10.8% and interobserver 11.5%) is considerably better than was found in 
infants in my study (CV, 35%).
In conclusion, I have demonstrated that myocardial velocity imaging and its off-line analysis 
using the available equipment in our laboratory was feasible in newborn infants, and 
therefore, would be feasible in older children as well. I have also demonstrated that
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intraobserver reproducibility for myocardial velocities, displacement and strain are adequate 
and these parameters can be used in clinical research. However, interobserver reproducibility 
for more advanced indices such as LV and RV longitudinal strain is sub-optimal suggesting 
that these measurements should be used cautiously for clinical diagnosis. Reproducibility for 
myocardial acceleration (IVA), a marker of contractile function, is currently unsatisfactory.
In this study, the images were acquired by two operators and three different GE vivid 
machines were used. The intra and interobserver variability of the analysis presented in this 
study does not take into account the inter-machine and inter-operator variation.
§
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Chapter Four: Cardiovascular Study
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4.1 Introduction
Right ventricular dysfunction and pulmonary arterial hypertension (PAH) are recognised 
causes of significant morbidity and mortality in infants with CLD (Evans and Archer 1991; 
Subhedar and Shaw 2000). Presence of moderate PAH beyond the first few months of life has 
been associated with 47% mortality within 2 years of diagnosis (Khemani 2007). In addition, 
cardiac catheterisation studies have shown that even mild hypoxia can cause marked elevation 
in pulmonary arterial pressure (PAP) (Mourani 2004). In Chapter 2 ,1 have demonstrated that 
prematurely bom children with CLD continue to have evidence of lung function abnormalities 
at school age. Given the evidence of abnormal myocardial function in adult patients with 
chronic obstructive pulmonary disease (COPD) (Sabit 2010), the children with prematurity 
related CLD may also be at high risk for developing subclincial myocardial dysfunction and 
pulmonary arterial hypertension, especially when exposed to hypoxic conditions. At present 
there is lack of data regarding natural progression of PAH in survivors of CLD beyond 
infancy. As the subjects in this study did not have any ongoing clinical problems regarding 
their cardiac health, I assumed that hypoxia indused pulmonary vascular stress would be a 
useful method of unmasking the underlying pulmonary vascular abnormalities and that any 
abnormality detected would be subclinical.
Left ventricular (LV) and right ventricular (RV) function both predict long-term outcome in 
adult patients with COPD (Barbera 2003, Wright 2005). As children with neonatal CLD 
continue to have abnormal pulmonary function as they grow older as described in Chapter 2, 
early diagnosis of left and right ventricular dysfunction in these children may allow early 
intervention and appropriate follow-up. Because of the right ventricular anatomy, it is not 
easy to accurately quantify right ventricular function using conventional 2-D and Doppler 
echocardiography. Myocardial velocity imaging (MVI) or tissue Doppler imaging (TDI)
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allows assessment of regional and global left and right ventricular function and thus helps 
detection of sub-clinical ventricular dysfunction.
In this study I hypothesized that 8-12 year old children with CLD will have
1. Subclinical right ventricular dysfunction
2. Evidence of raised pulmonary arterial pressure when exposed to acute hypoxia
3. Subclinical left ventricular dysfunction
4.2 Methods
The methods used for recruitment of the subjects have already been described in section 2.2.1. 
Cardiovascular tests were carried out in the Wales Heart Research Institute at Cardiff 
University, Cardiff. All cardiovascular tests were done in the morning and the children were 
asked to attend after an overnight fast. The following tests comprised the cardiovascular 
function;
• 12-lead ECG
• Measurement of biochemical markers of cardiovascular function
• Baseline echocardiography
• Hypoxic challenge test
• Measurement of the flow-mediated dilatation of brachial artery*
• Conduit arterial function and wave travel*
• Measurements of the flow- mediated dilatation of brachial artery and the conduit arterial 
function of carotid arteries were carried out by other colleagues of the research team (T 
Powell, E Ellins and N Pickerd) and the methods and results of these measurements are not 
included as a part of this thesis.
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4.2.1 General a s s e s s m e n t
The parents of the participants were requested to fill in their child’s medical history proforma 
that included history of past and current cardiac conditions. The history proforma is shown in 
Appendix B. The participants also had physical examination including cardiovascular 
examination, baseline pulse oximetry, heart rate and blood pressure measurements.
4.2.2 Biochemical te s ts
The children who consented to having a capillary blood sample were asked to attend the 
Wales Heart Research Institute after an overnight fast. The children had a finger prick blood 
sampling using a lancet (Accu-check Softclix, UK) and blood samples were collected in a 
15pL, a 40 pL and a lOOpL capillary blood collectors. A handheld blood analyser (Cardio 
Check PA analyser, USA) was used to measure blood glucose, cholesterol, high density 
lipoprotein and triglycerides. Blood sample from the 15pL collector was introduced in the 
glucose panel in the analyser to measure fasting blood glucose, followed by the sample from 
the 40pL collector to the lipid panel to measure total cholesterol, high density lipoprotein and 
triglycerides. The blood sample collected in the lOOpL collector was transported immediately 
to the Special Care Baby Unit at University Hospital of Wales to measure capillary blood gas 
using a blood gas analyser (ABL 735, Radiometer, Copenhagen).
4.2.3 Hypoxic challenge test
4.2.3.1 Hvooxic challenge test protocol
The detailed study protocol for the hypoxic challenge test is given in Appendix A2. After 
acquisition of the baseline echocardiographic images, the children were asked to breathe 
through a non re-breathing mask connected to a cylinder containing 15% oxygen. After 20 
minutes of inhalation of 15% oxygen, echocardiography was repeated while the children 
continued to inhale 15% oxygen. Following this, they inhaled 12% oxygen for 20 minutes 
followed by repeat echocardiography while continuing to inhale 12% oxygen. The hypoxic 
challenge test was then terminated.
4.2.3.2 Delivery of hvnoxic oxygen
British Oxygen Company Limited (BOC, UK) provided the premixed cylinders of 15% and 
12% oxygen with nitrogen blend. This hypoxic oxygen blend was delivered to the child via a 
paediatric non re-breathing mask with a bag (Figure 4.2). Oxygen delivery rate was set at 
lOL/min using a regulator attached to the gas cylinder. High oxygen delivery rate was 
selected so as to keep the bag inflated throughout the experiment. Although I did not use 
sealed mask for the delivery of oxygen, by using high gas flow rate and ensuring that the bag 
was inflated and that the mask was fitted as tightly as practically possible, I maintained the 
inspiratory oxygen concentration as close as possible to the desired 15% or 12%.
4.2.3.3 Monitoring the child during hypoxic challenge
As induction of hypoxia in a child is a matter of anxiety for the parents as well as for the 
ethical committee, this part of the study had been scrutinized in detail both by the research 
ethics committee and the external reviewer. This study was initially set-up at Leicester
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University by Professor Kotecha where the study protocol had been given a favourable review 
by an independent external reviewer as well as the local ethics committee. Due to Professor 
Kotecha’s move to Cardiff, the study could not be undertaken in Leicester. Prior to 
conducting this study at Cardiff University, the study protocol had again been reviewed by the 
South East Wales regional ethics committee and was granted a favourable opinion in October 
2007 (Reference: 07/WSE03/77).
As advised by the ethics committee, per-cutaneous oxygen saturation was monitored and 
recorded continuously using Nellcor pulse oximetry (Nellcor, Tyco Healthcare, UK) and the 
low alarm limit in the pulse oximetry was set at 80% in keeping with the study protocol 
(Appendix A2); which stated that ‘the hypoxic oxygen should be stopped i f  the oxygen 
saturation drops below 80% for >30 seconds or below 80% for <30 seconds on more than 3 
occasions, and should be discontinued immediately i f  oxygen saturation drops to < 75%> . The 
pulse oximetry recording stored during the hypoxic challenge test was downloaded in the 
computer system and the average as well as the lowest oxygen saturation during inhalation of 
15% oxygen and 12% oxygen was noted.
At the end of the hypoxic challenge test, pulse oximetry was continued until the oxygen 
saturation returned to baseline. Heart rate and blood pressure were measured at baseline, at 
the end of 15% oxygen inhalation and at the end of 12% oxygen inhalation using the 
‘Dynamap Procare’ monitor. The adult size, small adult size or the paediatric size cuffs were 
selected as appropriate depending upon the size of the child. Respiratory rate was counted for 
1 minute.
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4.2.3.4 Echocardiography with blood flow and tissue Doppler methods 
Before subjecting the child to hypoxia, baseline echocardiography was performed firstly to 
rule out structural cardiac defects and secondly to assess baseline left and right ventricular 
function. Blood flow and tissue Doppler images were also acquired to measure the surrogate 
markers of pulmonary hypertension. The M-mode image of the inferior vena cava was 
acquired in order to estimate right atrial pressure at baseline (Figure 4.6). While acquiring the 
M-mode image of the inferior vena cava (IVC), the child was asked to sniff and the 
inspiratory collapse of the inferior vena cava during the ‘sniff test’ was assessed. The right 
atrial pressure can be estimated by the degree of collapse of the IVC on inspiration (Kircher 
1990). If the collapse of IVC is less than 50%, the right atrial pressure is estimated to be >10 
mm Hg. If the inferior vena caval collapse is more than 50%, the right atrial pressure is 
estimated to be <10 mm Hg.
After each phase of hypoxic challenge, echocardiography was repeated whilst the child 
continued to breathe the prescribed oxygen. Images were acquired to assess RV function and 
surrogate markers of pulmonary hypertension. The echocardiography acquisition protocol is 
given in Appendix A3.
All images were acquired as 3-beat loops. Images were acquired using a commercially 
available system (Vivid 7.0, GE Vingmed Ultrasound AS, Horten, Norway, Figure 4.1) with a 
3S MHz transducer.
Pulsed wave Doppler of the left ventricular outflow tract (LVOT) in the apical 4-chamber 
view was acquired to measure LVOT velocity time integral (Figure 4.4). 2-D image of the 
long axis view of the LVOT was obtained to measure the LVOT diameter (Figure 4.3). 
Conventional pulsed wave Doppler of mitral (Figure 4.5) and pulmonary flow (Figure 4.9)
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were acquired from the apical 4-chamber and the parasternal short axis views respectively. 
Continuous wave Doppler image of the tricuspid flow (Figure 4.7) and pulsed wave Doppler 
of the pulmonary flow (Figure 4.8) were acquired to measure tricuspid regurgitation systolic 
velocity and pulmonary regurgitation end-diastolic velocity respectively. For lateral and 
medial mitral annular velocities (Figure 4.10) and right ventricular relaxation time, ‘IVRT’ 
(Figure 4.11) real-time pulsed velocity profiles were acquired from the mitral and tricuspid 
annulus respectively. Colour tissue Doppler images were acquired separately of the left and 
right ventricles. The Nyquist limit was optimised to avoid aliasing, and the depth of imaging 
and the sector angle were adjusted to obtain high frame rates. The Nyquist limit, which is 
50% of the sampling frequency, is the highest frequency that can be coded at a given 
sampling rate in order to be able to fully reconstruct the signal.
All images were stored as 3-beat loops in magneto-optical disks for post- processing.
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Figure 4.1 Photograph o f  a GE Vivid 7 equipment
GE V ivid 7 equipm ent used for echocardiography
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Figure 4.2 Photograph o f  a child having echocardiography while breathing 12% oxygen via a
non-rebreathing face mask.
(A w ritten parental consent and the assen t from  the child  w as obtained for the pub lication  o f  
this im age)
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4.2.3.5 Analysis of the echocardiography images
Images were analysed using commercially available EchoPAC software (GE Vingmed 
Ultrasound EchoPAC 7-00, Horten, Norway). Images were stored only with coded identity so 
that I was blinded to the clinical status of the subjects while analysing the images.
25 parameters (Tables 4.1 and 4.2) were measured from each study, including 8 blood flow 
Doppler parameters, 3 tissue Doppler parameters from real-time tissue Doppler images and 7 
post-processed parameters from LV and RV tissue Doppler loops. Each tissue Doppler 
parameter was measured at the basal segments of the LV and RV. The cursor was positioned 
within each segment so that it did not encroach upon the annulus during systole.
Left ventricular pre-ejection period (PEP) was measured as the time interval between the 
onset of the QRS complex and the onset of the left ventricular outflow (Figure 4.4).
The velocity time integral of LV outflow (VTI) (Figure 4.4), the mitral E and A velocities 
(Figure 4.5), tricuspid regurgitation (Figure 4.7) and pulmonary regurgitation (Figure 4.8) 
velocities, and the pulmonary artery acceleration time (Figure 4.9) were measured 
conventionally from blood pool Doppler.
The area of the L V outflow tract was calculated as rcr2 where r is the radius of the L V outflow 
tract (r=diameter of LV outflow tract/2). Stroke volume was calculated by multiplying the 
velocity time integral (VTI) by LV outflow tract area. Multiplying stroke volume by heart rate 
yields cardiac output (Thomas and Popovic 2006). In order to correct cardiac output for body 
size, cardiac index (Cl) was calculated as cardiac output (L/min)/ (height in m)2.
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Pulmonary artery acceleration time (AT) was calculated as the time interval between the onset 
of flow to the peak velocity and the ejection time (ET) was calculated as the time interval 
between the onset of pulmonary flow to the end of flow (Figure 4.9). The ratio of the 
acceleration time to the ejection time (AT:ET) was also calculated.
The mitral annular early diastolic velocity (Ve’) was measured at both the medial and lateral 
mitral annulus and averaged.
Right ventricular relaxation time ‘IVRT’ was measured as the time interval between the end 
of systole and the beginning of diastole during the tricuspid annular motion (Figure 4.11).
Myocardial systolic velocity (Vs), early diastolic velocity (Ve) and diastolic velocity during 
atrial contraction (Va) were measured at the basal segments (Figure 4.12) of the LV and the 
RV lateral walls. When myocardial Ve and Va were fused due to rapid heart rate, a single 
diastolic velocity was recorded and noted as Ve. Time to peak systolic velocity ( T q .Vs)  was 
measured as the time interval between the start of the QRS complex and the peak myocardial 
velocity during ejection (Figure 4.12). The measurement for the myocardial isovolumic 
acceleration (IVA) was made by dividing the peak positive velocity during the IVC by time to 
this peak velocity from the onset of the signal at the zero crossing (Figure 4.12.).
Annular displacement (Ds’) was measured at the mitral and tricuspid annulus using tissue 
tracking (Figure 4.13).
Peak systolic strain at end-systole (S) was measured within the basal and the apical portions 
of the lateral wall (Figure 4.14). For computation, strain length of 12 mm was used. To ensure 
measurement of end-systolic strain during systole, event timing was superimposed from left
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ventricular outflow tract and right ventricular outflow tract blood flow Doppler recordings for 
the LV and RV respectively.
All of the above parameters were measured in 3 beats and averaged.
4.2.3.6 Statistical methods
I studied 90 subjects with 30 in each of the three groups (Preterm CLD, preterm control and 
term control). Based on the data from Sartori et al (Sartori 1999), I calculated that I would 
need to study 30 children in each arm to be 90% certain of a difference of 30% in pulmonary 
arterial pressure in response to hypoxia at a p< 0.05 between the groups.
Results are presented as mean and standard deviation (SD). Differences between groups were 
tested by ANOVA with Tukey’s posthoc analyses. SPSS 16.0 (SPSS Inc., Chicago, IL) was 
used to perform analyses
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Figure 4.3 2-D image o f the left ventricular outflow tract diameter
2-D  parasternal long axis view  o f  the left ventricular ou tflow  tract. The vertical w h ite  line 
show s the m easurem ent o f  the left ventricular outflow  tract d iam eter w hen the aortic valve is 
open.
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Figure 4.4 Pulsed wave D oppler o f  the left ventricular outflow  tract, LVOT
LVOT
A. P re-ejection  period, P E P  is the  in terval betw een the  b eg in n in g  o f  Q R S  com plex  and the 
start o f  left ven tricu lar ou tflow .
B. E nhanced view  o f  the  left ven tricu la r ou tflow  velocity  w ith  th ick  trac in g  o f  the  L V O T  flow  
to m easure the velocity  tim e in tegral, VTI.
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Figure 4.5 Pulsed w ave D oppler o f  the m itral valve show ing early (E) and late (A ) diastolic 
velocities
E -  Mitral early diastolic velocity, A = m itral late d iasto lic  velocity  during atrial con traction
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Figure 4.6 2-D image showing collapse o f  the inferior vena cava during a ‘sniff test’
The arrow  is pointed to  the ‘co llapse’ o f  the inferior vena cava (IV C ) w hen the child  sniffed.
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Figure 4.7 Continuous wave Doppler o f the tricuspid valve showing tricuspid regurgitation
-  1
J L \ Ik'i *Jkht i*
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-  -3
T he arrow  is pointed at the peak  tricusp id  regurg ita tion  velocity
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Figure 4.8 Pulsed wave D oppler o f the pulmonary valve showing pulmonary regurgitation
The arrow  is pointed  at th e  pu lm onary  regurg ita tion  end-diastolic velocity
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Figure 4.9 Pulsed wave Doppler o f the pulm onary valve illustrating measurements o f
acceleration time and ejection time
Pulm onary arterial accelera tion  tim e, A T  is m easu red  as the interval betw een the onse t o f  
flow  and the peak flow.
Pulm onary arterial e jection  tim e, E T  is m easu red  as the interval betw een the onset o f  flow  and 
the end o f  flow.
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Figure 4.10 Real time pulsed tissue Doppler at the lateral mitral annulus
The arrow  is pointed  to  the lateral m itral annular early d iasto lic velocity  (V e’). V e’ w as 
m easured at lateral and m edial m itral annulus and the m ean V e’ is reported.
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Figure 4.11 Real time pulsed wave Doppler at the lateral tricuspid annulus illustrating right
ventricular relaxation time ‘IVRT’
16/03/2008 13:14:53 
Freq : 1.7 MHz/3.4 MHz 
FPS: 12.5/12.5 
Depth: 10.0 cm 
Gain: 3.0 dES 
Scale: 1.60 kHz 
Freq : 2.4 MHz
,26
-.26
-  10
[cm/s]
-  -10
-  -20RV ‘IVRT ’
f rrwh .  0 .0 75H R■2.0 -1.5 - 1.0 -0.5
Right ventricular ‘IV R T ’ is the tim e interval betw een the end o f  systole and the beg inn ing  o f  
diastolic m otion o f  the tricuspid  annulus
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Figure 4.12 E xam ple o f  a  m yocard ial velocity  trace at the basal segm ent o f  the right 
ventricular free wall
Figure show ing the post-processed  regional m yocardial velocities o f  the righ t ven tricle . A 
circular sam ple vo lum e is placed at the base o f  the lateral wall.
PV O = Pulm onary valve opening  and PV C = Pulm onary  valve closure. P V O  and P V C  w ere 
m easured from  blood-flow  D opp ler traces o f  pulm onary flow.
1= Peak systolic velocity  (V s), 2=  Early d iastolic velocity  (V e), 3=  Late d iasto lic velocity  due 
to  atrial contraction (V a), 4=  T im e interval betw een onset o f  the Q R S com plex  and peak 
systolic velocity  (T  q.Vs) and 5=  R ight ven tricu lar isovolum ic acceleration , IVA.
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Figure 4.13 Illustration o f  annular displacem ent at the lateral tricuspid annulus
Figure show ing  the m easurem ent o f  right ven tricu lar annu lar d isp lacem ent using  tissue 
tracking. The arrow s point to  the annular d isp lacem ent m easured  in m illim etres.
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Figure 4.14 Illustration o f  strain imaging at the basal segment o f the right ventricular free wall
i o . / o s
3 7 3 :3 /3  H R
Figure show ing  righ t ven tricu lar systo lic strain  at the basal (yellow ) and at the apical (b lue) 
segm ents o f  the right ventricle . PV O = Pulm onary  valve open ing  and PV C = P u lm onary  valve 
closure. Pulm onary valve closure m arks the end o f  systole. The arrow s po in t to  the  end- 
systolic strain.
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4.2.3.7 Echocardiographic indices of left and right ventricular function
The echocardiographic indices that were used to assess left and right ventricular function are 
summarised in Table 4.1. Both systolic and diastolic function were assessed using 2-D, 
conventional blood flow Doppler and tissue Doppler methods also known as myocardial 
velocity imaging.
Cardiac index and LV pre-ejection period (LV PEP) were used as markers of LV systolic 
function. The ratio of the mitral inflow velocities E:A was measured to assess the LV filling 
pattern. The mitral annular Ve’ velocity measured by myocardial velocity imaging was used 
to calculate E:Ve’ ratio which gives an estimate of mean LV filling pressure.
Myocardial velocity imaging was used to quantify both LV and RV global and regional long- 
axis function. Mitral annular displacement (Ds’) is annular excursion, which in turn correlates 
with the global myocardial systolic function. Isovolumic acceleration, IVA, is a marker of 
myocardial contractile function. The myocardial function at the basal segments of the LV and 
RV lateral walls was quantified by myocardial systolic velocity, Vs, early diastolic velocity, 
Ve, and the late diastolic velocity, Va. T q . v s, the time interval from the onset of QRS complex 
to the peak systolic velocity (Vs), is a measure of electromechanical delay for myocardial 
systolic function. RV and LV systolic strain are indices of regional myocardial deformation.
Echocardiographic evidence of increased pulmonary arterial pressure (PAP) was also 
assessed using standard blood-flow Doppler methods and myocardial velocity imaging as 
summarised in table 4.2. Standard Doppler methods were used to measure tricuspid 
regurgitant velocity, and RV systolic pressure was calculated by applying the modified 
Bernoulli equation (AP=4V2). As none of the children had evidence of increased right atrial 
pressure, right atrial pressure was estimated at 5 mm Hg for all the subjects. Therefore,
pulmonary arterial systolic pressure was estimated as, calculated RV systolic pressure + 5 mm 
Hg.
Pulmonary arterial acceleration time, AT, and ejection time, ET, and the ratio of ET:AT, were 
also used to assess pulmonary arterial systolic pressure.
The relaxation time of the myocardium in the basal lateral segment of the free wall of the RV 
‘IVRT’, measured by using tissue Doppler imaging was also used as a surrogate for 
pulmonary arterial systolic pressure. In patients with raised PA pressure, due to increased RV 
pressure, there is delay in the onset of diastole. This time lag is the isovolumic relaxation time 
‘IVRT’, which is used as a surrogate of PA pressure.
RV basal strain was also measured before and after hypoxic stimulus as a surrogate of PA 
hypertension (Dambrauskaite 2007).
Table 4.1 Echocardiographic markers of left and right ventricular function
Markers of LV function Markers of RV function
Pulsed-Doppler parameter 
LV velocity time integral (VTI)
LV pre ejection period (LV PEP)
Mitral early diastolic velocity (E)
Mitral late diastolic velocity (A)
Real-time annular myocardial velocity imagine 
Medial mitral annular velocity (MMA Ve’)
Lateral mitral annular velocity (LMA Ve’)
Colour processed myocardial velocity imaging
LV annular displacement (LV Ds’) RV annular displacement (RV Ds’)
LV basal systolic velocity (LV Vsbl) RV basal systolic velocity (RV Vsbl)
LV basal e velocity (LV Vebl) RV basal e velocity (RV Vebl)
LV basal a velocity (LV Vabl) RV basal a velocity (RV Vabl)
LV isovolumic acceleration (LV IVA) RV isovolumic acceleration (RV IVA) 
LV end systolic apical and basal strain RV end-systolic apical and basal strain
. Table 4.2 Surrogate markers of pulmonary arterial pressure
Blood pool Doppler markers Tissue Doppler markers
Tricuspid regurgitation velocity (TR) RV relaxation time (IVRT)
Pulmonary regurgitation end-diastolic velocity (PR) RV basal systolic strain (RV Ssbl)
Pulmonary artery acceleration time (AT)
Pulmonary artery ejection time (ET)
4.3 Results
Out of 92 children who were recruited for the study, a total of 90 children (28 with CLD, 32 
PT controls and 30 Term controls) participated in the cardiovascular studies. One child from 
the CLD group and one child from the preterm control group attended the pulmonary function 
tests but did not keep the appointment for the cardiovascular studies.
4.3.1 D em ographics an d  g en era l c h a rac te ris tic s
General characteristics of the participants including baseline heart rate, blood pressure and 
oxygen saturation at rest are summarised in Table 4.3. The gender and the age of the children 
were similar between the three groups. Children who had CLD were lighter than the term- 
born controls (p<0.05) but there was no significant difference in the mean height. Baseline 
heart rate, respiratory rate, oxygen saturation and blood pressure were also similar between 
the 3 groups.
4.3.2 B iochem ical m ark e rs  o f c a rd io v asc u la r  function
75/90 (84%) subjects consented to the finger prick blood test. The fasting blood glucose, total 
cholesterol, triglycerides and high density lipoprotein were within normal range in all the 
subjects and were similar between the 3 groups. 68 children (76%) also had the capillary 
blood gas analysis. Mean PaC>2 was 17% lower in the children with CLD compared with the 
term-born controls (p<0.05). There were no significant differences in the other blood gas 
parameters between the term and the preterm groups (Table 4.4)
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Table 4.3 General characteristics of the subjects (Cardiovascular study)
Parameters CLD
(n=28)
Preterm
control
(n=32)
Term control 
(n=30)
p-value
Demographics
Male: Female 17: 11 15: 17 15: 15 0.539
Gestation (wks) 27.3 (2.2) 30.0 (2.0) 39.7(1.5) <0.001 §’§§’§§§
Age (years) 10.3(1.5) 10.4(1.2) 10.6(1.5) 0.668
Height (cm) 138.0 (9.8) 141.5 (9.3) 144.3 (10.6) 0.061
Weight (kg) 30.7 (8.9) 35.6(10.9) 38.0(13.7) 0.053ft
Physiological measurements
Heart rate (per minute) 77.5 (12.0) 77.0(11.9) 73.3 (9.5) 0.289
Respiratory rate (per minute) 21.3 (4.6) 20.6 (3.7) 20.5 (3.4) 0.757
SBP (mm Hg) 105.7 (6.9) 103.6 (9.1) 101.7 (7.5) 0.158
DBP (mm Hg) 63.9 (6.7) 61.8 (8.2) 63.5 (5.9) 0.187
PP (mm Hg) 41.8 (7.6) 41.8 (9.1) 38.2 (6.4) 0.123
Oxygen saturation (%) 99.3 (0.84) 98.6(1.0) 98.8 (0.91) 0.036f
§ p<0.001 (CLD vs. preterm control), §§ p<0.001 (CLD vs. term), §§§ pO.OOl (preterm vs.
term control),t+ p<0.05 (CLD vs. term),+ p<0.05 (CLD vs. preterm control)
Table 4.4 Biochemical markers of cardiovascular function
Parameters CLD
(n=22)
Preterm
control
(n=29)
Term control 
(n=24)
p-value
Biochemical markers
Glucose 4.3 (0.94) 4.0 (0.58) 4.3 (0.78) 0.411
Cholesterol 3.8 (0.66) 3.6 (0.68) 3.6 (0.53) 0.362
Triglycerides 0.72 (0.31) 0.72 (0.20) 0.74 (0.39) 0.985
HDL 1.2 (0.37) 1.1 (0.4) 1.1 (0.27) 0.176
Capillary blood gas analysis
pH 7.4 (0.02) 7.4 (0.02) 7.4 (0.01) 0.951
p c o 2 5.2 (0.33) 5.2 (0.29) 5.1 (0.32) 0.584
po 2 9.6 (1.5) 10.4(1.0) 11.5 (2.0) 0.001§§
h c o 3 24.5 (0.97) 24.6(1.0) 24.4 (0.98) 0.811
Base excess 0.11 (1.3) 0.17(1.2) 0.02(1.1) 0.905
Results are presented as mean (SD) 
§§ p <0.001 (CLD vs. term control)
4.3.3 Electrocardiography
12-lead electrocardiography (ECG) was performed on all participants. All the children were in 
sinus rhythm. None of the children had ECG evidence of right ventricular hypertrophy. R 
wave amplitude in lead VI, QRS axis, and duration of the QRS complex, were all within 
normal limits in the control groups as well as those with CLD (Table 4.5). QRS duration was 
7% lower in the preterm children without CLD compared to the term-born children but the 
values were within normal limits in all children. 4 (15%) children in the CLD group, 4 (13%) 
children in the preterm control group and 6 (20%) children in the term control group had 
evidence of incomplete right bundle branch block.
Table 4.5 Electrocardiographic indices of right ventricular hypertrophy
ECG index CLD
(n=28)
Preterm
Control
(n=32)
Term control 
(n=30)
p-value
R wave amplitude in VI (mm) 5.4 (2.2) 5.3 (2.9) 4.5 (1.9) 0.324
QRS axis (degrees) 61.1 (57.6) 57.6 (22.1) 53.5 (28.2) 0.520
QRS duration (milliseconds) 80.6 (9.1) 78.5 (9.1) 84.5 (7.3) 0.024ftt
Results are presented as mean (SD). 
t t tp <0.05 (preterm control V Term control)
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4.3.4 Echocardiographic markers of left and right ventricular function
Left and right ventricular function
The results of the echocardiography of left and right ventricular function at baseline are 
summarised in Table 4.7.
While breathing in room air, the preterm and term-born children had normal LV and RV 
function. There were no significant differences in systolic or diastolic function either in the 
LV or the RV between those with CLD compared with the preterm and the term control 
groups. The left ventricular outflow diameter was smaller in the preterm children compared to 
the term groups but cardiac index was similar between the three groups.
Tricuspid regurgitation was present in 20/28 (71.4%) children with CLD, 20/32 (62.5%) 
preterm controls and 18/30 (60%) term-born controls. PR end-diastolic velocity was 
measurable in 25 (89.3%) in the CLD, 25 (78.1%) in the preterm control and 25 (83.3%) in 
the term control groups.
During the sniff test, all the children had >50% collapse of the inferior vena cava. Thus, there 
was no evidence of increased right atrial pressure in any of the children and RA pressure was 
estimated to be <10mm Hg (Kircher 1990).
The estimated pulmonary arterial systolic pressure at baseline was similar in all three groups: 
22 mmHg in the children with CLD, 24 mmHg in the preterm control group and 22 mmHg in 
the term-born controls.
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Subclinical changes in cardiac function after hvnoxia 
Oxygen saturation
After exposure to hypoxia, oxygen saturation measured by pulse oximetry decreased in all 
three groups. When average oxygen saturation during each period of hypoxic challenge was 
analysed, after inhalation of 15% oxygen for 20 minutes, mean oxygen saturation decreased 
by 4.4% (95% Cl, 3.7% to 5.1%, p<0.001) in the CLD group, 3.0% (95% Cl, 2.5% to 3.5%, 
p<0.001) in the preterm control group and by 3.3% (95% Cl, 2.9% to 3.7%, p<0.001) in the 
term control group. Similarly, after exposure to 12% oxygen for 20 minutes the differences in 
oxygen saturation from baseline were 7.8% (95% Cl, 6.4% to 9.1%, p<0.001), 6.1% (95% Cl, 
5.4% to 6.8%, p<0.001) and 6.3% (95% Cl, 5.6% to 7%, p<0.001) in the CLD, preterm and 
the term control groups respectively. Although the levels of average oxygen saturation 
dropped significantly in all three groups after hypoxic exposure, the levels were not 
significantly different between the three groups at any stage.
It was noted that the average oxygen saturation did not accurately represent the lowest oxygen 
saturation that the children reached at the end of the hypoxic challenge. The average and the 
lowest oxygen saturation reached at the end of each phase of the hypoxic challenge are 
summarised in Table 4.6. After exposure to 15% oxygen for 20 minutes, the mean drop in 
oxygen saturation was -13% (95% Cl, -10.1% to 15.8%, p<0.001) in the CLD group, -9% 
(95% Cl, -7.6% to -10.4%, p<0.001) in the preterm control group and -10% (95% Cl, -8.3% 
to -11.6%, p<0.001) in the term control group. Taking the lowest oxygen saturations reached, 
the mean drop in oxygen saturation at the end of hypoxic challenge with 12% oxygen was - 
17.4% (95% Cl, -15.3% to -19.4%, p<0.001) in the CLD group, -13.6% (95% Cl, -12.4% to - 
14.7%, p<0.001) in the preterm control group and -14.1% (95% Cl, -12.8% to -15.4%, 
p<0.001) in the term control group. At the end of the hypoxic challenge with 15% oxygen,
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oxygen saturation level was significantly lower in the CLD group compared to the preterm 
control group (86.2% ± 6.7% vs 89.7% ± 3.5%, p<0.05). Similarly, children with CLD had 
significantly lower level of oxygen saturation at the end of the hypoxic challenge with 12% 
oxygen compared with those in the preterm control group (81.9% ± 5.4% vs 85.1% ± 3.3%, 
p< 0.01) and the term control group (81.9% ± 5.4% vs 84.7 ± 3.6%, p< 0.05).
Table 4.6 Oxygen saturation at baseline and after hypoxic challenge
Study groups Oxygen saturations
Room air 15% Oxygen 12% Oxygen
Mean Lowest Mean Lowest
CLD 99.3% (0.84) 94.9% (1.5) 86.2% (6.7) 91.5% (3.0) 81.9% (5.4)
Preterm control 98.6% (1.0) 95.6% (1.3) 89.7% (3.5) 92.5% (2.0) 85.1% (3.3)
Term control 98.8% (0.91) 95.5(1.1) 88.8% (4.1) 92.6% (1.9) 84.7% (3.6)
ANOVA 0.036t 0.052 0.032t 0.152 0.008I)TT
Results are expressed as mean (%) and SD
+ p<0.05 (CLD vs. preterm control), * p<0.01 (CLD vs. preterm control),+t p<0.05 (CLD vs. 
term control)
Respiratory rate
Change in respiratory rate was <1% after acute hypoxia (after inhalation of 15% oxygen and 
12% oxygen compared with baseline) in all three groups of children.
After inhalation of 15% oxygen for 20 minutes, heart rate increased by 3.1% (95% Cl, 1.0% 
to 7.2%) in the CLD group, 1.4% (95% Cl, 0.7% to 5.5%) in the preterm controls and by
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4.5% (95% Cl, 1.6% to 7.3%) in the term control group. After inhalation of 12% oxygen for a 
further 20 minutes, heart rate increased by 4.7% (95% Cl, 0.04% to 9.3%), 3.9% (95% Cl, 
0.3% to 7.6%) and 6.6% (95% Cl, 3.8% to 9.5%) in the children vvith CLD, preterm and term- 
born controls respectively.
Blood pressure
Systolic blood pressure was reduced by 4.2% (95% Cl, -1.4% to -9.8%) in the prematurely 
bom children with CLD after exposure to 12% oxygen compared with baseline. In the control 
population, the change in systolic blood pressure was <1% after exposure to acute hypoxia. 
Compared with the baseline reading, diastolic blood pressure increased by 2.0% (95% Cl, 
1.0% to 4.9%) in the CLD group after inhalation of 12% Oxygen for 20 minutes. Similarly, 
diastolic blood pressure increased by 3.9% (95% Cl, 1.2% to 6.6%) in the preterm control 
group after exposure to 12% oxygen. Change in diastolic blood pressure was <1% in the term 
control group after hypoxia. Compared to the baseline, pulse pressure was reduced by -6.2% 
(95% Cl, -12.3% to -0.2%) in the CLD group and by -3.6% (95% Cl, -6.7% to -0.4%) in the 
preterm control group after exposure to 12% oxygen for 20 minutes. The mean change in 
pulse pressure was <1% in the term control group. None of these changes were statistically 
significant.
Echocardiographic parameters
The change in the echocardiographic markers of right ventricular function and surrogate 
markers of pulmonary hypertension after inhalation of 15% and 12% oxygen are summarised 
in Tables 4.8,4.9 and 4.10 for the CLD, preterm control and term control groups respectively.
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Following the hypoxic challenge, the surrogate markers for PAH changed as expected in all 
three groups of children. After inhalation of 12% oxygen, the maximum velocity of the 
tricuspid regurgitation increased by 0.38 m s'1 (95% Cl, 0.24 to 0.53 m s'1, p<0.001) in the 
children with CLD of prematurity compared to 0.18 m s'1 (95% Cl, 0.09 to 0.26 m s'1, 
p>0.05) in the preterm controls and 0.25 m s'1 (95% Cl, 0.13 to 0.36 m s'1, p<0.001) in the 
term-born controls.
Pulmonary arterial acceleration time shortened with acute hypoxia in all three groups but the 
difference was greater in the children with CLD compared to the control groups. Compared to 
the baseline, the mean difference in acceleration time was -23.8 ms (95% Cl, -32.9 to 14.7 
ms, p<0.001), -15.6 ms (95% Cl, -24.2 to -7.0 ms, p<0.001) and -19.2 (95% Cl, -25.8 to - 
12.6 ms, p<0.001) in the CLD, preterm and term control groups respectively after inhalation 
of 12% oxygen for 20 minutes. Similarly, the ratio of acceleration time to ejection time, 
AT:ET was reduced in all 3 groups after acute hypoxia. The mean difference in AT:ET after 
exposure to 12% oxygen compared to the baseline was, -0.07 (95%CI, -0.4 to 0.09, p<0.001), 
-0.05 (95% Cl, -0.02 to -0.07, p<0.05) and -0.05 (95% Cl, 0.02 to 0.08, p<0.05) in the CLD, 
preterm and term control groups.
RV relaxation time ‘IVRT’ was another surrogate marker of pulmonary arterial pressure that 
altered with hypoxia. IVRT increased by 14.3ms (95% Cl, 8.2 to 14.3 ms, p<0.05) in the CLD 
group, 8.6 ms (95% Cl, 4.0 to 12.6 ms, p<0.05) in the preterm control group and by 12.8 ms 
(95% Cl, 8.4 to 17.2 ms, p=0.001) in the term control group after exposure to 12% oxygen.
There were no statistically significant changes in the end-systolic strain after the hypoxic 
challenge in either of the groups. The end-systolic strain remained within normal limits 
throughout the hypoxic challenge test in all three groups.
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Cardiac index, which is a marker of the left ventricular output, increased by 0.2 Lmin'W2 
(95% Cl, 0.04 to 0.35 Lmin'W 2, p<0.01) after inhalation of 12% oxygen in those with CLD 
but did not alter significantly in the control groups. The rest of the echocardiographic markers 
of left ventricular function did not alter with hypoxia.
Table 4.7 Baseline echocardiographic parameters of left and right ventricular function
Echocardiographic indices
CLD
Mean (SD) 
Preterm control Term
Significance
ANOVA
LV indices
LVOT diameter (cm) 1.5(0.16) 1.6 (0.15) 1.7 (0.20) 0.00188 ttt
LV VTI (cm) 21.6(3.9) 22.1 (3.4) 23.3 (3.7) 0.200
HR (beats/min) 73.5(11.6) 72.0(11.8) 72.1 (8.7) 0.851
Cardiac index (L//min/m2) 1.6(0.41) 1.6(0.41) 1.7 (0.36) 0.364
LV PEP (ms) 65.2(16.2) 68.6(13.0) 62.4(16.4) 0.288
Mitral E velocity (m/s) 1.0 (0.13) 1.0 (0.17) 0.95(0.11) 0.310
Mitral A velocity (m/s) 0.53 (0.11) 0.51(0.13) 0.49 (0.87) 0.523
Mitral E:A 2.0 (0.47) 2.05 (0.45) 2.0 (0.35) 0.637
MMA Ve’ (m/s) 0.16(0.03) 0.14(0.02) 0.15(0.02) 0.140
LMA Ve’ (m/s) 0.18(0.04) 0.17(0.03) 0.18(0.03) 0.758
Mitral Ve’ (m/s) 0.17(0.03) 0.16(0.02) 0.16(0.02) 0.058
E:e’ 6.1 (1.0) 6.4 (1.2) 6.0 (0.96) 0.332
LV Ds’ (mm) 11.0(1.95) 11.0 (2.2) 11.6 (2.0) 0.463
LV Vsbl (cm/s) 6.3 (1.4) 6.5 (2.0) 6.7 (1.8) 0.673
LV Vebl (cm/s) 14.0 (2.0) 13.9 (2.2) 14.0 (2.7) 0.991
LV Vabl (cm/s) 2.5 (1.2) 2.7 (0.93) 14.0 (2.7) 0.800
LV T Q_vs (ms) 89.6(14.6) 112.7(42.4) 94.3 (17.7) 0.006tf t t
LV IVA (cm/s2) 1.09 (0.47) 1.06 (0.52) 0.87 (0.32) 0.199
LV Ssbl (%) -21.4 (5.8) -22.6 (7.5) -23.7 (5.7) 0.432
LV Ssal (%) -13.0 (3.8) -13.1 (4.9) -15.1 (4.2) 0.148
RV Indices
RV Ds’ (mm) 18.0 (3.3) 18.4 (2.1) 17.6 (2.4) 0.487
RV Vsbl (cm/s) 8.4 (1.9) 8.9 (1.4) 8.8 (2.0) 0.586
RV Vebl (cm/s) 11.4 (2.8) 10.7 (2.5) 10.3 (2.5) 0.257
RV Vabl (cm/s) 4.3 (2.0) 5.4 (2.2) 4.7 (2.0) 0.107
RV T Q-Vs (ms) 178.5(27.9) 175.4 (26.4) 177.9 (26.3) 0.895
RV IVA (cm/s2) 1.3 (0.64) 1.4 (0.66) 1.0 (0.37) 0.02 l +tt
RV Ssbl (%) -34.4 (9.5) -33.6 (8.4) -30.9 (9.1) 0.290
RV Ssal (%) -24.0 (8.2) -22.3 (9.5) -21.0 (6.7) 0.390
Surrogate markers for PAH
TR vel (m/s) 2.1 (0.25) 2.1 (0.36) 2.0 (0.20) 0.394
PR vel (m/s) 0.77 (0.13) 0.78 (0.16) 0.76 (0.15) 0.776
PA AT (ms) 127.4(19.9) 127.5(18.2) 122.6(19.8) 0.535
PA ET (ms) 316.8(27.4) 310.2 (28.5) 320.9 (23.0) 0.285
AT.ET 0.40 (0.05) 0.41 (0.05) 0.38 (0.05) 0.073
IVRT (ms) 53.2 (9.5) 52.6(11.9) 52.3(11.9) 0.961
88 p<0.001 (CLD vs. term control), t++ p<0.05 (preterm control vs. term control), + p<0.05 (CLD vs. preterm 
control)
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Table 4.8 Changes in echocardiographic parameters with hypoxia in children with chronic
lung disease (CLD group)
Echocardiographic
Indices
21% oxygen 
Mean (SD)
15% oxygen 
Mean (SD)
12% oxygen 
Mean (SD)
p value
LV indices
Cardiac index (L min 1 m '2) 1.6 (0.41) 1.7 (0.45) 1.8 (0.57) 0.355
LV PEP (ms) 65.2(16.2) 62.2(14.5) 60.4(13.9) 0.901
Mitral E:A 2.0 (0.47) 1.9 (0.58) 1.8 (0.48) 0.612
Mitral Ve’ (m s*1) 0.17(0.03) 0.16(0.03) 0.17(0.04) 0.623
Mitral E: Ve’ 6.1 (1.04) 6.1 (1.0) 6.0 (1.2) 0.913
RV indices
RV Ds’ (mm) 18.0 (3.3) 17.9 (3.3) 18.1 (3.5) 0.981
RV Vsbl (cm s’1) 8.4 (1.9) 8.8 (1.8) 8.9 (2.0) 0.585
RV Vebl (cm s'1) 11.4 (2.8) 11.7 (2.0) 12.3 (2.7) 0.468
RV Vabl (cm s'1) 4.3 (2.0) 4.7 (1.9) 5.8 (2.2) 0.222
RV Tq.vs (ms) 178.5 (27.9) 174.2 (25.8) 166.5 (24.8) 0.227
RV IVA (cm s'2) 1.3 (0.64) 1.3 (0.62) 1.4 (0.75) 0.373
RV Ssbl (%) -34.4 (9.5) -32.7 (9.0) -33.5 (10.3) 0.800
RV Ssal (%) -24.0 (8.2) -24.0 (6.1) -24.7 (6.3) 0.915
Surrogate markers for PAH
TR velocity (m s'1) 2.1 (0.25) 2.2 (0.26) 2.4 (0.33) <0.001§§
PR end-diastolic velocity ( m s 1) 0.77 (0.13) 0.90(0.16) 0.98 (0.26) <0.001§§
PA AT (ms) 127.4(19.9) 115.9(17.4) 103.6(21.0) <0.001§§
AT:ET 0.40 (0.05) 0.37 (0.04) 0.33 (0.06) <0.001§§
RV relaxation time ‘IVRT’ (ms) 53.2(9.5) 64.4(17.2) 65.7(18.9) 0.01 l f’n
p<0.001 (21% vs. 12%), +p<0.05 (12% vs. 15%), TT p<0.05 (21% vs. 12%)
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Table 4.9 Changes in echocardiographic parameters with hypoxia in preterm children without
chronic lung disease (Preterm control group)
Echocardiographic
Indices
21% oxygen 
Mean (SD)
15% oxygen 
Mean (SD)
12% oxygen 
Mean (SD)
p value
LV indices
Cardiac index (L min A m '2) 
LV PEP (ms)
Mitral E:A 
Mitral Ve’
Mitral E: Ve’
1.6 (0.41) 
68.6(13.0) 
2.1 (0.45) 
0.16(0.02) 
6.4 (1.2)
1.6 (0.51) 
68.5 (9.4) 
1.9 (0.43) 
0.15(0.02) 
6.3 (1.3)
1.6 (0.44) 
67.4(10.4) 
1.8 (0.36) 
0.15(0.02) 
6.4 (1.4)
0.890
0.881
0.037n
0.495
0.958
RV indices
RV Ds’ (mm)
RV Vsbl (cm s'1) 
RV Vebl (cm s'1) 
RV Vabl (cm s'1) 
RV Tq.vs (ms) 
RV IVA (cm s'2) 
RV Ssbl (%)
RV Ssal (%)
18.4 (2.1) 
8.9 (1.4) 
10.7 (2.5)
5.4 (2.2)
175.4 (26.4)
1.4 (0.66) 
-33.6 (8.4) 
-22.3 (9.5)
18.4 (2.5)
8.9 (1.8) 
10.8 (2.6)
5.2 (1.7)
173.9 (25.4)
1.2 (0.49) 
-35.3 (10.6) 
-23.1 (9.5)
18.4(1.9) 
8.8(1.50) 
11.0 (2.7) 
5.6 (2.3)
170.1 (26.0)
1.1 (0.47) 
-34.7 (7.8) 
-23.6 (9.6)
1.00
0.974
0.883
0.363
0.705
0.298
0.739
0.864
Surrogate markers for PAH
TR velocity (m s'1)
PR end-diastolic velocity (m s'1) 
PA AT (ms)
AT:ET
RV relaxation time ‘IVRT’ (ms)
2.1 (0.36) 
0.78 (0.16) 
127.5(18.2) 
0.41 (0.05) 
52.6(11.9)
2.2 (0.35) 
0.80(0.15) 
120.8(15.3) 
0.39 (0.05) 
55.2(13.7)
2.3 (0.30) 
0.91 (0.20) 
111.4(18.3) 
0.37 (0.07) 
60.5(11.3)
0.183
0.014ft
0.002§§
0.037ft
0.040t+
p<0.05 (21% vs. 12%),TT p<0.001 (21% vs. 12%)
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Table 4.10 Changes in echocardiographic parameters with hypoxia in term-born children
(Term control group)
Echocardiographic
Indices
21% oxygen 
Mean (SD)
15% oxygen 
Mean (SD)
12% oxygen 
Mean (SD)
p value
LV indices
Cardiac index (L min-1 m '2) 
LV PEP (ms)
Mitral E:A 
Mitral Ve’
Mitral E: Ve’
1.7 (0.36) 
62.4 (16.4)
2.0 (0.35) 
0.16(0.02)
6.0 (1.0)
1.7 (0.39) 
65.8(14.8)
1.8 (0.36) 
0.15(0.02) 
6.2 (1.1)
1.7 (0.48) 
65.0(16.3)
1.7 (0.29) 
0.15(0.02) 
6.3 (1.1)
0.802
0.694
0.006**
0.124
0.546
RV indices
RV Ds’ (mm)
RV Vsbl (cm s'1) 
RV Vebl (cm s'1) 
RV Vabl (cm s'1) 
RV Tq.vs (ms) 
RV IVA (cm s'2) 
RV Ssbl (%)
RV Ssal (%)
17.6 (2.4) 
8.8 (2.0) 
10.3 (2.5) 
4.7 (2.0) 
177.9 (26.3) 
1.0 (0.37) 
-30.9 (9.1) 
-21.0 (6.7)
17.8(2.7)
9.1 (2.2) 
10.4 (2.6)
4.6 (1.8)
180.6 (26.6)
1.1 (0.35) 
-32.9(10.9) 
-22.7 (6.0)
18.5 (3.0) 
9.3 (1.9)
11.1 (2.6) 
5.6 (2.4) 
170.7 (28.0) 
1.0 (0.36) 
-35.1 (10.9) 
-22.5 (8.4)
0.418
0.615
0.412
0.101
0.341
0.306
0.287
0.576
Surrogate markers for PAH
TR velocity (m s'1)
PR end-diastolic velocity (m s'1) 
PA AT (ms)
AT:ET
RV relaxation time ‘IVRT’ (ms)
2.0 (0.20) 
0.76 (0.15) 
122.6(19.8) 
0.38 (0.05) 
52.3(11.9)
2.1 (0.22) 
0.84 (0.22) 
111.9(17.6) 
0.36 (0.05) 
56.2 (14.0)
2.3 (0.16) 
0.88 (0.20) 
103.4 (23.3) 
0.33 (0.08) 
65.6 (14.4)
<0.001§§ 
0.051 
0.002** 
0.017ft 
0.001§
**p<0.01 (21% vs. 12%), ” p<0.001 (21% vs. 12%), n p<0.05 (21% vs 12%),
§p<0.001 (21% vs. 15%)
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Figure 4.15 Bar diagram show ing change in heart rate with hypoxia
* p <.05
Figure 4.16 B ar d iagram  show ing  change in resp ira tory  rate w ith  hypox ia
T here w as no sign ifican t d iffe rence betw een  g roups at baseline or after hypoxia. R espiratory 
rate did not alter sign ifican tly  in e ither o f  the g roups w ith  hypoxia.
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Figure 4.17 Bar diagram showing change in systolic blood pressure with hypoxia
140
3
*  120
100
x 80
■o 60
40
*  20 >. w
■ 21% 02  
□ 15% 02  
■ 12% 02
CLD PT Term
T here w as no sign ifican t d ifference betw een  groups at baseline o r after hypoxia. Systolic 
b lood pressure did not alter sign ifican tly  in e ither o f  the groups w ith hypoxia.
F igure 4.18 B ar d iagram  show ing  change in d iasto lic  b lood pressure w ith hypoxia
T here w as no sign ifican t d ifference betw een  groups at baseline or after hypoxia. D iastolic 
b lood pressure did not alter sign ifican tly  in e ither o f  the groups w ith hypoxia.
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Figure 4.19 Bar diagram showing change in tricuspid regurgitation systolic velocity with
hypoxia
Term
* p<0.001
Figure 4.20 Bar d iagram  show ing  change in pulm onary  regurg ita tion  end-d iasto lic  velocity  
w ith hypoxia
* p=0.001, ** p<0.05
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Figure 4.21 Bar diagram showing change in pulmonary arterial acceleration time, AT with
hypoxia
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* p<0.001, ** p=0.002
Figure 4.22 B ar d iagram  show ing  change in A T :E T  w ith  hypoxia
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Figure 4.23 Bar chart show ing change in RV relaxation time iV R T ’ with hypoxia
■ 21% 02  
□ 15% 02 
■ 12% 0 2
CLD PT Term
* p<0.05, ** p=0.001
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Figure 4.24 Figure demonstrating an example of the change in surrogate markers of 
pulmonary arterial pressure during the ‘hypoxic challenge’
21% 0 2 15% 0 2 12% 0 2
B
A. Velocity of the tricuspid regurgitation increased with increasing hypoxia
B. Pulmonary arterial acceleration time decreased with increasing hypoxia
C. Right ventricular relaxation time ‘IVRT’ increased with increasing hypoxia
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4.4 Discussion
To my knowledge, this is the first study that explores cardiovascular response to acute 
hypoxia in school aged children who had CLD in infancy. This study gives an insight into the 
myocardial function in ex-preterm school-aged children who are clinically asymptomatic.
Despite its limitations, at present, echocardiography remains the best available non-invasive 
diagnostic tool for monitoring ventricular function and for the early diagnosis of PAH in 
children with CLD. Other non-invasive methods such as CT and MRI can be used to measure 
RV volume but are more expensive and are not readily available. Claustrophobia can also be 
an issue with young children undergoing MRI study.
Specific data on echocardiographic parameters of RV function and pulmonary hypertension in 
children is currently limited.
Baseline right ventricular function
Due to the nature of the right ventricular anatomy, it is not convenient to quantify RV 
function precisely by using conventional 2-D and blood flow Doppler echocardiography. 
Therefore, I used myocardial velocity imaging to quantify RV long axis systolic and diastolic 
function. I used the measurements from the term-born control population in our study as a 
comparison to asses RV myocardial function in those born prematurely with and without the 
history of CLD in infancy.
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RV annular displacement, a marker of global RV systolic function was similar to that of the 
preterm and term-born controls. Similarly, the peak systolic and diastolic velocities were also 
similar to the control groups.
The statistical difference in the RV isovolumic acceleration between the preterm and the term 
control groups is unlikely to have any clinical significance as the indices are within normal 
limits and there is no ‘trend’ in the differences between the term and the preterm groups. 
Besides, the reproducibility of this index is not reliable (Joshi 2010).
RV systolic strain in our study population was normal at baseline. The values of RV systolic 
strain were comparable to the published data on healthy children (4-16 year old) (Weidemann 
2002). In an adult study, non-invasively measured RV peak systolic strain has been shown to 
correlate well with invasively measured RV haemodynamics in patients with normal LV 
function (Rajagopalan 2008). In my study, none of the children had LV dysfunction clinically 
or echocardiographically. Therefore, the normal RV strain in these children should indicate 
normal RV haemodynamics at rest.
The RV myocardial velocity, displacement indices and strain indices were similar in those 
with CLD of prematurity and the preterm and term-born control population. This indicates 
that there was no evidence of RV systolic or diastolic dysfunction in the children with CLD at 
rest.
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Baseline left ventricular function
The LV outflow tract diameter was smaller in the children with CLD compared to the 
children in the control groups but cardiac index was within normal limits in all three groups 
and the difference between the groups was not statistically significant.
Left ventricular filling pressure is an important marker of LV diastolic function. Trans-mitral 
E and A velocities were measured to assess LV filling pattern. The mean ratio of E:A was >1 
in all three groups of children implying normal LV filling pressure.
I also used the myocardial velocity imaging to measure LV annular displacement. The 
displacement of the mitral annulus during systole provides a surrogate measure of the LV 
myocardial long axis systolic function. There was no statistically significant difference 
between the LV annular displacements between the children with CLD and those in the 
control groups.
The normal cardiac index and normal ratio of the mitral inflow velocities (E:A >1) along with 
normal LV displacement indicate normal LV global systolic function in the children with 
CLD.
Left ventricular filling pattern (E:A) reflects early diastolic changes and the ratio of early 
diastolic mitral inflow velocity to early diastolic velocity of the mitral annular motion, E:Ve’ 
has been shown to correlate well with mean ventricular filling pressure. This has been 
validated in adults as a useful tool to assess LV diastolic function in adults (Sohn 1997; 
Ommen 2000). In one adult study, E:Ve’ >10 was shown to correlate with raised filling 
pressure when lateral Ve’ was used (Nagueh 1997) whereas another study has shown that 
E:Ve’ ratio of >15 correlated with elevated filling pressure when medial Ve’ was used
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.(Ommen 2000). As it is not yet clear whether the medial or the lateral mitral annular velocity 
is more useful for diagnosing diastolic dysfunction, I opted to measure both medial and lateral 
mitral annular velocities and used the average of the medial and lateral mitral annular e’ 
velocity as mean Ve’ to calculate the ratio E:Ve’. In this study, all three study groups had 
mean E:Ve’ ratio of <7. Thus there was no evidence of LV global diastolic dysfunction in 
children with CLD.
In order to assess the regional LV myocardial function, I measured the systolic and diastolic 
velocities of the basal segment of the LV wall using myocardial velocity imaging. I also 
measured the LV systolic strain which is a deformation index at the basal and the apical wall 
of the LV. We used the data from our term-born control population as reference values for 
healthy subjects. On comparing the LV myocardial systolic and diastolic velocities between 
different groups, I did not find any difference between the values in the children with CLD to 
the preterm and term-born controls. Similarly, LV myocardial strain at the apical and the 
basal segments were also similar between the groups indicating normal deformation indices.
I noted that the mean value for the time interval between QRS complex and peak systolic 
velocity (T q.Vs) was lower in the preterm group compared to those with CLD and term-born 
controls. T Q.Vs is a marker of electromechanical delay in the LV systolic function. However, 
as there was no trend of this time interval being longer in the children with CLD compared to 
the control groups, and given the evidence that this echocardiographic index has a wide 
observer variation (Joshi 2010), I think that this difference may be a result of a type I error 
due to multiple comparisons and is unlikely to be of clinical significance.
Thus, I noted that at school age, ex-preterm children with CLD had normal global and 
regional systolic and diastolic LV function at rest.
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Cardiovascular response to hypoxia
Following hypoxic stimulus, I noticed a clear physiological response in all three groups of 
children. In healthy adult population, Ingram et al had reported that arterial oxygen saturation 
fell from 98 ± 0.2% to 83 ± 1.7% following exposure to 12 % oxygen in a hypoxic chamber 
(Ingram 2010). The drop in oxygen saturation from baseline to the end of hypoxic challenge 
with 12% oxygen in our study groups (99.3 ± 0.8% to 81.9 ± 5.4% in CLD, 98.6 ± 1.0% to 
85.1 ± 3.3% in preterm CLD and 98.8 ± 0.9% to 84.7 ± 3.6% in term control) were similar to 
that reported by Ingram et al. The fact that the children had all responded by dropping their 
oxygen saturation after exposure to 15% oxygen and 12% oxygen, we can be certain that the 
desired physiological effect had been achieved.
Although those with CLD had a higher mean pulmonary arterial systolic pressure at baseline 
and after hypoxic stimulus, this difference did not reach statistical significance compared to 
other groups even after hypoxic stimulus. Similarly, PA AT and AT:ET ratio shortened in all 
three groups of children following hypoxic stimulus. This reflects the increasing PA pressure 
with acute hypoxia. However, the difference in PA AT or the AT:ET ratio was not 
significantly different between those with CLD and the control population.
In addition to the above methods, which have been traditionally used to estimate pulmonary 
arterial pressure, I also used the more advanced tissue Doppler methods to overcome the 
drawbacks of the conventional methods as described in section 1.6. In adult patients, RV 
relaxation time has been shown to have a significant correlation with pulmonary artery 
systolic pressure (r=0.71, p<0.01) in adults undergoing cardiac catheterization for different 
cardiac conditions (Lindqvist 2006) This has not yet been validated in the paediatric
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population. In the subjects in this study, I noted that RV relaxation time ‘IVRT’ increased 
with hypoxia as expected in all three groups of children. Again the difference in the RV 
relaxation time remained insignificant between groups even after the hypoxic stimulus. This 
indicates that although RV early diastolic pressure increased with exposure to acute hypoxia 
in all groups, the differences between groups were not statistically significant.
Some adult studies have also suggested that RV myocardial systolic strain correlates well 
with pulmonary vascular resistance (Dambrauskaite 2007; Rajagopalan 2008) Therefore I 
measured RV myocardial strain at the apical and the basal segments before and after hypoxic 
challenge test. I noted that the RV systolic strain at the basal segment increased following the 
hypoxic stimulus but remained stable in the preterm groups with and without CLD. The RV 
basal strain remained within normal limits in the CLD group as well as the control groups 
throughout the study, and the differences in the RV basal strain before and after the hypoxic 
stimulus was not statistically significant.
Thus, I conclude that the 8-12 year old children with CLD had normal cardiovascular function 
at rest and there was no echocardiographic evidence of subclinical pulmonary arterial 
hypertension even after exposure to acute hypoxia.
Limitations
Sample size
As there are no previous studies on pulmonary vascular response to hypoxia in ex-preterm 
children, I based my sample size on a study by Sartori et al (Sartori 1999). Sartori and 
colleagues had studied term-born young adults who had persistent pulmonary hypertension
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rather than those with CLD of prematurity. Thus, the sample size was based on a study that 
had a different study population with regards to their disease pathology.
Hypoxic challenge test: Challenees and limitations
Induction of hypoxia in children was technically and ethically challenging. I used delivery of 
high-flow oxygen via a non-rebreathing mask to deliver 15% and 12% oxygen to the subjects. 
Although this method has been validated for hypoxic challenge tests, I had no means to 
measure the accuracy of the concentration of inhaled oxygen. Use of an environmental 
chamber to create hypobaric hypoxic environment would have been an ideal choice to 
replicate altitude induced hypoxia and would also have ensured continuous gas exchange 
without alteration in CO2 level. The problem with using a hypoxic chamber was two-fold. 
Firstly, the chamber was not available on-site at Cardiff University and secondly, it takes 
about an hour to change the concentration of oxygen within the environmental chamber 
(Ingram 2010). To ensure, that the hypoxic challenge was conducted in a safe and controlled 
manner, the study was designed for step-wise hypoxic induction with initial exposure to 15% 
oxygen and then to 12% oxygen. This meant that use of environmental chamber would have 
been impractical.
It can be argued that if the children were allowed to achieve lower levels of oxygen saturation 
(eg <80%), the hypoxic stimulus may have unmasked subclincial pulmonary hypertension and 
RV dysfunction more accurately. However, in order to abide by the advice given by the ethics 
committee, I had to ensure that the children did not desaturate below 80% for >30 seconds.
Limitations of tissue Doppler echocardiography
Although myocardial velocity and strain imaging provide accurate measures of regional 
myocardial function, they are associated with a number of technical problems. Strain images
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may be characterised by signal noise compromising image quality. It is also angle dependent 
and tissue direction should be within 30° of the beam for meaningful measurements to be 
made. As evident from our reproducibility study (Joshi 2010), the intraobserver variability for 
most of the myocardial velocity indices are acceptable (CV<15%), but interobserver 
variability for some of the more complex indices such as strain (CV >30%) and isovolumic 
acceleration (CV>40%) are sub-optimal.
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Chapter Five: Body Composition and its Subclinical 
Relationship to Lung Function and Cardiovascular 
Function
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5.1 Introduction
Preterm children with CLD can often suffer from malnutrition in infancy (Huysman 2003). In 
infants with CLD, higher resting metabolic demand has been speculated to be one of the 
important causes of relative malnutrition (Kurzner 1988). As I discussed in Chapter 2, 
prematurely bom children with CLD continue to have lower body weight compared with age 
and gender matched control population at school age. My data has also suggested that 
children who had CLD in infancy use higher ventilatory reserve to reach the same exercise 
limit as the preterm and term-born control children (Section 2.3.3.4). There is some evidence 
that malnutrition at a younger age is related to impaired lung function in school aged children 
with CLD (Bott 2006). Low birth weight has also been shown to be associated with impaired 
endothelial function in adulthood (Goodfellow 1998). It is not clear if school aged children 
with CLD continue to have altered body composition and whether this has any effect on their 
cardiopulmonary health.
Although body mass index (BMI) is widely used as a surrogate measure of adiposity, it is a 
measure of excess weight relative to height rather than excess body fat relative to height. BMI 
has in fact been shown to be strongly associated with fat mass index in those with BMI >85* 
centile but associated more with fat free mass index in those with BMI <50* centile 
(Freedman 2005). Bioelectrical impedance analysis (BIA) is a simple and quick method of 
assessing body composition. This method of measurement of impedance has been validated 
against DXA in healthy children (Sung 2001). In this study, the 95% limits of agreement 
between BIA and DXA methods were considered acceptable (-3.34 kg to -0.52 kg for fat 
mass and -0.39 g to 2.36 kg for fat free mass). BIA has also been validated in children with 
CLD (Bott 2006). In children with CLD, BIE was shown to overestimate fat mass (mean 
difference: 0.34 kg ± 2.06) and underestimate fat free mass (mean difference: -1.24 kg ± 3.32)
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compared to DXA. The adjustments of fat mass and fat free mass for height as fat 
mass/height2 = Fat mass index (FMI) and fat free mass/height2 = Fat free mass index (FFMI) 
respectively have also been validated in children (Wells 2002). Using FMI and FFMI as 
indices for measurement of body composition, Fewtrell et al have demonstrated that 
prematurely bom children had significantly lower FMI compared to term-born children at 8- 
12 years but there was no difference in FFMI between the two groups (Fewtrell 2004).
I aimed to study the differences in body composition parameters between preterm children 
with CLD compared with preterm and term-bom controls, and also the relationship of body 
composition with respiratory and cardiovascular functions.
5.2 Methods
5.2.1 Measurement of body composition
All children had their body composition measured by bioimpedance analysis using a leg to leg 
body composition analyser (Tanita BC-418MA, UK). Prior to the measurement of the body 
composition, the children were asked to empty their bladder, remove their shoes, socks and 
heavy clothing, empty their pockets and it was ensured that they did not have any internal 
medical devices. One child with internal medical device/ implants was excluded from this part 
of the study. Height was measured using a stadiometer. The child’s height and age were 
entered manually. The children were then asked to stand on the weighing platform of the body 
composition analyser and to grasp the hand grips with both hands until the analyser calculated 
the body weight, body mass index, percentage of total body fat, fat free mass and total body 
water.
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Fat mass index (FMI) was calculated as fat mass/ht2 and fat free mass index (FFMI) was
calculated as fat free mass / ht2.
Statistical analysis
Body composition parameters are presented as mean and standard deviation. The difference 
between the groups was tested using analysis of variance (ANOVA) and p<0.05 was 
considered to be significant.
Correlations between the body composition parameters and the pulmonary function or the 
cardiovascular parameters were tested using a Pearson’s test, p value of <0.05 was considered 
to be statistically significant. This was tested across the study population and not for 
individual groups. Results are presented as Pearson’s correlation coefficient (r) and the p 
value.
5.3 Results
5.3.1 Body composition
One child from the CLD group did not have the body impedance measured because of an 
internal medical device (cochlear implant).
The results of the body composition are summarised in Table 5.1.
Children with the history of neonatal CLD were 16% lighter than the preterm controls and 
24% lighter than the term-born controls (p<0.05) but they had achieved similar height to the
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children in the control groups. Body mass index was 10% lower in those with CLD compared 
with PT controls and 13% less compared with the term-born controls. Those with CLD also 
had lower fat% (23% less vs preterm controls and 22% less vs term controls), lower fat mass 
index (38% less vs preterm controls and 45% less vs term controls), lower fat free mass index 
(4% less vs preterm controls and 5% less vs term controls), lower total body water (11% less 
vs preterm controls and 16% less vs term controls) and lower basal metabolic rate (4% less vs 
preterm controls and 7% less vs term controls). Although the mean values for the above 
parameters were less in the CLD group, apart from the body weight, none of the other 
differences in the body composition (FMI, FFMI, total body water) were statistically 
significant.
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Table 5.1 Results of the measurement of body composition
Parameters CLD
(n=27)
Preterm control Term control 
(n=32) (n=30)
ANOVA
Weight 30.7 (8.9) 35.6(10.9) 38.0(13.7) 0.053tt
Body mass index (kg m'2) 15.8 (2.9) 17.4 (3.7) 17.9 (4.6) 0.122
Fat % 17.6(4.4) 21.7 (6.2) 21.5 (8.6) 0.044*
Fat mass index (kg m'2) 2.9 (1.2) 4.0 (2.2) 4.2 (2.9) 0.068
Fat free mass index (kg m'2>13.0(1.9) 13.5(1.7) 13.7(1.9) 0.341
Total body water (kg) 18.3 (4.8) 20.1 (4.7) 21.2 (5.3) 0.106
Basal metabolic rate (kcal) 1180.9(180.7) 1225.3 (184.5) 1262.7 (205.6) 0.276
Results are presented as mean (SD) 
p<0.05 (CLD vs. Term)
* Tukey’s post hoc test did not show significant difference between the individual groups.
5.3.2 Subclinicial relationship between body composition and lung 
function
Across the study population, BMI was positively related to total duration of exercise, 
maximum load at peak exercise, maximum voluntary ventilation (M W ) and ventilatory 
reserve (VR). Maximum load at peak exercise was correlated with FFMI, but not with FMI. 
M W  and VR were correlated to both FMI and FFMI. Oxygen consumption at peak exercise 
(V 0 2) had negative correlation with BMI. FEVi and alveolar diffusion capacity (DLCo) did 
not correlate with BMI (Table 5.2).
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Table 5.2 Correlation between body composition and pulmonary function
FEVi
(%)
DLco
(% )
vo2
(ml/kg/min)
Exercise
Duration
(seconds)
Load
(Watts)
M W VR
BMI
(kg m'2)
0.093 0.156 -0.673§ 0.407§ 0.335* 0.463§ 0.305*
FMI 
(kg m'2)
0.046 0.107 -0.698^ 0.234* 0.195 0.349* 0.287*
FFMI
(kgm-2)
0.137 0.198 -0.549§ 0.549§ 0.447§ 0.538§ 0.282*
Results are expressed in Pearson’s r 
*p<0.05,* p<0.01,§ p<0.001
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Figure 5.1 Scatter plot show ing relationships betw een peak V O , and body com position
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5.3.3 Subclinical relationship between body composition and markers of 
cardiovascular function
Relationship with physiological markers of cardiovascular function
Body mass index, including both fat mass index and fat free mass index moderately correlated 
with the systolic blood pressure and the pulse pressure, but not the diastolic blood pressure. 
Pearson’s correlation coefficients for these relationships are shown in Table 5.3. There was no 
significant correlation between the body composition and the resting heart rate.
Table 5.3 Correlation between body composition and systemic blood pressure
BMI FMI FFMI
SBP (mm Hg) 0.323* 0.3381 0.225+
DBP (mm Hg) -0.007 0.063 -0.066
PP (mm Hg) 0.326* 0.278* 0.282*
BMI = Body mass index, FMI = Fat mass index, FFMI = Fat free mass index 
SBP = Systolic blood pressure, DBP = Diastolic blood pressure, PP = Pulse pressure 
Results are expressed in Pearson’s r 
+p<0.05, * p<0.01,§ p<0.001
Relationship with biochemical tests and body composition
Fasting serum triglyceride had a positive correlation with BMI (r=0.368, p<0.01), FMI 
(r=0.443, p<0.001) and FFMI (r=0.313, p<0.01). As expected, high density lipoprotein had a 
negative correlation with BMI (r= -0.406, p<0.001), FMI (r= -0.300, p<0.01) and FFMI 
(r= -0.387, p<0.001). Fasting blood glucose and cholesterol were not associated with the BMI.
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Table 5.4 Correlation between body composition and biochemical markers of cardiovascular
function
BMI FMI FFMI
Fasting glucose 0.210 0.148 0.227
Cholesterol -0.028 0.023 -0.122
Triglycerides 0.368* 0.443§ 0.313*
High density lipoprotein -0.406§ -0.386* -0.371*
Results are expressed in Pearson’s r
V 0 .0 5 ,* p<0.01,§ p<0.001
Relationship with echocardiograohic parameters of left ventricular function 
BMI was noted to have a negative correlation with the cardiac output (r= -0.475, p<0.001). 
This relationship was noted both with FMI (r= -0.383, p<0.001) and with FFMI (r= -0.591, 
p<0.001). Mitral annular e velocity (Ve’) at the septal wall also demonstrated a negative 
correlation with FMI (r= -0.225, p<0.05) but not with the FFMI. The other echocardiographic 
parameters for LV function did not demonstrate any relationship with the body composition.
Relationship with echocardiographic parameters of right ventricular function 
RV annular displacement at rest was noted to be negatively correlated to FMI (r= -0.295, 
p<0.01). Similar negative relationship with FMI were also demonstrated by RV e velocity (r= 
-0.236, p<0.05) and RV end-systolic strain at rest (r=0.257, p<0.05) at the basal wall. There 
were no significant correlations with the FFMI. RV systolic velocity did not demonstrate any 
relationship with body composition.
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Relationship with surrogate markers of pulmonary arterial pressure
Positive correlation was demonstrated between the TR maximum velocity and FMI (r=0.416, 
pO.OOl) and FFMI (r=0.415, p<0.001). There was a clear negative correlation between FMI 
and pulmonary arterial acceleration time, AT (r= -0.385, pO.OOl) as well as with the ratio of 
acceleration time to ejection time, AT: ET (i= -0.336, pO.OOl). RV relaxation time ‘IVRT’ 
did not demonstrate any correlation with body composition.
5.4 Discussion
Previous studies have demonstrated that preterm infants without CLD tend to catch up term- 
born controls with their height and weight by 2 years of age (Carver 2001; Lucas 2001). The 
effect of CLD on catch-up growth has not yet been studied. My study has demonstrated that 
children with CLD continue to have lower body weight compared with the preterm and term- 
born control subjects at school age. It is also clear from the body composition data that the 
lower body weight in those with CLD is primarily contributed by their lower FMI rather than 
the FFMI. BMI in the children with CLD consisted of 18% FMI and 82% FFMI, whereas 
BMI in both the control groups consisted of 23% FMI and 77% FFMI. This is in keeping with 
the results from the study by Fewtrell et al. in which the authors reported significantly lower 
FMI (3.34 kg/m2± 1.62 vs 3.89 kg/m2 ± 1.74, p <0.005) in 497 preterm children compared to 
that of 95 term controls at 8 to 12 years. The authors used DXA to study body composition in 
this study. FFMI was not significantly different the two groups in this study. The difference in 
body composition in preterm children with and without CLD was not explored by the authors.
Although there is no current evidence of a clear relationship between nutritional status and 
airway obstruction in adults with COPD, weight loss and low body weight have been shown
to be associated with decreased diffusing capacity (Engelen 1994; Engelen 1999). 
Furthermore, lower body weight, which is presumably related to lower fat free mass has been 
associated with higher mortality in adults with COPD (Landbo 1999).
A previous study on 4-8 year old children with CLD did not show any correlation between 
body composition at the time of the study with their pulmonary function (Bott 2006). 
However, Bott et al had not performed cardiopulmonary exercise test in the subjects in their 
study. The lack of relationship between BMI and FEVi/ or DLco in my study may be because 
of normal FFMI in the subjects, including those with CLD. However, it is clear that those 
children with high BMI are likely to have lower V 0 2 at peak exercise despite being able to 
exercise for a longer period. It is also interesting to note that although the duration of exercise 
is positively related to BMI (FMI and FFMI), exercise load is positively related only to FFMI 
and not with FMI.
The adverse effect of childhood obesity on increased cardiovascular morbidity and mortality 
in adulthood is clear from epidemiological studies (Berenson 1998; Reilly 2003; Bjorge 
2008). The relationships between body composition and subclinical myocardial dysfunction 
in children have not yet been explored. In an adult study, 109 overweight (BMI 25-30 kg/m2) 
or obese (BMI>30 kg/m2) subjects without overt heart disease and 33 healthy controls with 
BMI<25 kg/m2 underwent transthoracic echocardiography of the left ventricle (Wong 2004). 
The authors noted that although LV ejection fraction was similar between the subjects and the 
controls, there were significant differences in regional and global LV strain as well as systolic 
and early diastolic LV myocardial velocities (pO.OOl). Mitral e’ velocity and LV early 
diastolic velocity was lower (pO.Ol) and the E/e’ ratio was increased in the obese population 
compared to the healthy controls, signifying LV diastolic dysfunction. In this study, 
significant correlations were demonstrated between BMI and LV septal strain (r= -0.44,
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pO.OOl), LV myocardial systolic velocity (r= -0.59, pO.OOl) and LV myocardial early 
diastolic velocity (r= -0.46, p 0 .001). In my study, I have demonstrated that higher BMI was 
related to increased systolic blood pressure (r=0.32, pO.Ol) in children. In the children in my 
study, cardiac output (r= -0.48, pO.OOl) and mitral early diastolic velocity (r= -0.23, p 0 .05 ) 
also correlated with FMI. In this study, none of the children had BMI>25. If these 
relationships are tested in children with wider range of BMI, including obese children, the 
subclinical correlation of obesity and LV dysfunction in childhood may become clearer.
In summary, as evident from the body composition data from my study, higher FMI seem to 
be a risk factor for impaired exercise capacity, impaired myocardial function and increased 
systemic as well as pulmonary hypertension. In view of these results, future studies designed 
to study the relationships between body composition and myocardial function in preterm 
children may clarify the role of malnutrition in cardiopulmonary health and thus help in long 
term management of nutritional and cardiopulmonary health in preterm children with and 
without CLD.
Lim itations
Measurement of body composition
I used bioelectrical impedance analysis (BIA) to measure body composition in the subjects of 
this study. Although BIA is not a reference criterion for measurement of body composition, 
BIA is a non-invasive, quick and easy method which has been validated for good estimation 
of body fat in general. One potential drawback of BIA is that it may underestimate fat mass 
and overestimate fat free mass in obese subjects (Coppini 2005). The average BMI of each 
group of children was below the level of obesity. Therefore, this should not cause inaccuracy 
in the results of this study. BIA is also hydration dependent. Taking this into account, I
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ensured that BIA was measured in the morning after voiding and also ensured that the 
subjects did not have caffeine prior to the measurement.
Subclinical relationships
The present study was powered to detect differences in outcomes other than body 
composition. Therefore, results presented in this section on body composition in children with 
CLD and its relationship with cardiorespiratory outcomes should be regarded as descriptive 
rather than conclusive.
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Chapter Six: Summary and Conclusions
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6.1 Overview
With improvements in neonatal care over the last two decades, there has been an 
epidemiological shift and a change in pathology of chronic lung disease of prematurity 
(CLD). Arrested lung growth and alveolar hypoplasia have replaced severe airway injury and 
fibrosis seen in children who had ‘old CLD’(Coalson 2003). In recent years, the ‘vascular 
hypothesis’ of CLD has also been proposed (Abman 2001). In this thesis, I have presented the 
findings of a detailed study on respiratory, cardiovascular and nutritional status of 8-12 year 
old children who were bom prematurely and had chronic lung disease in infancy, and 
compared the findings with age and gender matched preterm and term-born control 
population. I have also studied the effects of acute hypoxia on myocardial function and 
pulmonary vascular reactivity, and I have explored the subclinical relationships between 
nutritional, respiratory and cardiovascular functions. All the prematurely bom children in this 
study who required mechanical ventilation after birth had received surfactant. Therefore, this 
population represents true CLD in the ‘surfactant era’.
Summary of key findings 
Pulm onary function  s tu d ie s  (C hap ter two):
• Children with a history of CLD had lower percent predicted values for FEVi, FEF 2 5 -7 5  and 
PEF than the preterm and term-bom control population, thus demonstrating evidence of 
airway obstruction.
• The drop in FEVI after exercise was more profound in those who had CLD in infancy than 
in the control groups. Children with CLD also demonstrated a greater response to
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bronchodilator therapy compared to the two control groups, thus suggesting under­
diagnosed exercise induced bronchoconstriction.
• DLco and KCO adjusted for haemoglobin were significantly lower in the CLD group 
compared to preterm control and term control groups. These findings suggest impaired 
alveolar diffusion capacity in the CLD group.
• Children in the CLD group had significantly higher specific resistance, residual volume, 
and RV: TLC ratio than the control groups suggesting lung hyperinflation.
• During the cardiopulmonary exercise test, all three groups of children managed to achieve 
similar exercise load, exercise duration, maximum vo 2and maximum VC02 at peak 
exercise. However, those in the CLD group demonstrated lower maximal voluntary 
ventilation and ventilatory reserve.
• Multiple linear regression demonstrated linear relationship between ventilatory reserve and 
gestational age at birth, duration of oxygen dependency, DLco corrected for haemoglobin, 
maximum respiratory rate during exercise, maximum load and peakvo2.
• Finally, prematurely bom children who did not develop CLD in infancy i.e. preterm 
control population did not have any evidence of lung function limitation compared to the 
term-born population.
C ardiovascular s tu d ie s  (C hapter four):
• At baseline, indices for right ventricular function, surrogate markers for pulmonary arterial 
hypertension and left ventricular function were similar in the children who had CLD in 
infancy and the control groups.
• Arterial oxygen saturation decreased in all three groups of children in response to hypoxic 
stimulus but the response was greater in those with CLD (17% drop in the CLD V 13%
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drop in the preterm and term controls after inhalation of 12% oxygen compared to 
baseline) (statistically not significant).
• At the end of the hypoxic challenge i.e. after inhalation of 12% oxygen for 20 minutes, 
lowest oxygen saturation reached was significantly lower in the CLD group compared to 
both the preterm and the term control groups.
• In response to the hypoxic stimulus, all three groups of children demonstrated indirect 
evidence of increased pulmonary arterial pressure: Increase in TR systolic velocity, PR 
end-diastolic velocity, shortening of pulmonary AT, reduction in AT:ET ratio and the 
increase in RV relaxation time ‘IVRT’. The changes in these surrogate markers of 
pulmonary arterial pressure were statistically significant between the baseline and after 
inhalation of 12% oxygen. None of the indices were significantly different between the 
groups.
Body com position : (C hapter five)
• Prematurely bom children who had CLD in infancy were significantly lighter than the age 
and gender matched preterm and term-born controls.
• Although body mass index, including both fat mass index and fat free mass index were 
lower in the preterm CLD group compared to the control populations, these differences 
were not statistically significant.
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6.2 General discussion
6.2.1 Pulm onary function  in ch ild ren  with ch ron ic  lung d ise a se  of 
prem aturity
It is already known from previous studies that CLD is associated with increased respiratory 
morbidity (Greenough 1996; Greenough 2005) and increased hospitalization (Cunningham 
1991; Chye and Gray 1995) during infancy and early childhood. CLD is also associated with 
persistent small airway obstruction (Doyle 2006; Hennessy 2008; Fawke 2010) at school age, 
and impaired alveolar diffusion capacity in infancy (Balinotti 2010), childhood (Welsh 2010) 
and young adulthood (Vrijlandt 2006). There is limited evidence on reversibility of airway 
obstruction, exercise induced bronchospasm and exercise capacity in these children. Data on 
exercise capacity in children with CLD are inconsistent. Current scientific knowledge on 
association between perinatal factors and different aspects of pulmonary function is also 
limited.
In keeping with the previous studies (Balinotti 2010; Fawke 2010; Welsh 2010), children with 
CLD in this study had persistent airway obstruction and impaired diffusion capacity at 8-12 
years of age, compared to the age and gender matched preterm and term-born controls. This 
study also demonstrated exercise induced bronchoconstriction in children with CLD, who had 
a greater response to inhaled bronchodilator than the preterm and term control groups. Despite 
significantly higher response to bronchodilator, those with CLD had lower post- 
bronchodilator FEVi than the children in the control groups. Oxygen uptake and carbon 
dioxide production at peak exercise in children with CLD were similar to the preterm and 
term-born controls. Although children with CLD were capable of reaching similar exercise 
load as the control populations, this was at the expense of using greater ventilatory reserve. 
This study has also demonstrated some evidence that neonatal factors such as gestational age
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at birth and duration of oxygen dependency may affect respiratory outcome later in life. This 
needs to be explored further in future studies.
With increasing number of preterm survivors, there has been concern that these children may 
have impaired lung function and may develop COPD like disease as they grow older, 
especially if they smoke (Baraldi 2007). A recently published study on asymptomatic adult 
smokers has revealed that spirometric, plethysmographic and CO diffusion tests are useful in 
detecting signs of COPD in these clinically asymptomatic adult smokers. Decreased 
FEVi/FVC and increased RV/TLC were noted in heavy smokers although they did not have 
any clinical signs of COPD. Lung emphysema was seen in 17/50 chronic smokers and 10 of 
them had decreased DLco (Nagelmann 2011). Given that the children with CLD in my study 
had significantly lower FEVi, CO diffusion capacity and increased RV/TLC, this study has 
added to the current eveidence that prematurely bom children with CLD may be at higher risk 
of developing COPD as adults.
6.2.2 C ard iovascu lar fu n c tio n  in ch ild ren  with ch ron ic  lung d ise a se  of 
prem aturity
Premature birth is known to be associated with abnormal pulmonary vascular development 
(Hislop and Haworth 1990). Preterm infants with CLD have evidence of increased pulmonary 
arterial pressure (Evans and Archer 2001). Persistence of abnormal lung function in these 
children may be a potential risk factor for development of pulmonary hypertension and 
subclinical right ventricular dysfunction but there are limited data on cardiovascular follow- 
up of children with CLD. In view of the ‘vascular hypothesis’ suggesting that ‘angiogenesis is 
necessary for alveolization during normal lung development, and that injury to the developing 
pulmonary circulation during a critical period of growth can also contribute to lung
hypoplasia’ (Abman 2001), it is reasonable to assume that impaired lung function in 
prematurely bom children would correlate with subclinical pulmonary hypertension and right 
ventricular dysfunction.
Historically, it has been assumed that precise assessment of right ventricular function using 
non-invasive methods is technically difficult. With recent technological advances, it is now 
possible to assess right ventricular function and pulmonary arterial pressure using ‘myocardial 
velocity imaging’. Although myocardial velocity imaging has previously been used to study 
subclinical right ventricular dysfunction in adult patient with cystic fibrosis (Ionescu 2001) 
and chronic obstructive pulmonary disease (Caso 2001; Sabit 2010), this method has not been 
used to study subclinical myocardial dysfunction in children with CLD of prematurity. I used 
conventional blood-flow Doppler methods as well as new methods of tissue Doppler imaging 
or myocardial velocity imaging to assess right ventricular function and surrogate markers of 
pulmonary arterial hypertension at rest and after exposure to acute hypoxia.
Although 8-12 year old children with CLD had persistently limited lung function, their right 
and left ventricular function at rest was normal. The echocardiographic parameters for their 
myocardial function were similar to those of the preterm and term-born control population. 
The haemodynamic response to acute hypoxia in children with CLD was in general similar to 
that of children in the control groups but the children with CLD achieved lower oxygen 
saturation compared to the control population after hypoxic stimulation. Whether or not this 
has any clinical significance is not yet clear. There was no evidence of myocardial 
dysfunction or raised RV systolic pressure after exposure to acute hypoxia in either the CLD 
group or the control groups.
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The physiological and biochemical markers of cardiovascular disease were normal in the 
children with CLD in this study. The results of the body composition suggest that lower fat 
mass index may have helped the children with CLD to maintain normal systemic blood 
pressure, blood lipids and normal myocardial function.
6.3 Clinical implications of this study
• Prematurely bom children with CLD continue to have impaired lung function at school 
age, and may benefit with clinical follow-up, including ‘pulmonary function tests’ even if 
they are clinically asymptomatic.
• If future studies confirm that children with CLD have subclinical reversible airway disease, 
the benefit of bronchodilator treatment in these children should be considered.
• In view of the evidence that children with CLD have impaired lung function and that they 
maintain their exercise level at the expense of their ventilatory reserve, these children 
should be actively discouraged to smoke tobacco as they grow into young adults.
• As children with CLD are at risk of developing right ventricular dysfunction secondary to 
pulmonary disease, these children may benefit with dietary advice to maintain relatively 
low fat mass without compromising their general weight.
• In view of the normal cardiovascular function in children with CLD in this study, there is 
no evidence for routine cardiovascular follow-up in these children if they remain 
asymptomatic. However, deteriorating pulmonary function may warrant cardiovascular 
assessment even in asymptomatic children.
2 0 0
6.4 Future and ongoing research
• Prospective longitudinal studies of pulmonary function and pulmonary vascular reactivity 
in prematurely bom infants will be useful in determining the natural history of airway 
disease and pulmonary vascular resistance in patients with CLD of prematurity. 
Longitudinal studies would be the only way to determine whether or not pulmonary 
dysfunction in these children may lead to early aging of the lungs in young adulthood and 
whether or not this leads subclinical pulmonary hypertension.
• Although echocardiography is an extremely useful diagnostic tool for assessment of RV 
function and pulmonary arterial pressure, reproducibility of some of the more complex 
parameters such as deformation indices and isovolumic acceleration are sub-optimal at 
present. Magnetic resonance imaging (MRI) is now being explored to study RV function 
and pulmonary blood flow (Kondo 1992; Champion 2009). Further research on RV 
function and pulmonary haemodynamics in ex-preterm children using MRI is currently 
being undertaken within our department as well. Reproducibility of acquisition and 
analysis of images with these methods are not yet clear and need to be studied.
• Any future research on the pulmonary outcome of prematurity related lung disease should 
be focused on the need for clinical follow-up of apparently ‘normal’ preterm children with 
CLD and the role of bronchodilator therapy in subclinical airway obstruction and exercise 
induced bronchospasm in these children.
• The results of this thesis suggests that in children there may be subclinical relationships 
between body composition and cardiopulmonary exercise capacity, which is a measure of
pulmonary function, as well as left and right ventricular function. The current literature on 
body composition and its role on cardiopulmonary function in children with CLD are 
limited. Given the clear evidence of the relationship between fat mass index and 
triglycerides and the negative relationship with HDL, future studies on simultaneous 
measurement of body composition, preferably with a DXA scan, and vascular function 
may be useful to further clarify the relationship between nutritional status and 
cardiovascular function.
• Dietary habits of individuals play a major role on nutritional status and body composition. 
Assuming that children with CLD may have higher metabolic rates, their dietary intake 
may be crucial in maintaining their weight without increasing body fat to ensure optimal 
cardiorespiratory function. Ongoing research in our department includes a detailed study 
on dietary intake of children with CLD and its relationship with their body composition 
compared to the preterm and term-born controls.
6.5 Conclusion
This thesis includes a detailed study on respiratory, cardiovascular and nutritional status of 
prematurely bom children who had chronic lung disease in infancy (CLD), at 8-12 years of 
age. The study population represents children bom in the surfactant era and therefore presents 
outcome of ‘new CLD’. Every parameter measured in this study was compared between the 
prematurely bom children with CLD and age and gender-matched preterm and term-born 
control population. None of the children in this study had clinically evident cardiovascular 
symptoms. Thus, any relationships between cardiopulmonary and nutritional statuses are sub­
clinical.
2 0 2
In this thesis, I have demonstrated that prematurely bom children who had CLD in infancy 
continue to have impaired lung function including airway obstruction, impaired alveolar 
diffusion capacity, lung hyperinflation, exercise-induced bronchoconstriction and increased 
response to bronchodilator compared to term and preterm controls. Although their exercise 
capacity was similar to children in the control groups, this was at the expense of their 
ventilatory reserve. I have also suggested that there may be relationships between neonatal 
factors such as gestational age at birth and duration of oxygen dependency, and exercise 
capacity and alveolar diffusion capacity later in life. Further research is needed in this field.
Using both conventional and new methods of echocardiography, I have clearly demonstrated 
that school-aged children with CLD, who are asymptomatic, do not have evidence of 
cardiovascular impairment at rest. Their right ventricular function and pulmonary arterial 
pressure estimated using surrogate methods were similar to those of the control groups after 
exposure to acute hypoxia although children with CLD desaturated more after the hypoxic 
challenge.
In view of persistent lung function abnormalities in children with CLD, right ventricular 
function and pulmonary artery systolic pressure remain important determinants for long term 
outcome of these children. Appropriate follow-up and active management of pulmonary 
disease may help ameliorate early aging of lungs and pulmonary hypertension related to CLD.
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A1. Study Protocol for Pulmonary Function Tests
ID: Gender: DOB: Date of study:
Consent □  Assent □ General + Respiratory examination □
Baseline HR................ PHR (220-age in years)............... 90% PHR..................
Blood pressure................................................. Oxygen saturation............
Height............ ..m Weight................. kg
ECG □
Checklist □ 
-N ose clip 
- Mouthpiece 
between teeth
Calibrate all equipment and check resuscitation equipment □
1. Spirometry- Demonstration and Practice □  
-►Exhale to RV 
—►Inhale to TLC
2. Carbon monoxide transfer factor □
Start in training mode
-►Tidal breathing (at least 3 breaths,
RR>10<25)
—► Exhale to RV ( ‘Enter’ during expiration) 
—► Inhale to TLC
—► Hold breath until display reads 0.01 
-^HExhale to RV 
—► Tidal breathing
Checklist □
- Enter ID, height and weight
- ‘Sniffing’ position
- Nose clip and mouth piece
- Select ‘Body plethysmogra­
phy’ from menu
-Wait for 1 minute for tempera­
ture stabilization
3. Plethysmography (body box) □
—►Tidal breathing (RR >10<25continue until satis­
factory)
—> Close the loop (F4 ‘ASC settings’)
—► W arn the child that the shutter will be closed 
and instruct to breathe against shutter 
—► Activate ITGV (F3 TTGV’)*Repeat at least 3 
times*
Exhale—* Inhale to TLC —►Exhale to RV
QiscklkL.Cl 
-N ose clip
- Mouthpiece between
-
Spirometry □
—►Inhale to TLC
—► Exhale quickly to RV and maintain flow for >6 secs 
** Repeat at least 3 times **
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1 5 minutes
5 m in u tes  re s t
History □
2. 10 min □
4. 30 min □
1. S tart
3. 15 min □
5. 40 m in □
6. W ork of breathing test □
Checklist □  
-Nose clip 
- Mouthpiece
Checklist □ 
-Nose clip 
- Mouthpiece
-Nose clip 
- Mouthpiece 
between teeth
End o f  tes t 
H R .............. S a0 2 BP
7. Reversibility test □
—>Salbutamol 400m icrogram s
9. Re peat spiro me try in body box
Inhale to TLC
8. Spirom etry  in body box □
—♦Inhale to TLC
—♦ E>diale quickly to RV and main­
tain flow for >6 secs
5. Post exercise spirometry in body 
box □
—♦Inhale to TLC
—♦ Exhale quickly to RV and maintain flow
4. Exercise test □
Checklist
-ECG leads and face mask 
- Check settings
—♦ Unloaded pedalling for 3 minutes 
—♦ Increase load by 30 w atts every 3 mins
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A2. Study protocol for cardiovascular tests
ID: Gender: DOB: D ateofstudy:
Measure height □
Breakfast
Carotid Doppler □ 
FMD □
Baseline BP...
HR...
Sa02
RR...
Urine sample for ‘Cotinine’D
Collect in a universal container
Transfer to 5th floor lab and store at -70°C ASAP
Finger prick blood test
G lucose and cholesterol (Card iocheck analyser) □
■  Choi......................Trig...............
Capillary gas + haemoglobin (SCBU blood gas analyser-ASAP) □
Glu HDL
Body composition measurement □
Height (cm ).........................................
Weight (kg )........................................
BMI .....................................................
BM R(kJ)and (kca l)..........................
Fat (% ) .................................................
Fat mass (kg ).......................................
FFM (kg) ............................................
TBW (kg) ............................................
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15% oxygen inhalation 
Oxygen saturation at 
5 minutes..
15 minutes 
25 minutes 
35 minutes.
10 minutes 
20 minutes 
30 minutes. 
40 minutes
12% oxygen inhalation for 20 minutes □ 
(lOL/min. Increase if bag deflates)
12% oxygen inhalation 
Oxygen saturation at 
5 minutes..
15 minutes 
25 minutes 
35 minutes.
10 minutes 
20 minutes 
30 minutes. 
40 minutes,
Flow Rate:
Flow rate:
End of 15% 02
Start of 12% 02
End of 12% 02
Start of 15% 02
Hypoxic challenge test
Images
Images
Images
Baseline Echocardiography □
BP
HR
RR.
BP
HR
RR.
Repeat echocardiography 
(Continue 12% oxygen inhalation) □
15% oxygen inhalation for 20 minutes □ 
(lOL/min. Increase if bag deflates)
Repeat echocardiography 
(Continue 15% oxygen inhalation) □
Checklist
- Image storage (set at 3- beat loops)
- Child in left lateral position
- Keep bag inflated at all times
- Pulse oxymetry recording
Stop-if oxygen saturation drops < 80% for more than 30seconds 
Stop immediately- If oxygen saturation drops <70%
Stop- if oxygen saturation drops to 70% for less than 30 seconds on 3 
occasions.
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A3. Echocardiography acquisition protocol
Initial Phase Echo: (Baseline)
A. Parasternal Ions axis window
1. Conventional 2 D grey scale
B. Parasternal short axis window
1. Pulsed wave Doppler (PWD) - Pulmonary artery flow
2. PWD - Pulmonary regurgitation (if present)
3. Continuous wave Doppler (CWD) - T regurgitation (if present)
C. Apical window
1. 2D - Apical four chamber
2. PWD -  Left ventricular outflow tract
3. PWD - mitral flow
4. PWD - tricuspid flow
5. CWD - tricuspid regurgitation (if present)
6. PWD (tissue Doppler, TD) - medial mitral annulus
7. PWD (TD) - lateral mitral annulus
8. PWD (TD) - lateral tricuspid annulus
9. TD- Apical four chamber
10. 2D- Right ventricle only
11. TD- Right ventricle only
D. Subcostal window
1. PWD- Hepatic venous flow
2. 2D- Inferior vena cava (sniff test)
** Check AS, VS and all valves to rule out congenital structural defects **
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(Echocardiography acquisition protocol continued) 
Repeat Phase Echo after Hypoxic challenge:
A. Parasternal short axis window
1. PWD - Pulmonary artery flow
2. PWD - Pulmonary regurgitation (if present)
3. CWD - Tricuspid regurgitation (if present)
B. Anical window
1. PWD- Left ventricular outflow
2. PWD- Mitral flow
3. PWD- Tricuspid flow
4. PWD- Tricuspid regurgitation (if present)
5. PWD (TD) -  Medial mitral annulus
6. PWD (TD) - Lateral mitral annulus
7. PWD (TD) -  Lateral tricuspid annulus
8. 2D- Right ventricle only
9. TD- Right ventricle only
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A4. Echocardiography analysis protocol
ID: Gender: Date of birth: Date of scan:
Image Measurement Result 1
21% 0 2
Ref Result 2
15% O2
Ref Result 3
12% 0 2
Ref
Hepatic vein- 
PWD
Estimated RA pressure - - - -
IVC- MM Estimated RA pressure - - - -
PLAX LVOT (d) cm - - - -
CSA (a) = n r2 cm1
Blood Pool 
data
LVOT- PWD Stroke distance (VTI) cm 
Without angle correction 
With angle correction.......°
Stroke volume (SV) = 
a x VTI ml
Heart rate (HR) /min
Cardiac output (CO) = 
(SV x HR)/wt ml/kg/m in
LVOT - PWD QRS to onset of flow 
(LV PEP) ms
MV inflow- 
PWD
E m/s
A m/s
E:A
TV inflow- 
CWD
TR vel max m/s
TR pg mm Hg
PA- PWD PA AT ms
PA ET ms
HR bpm
PR-PWD PR end diastolic vel m/s
PR pg mm Hg
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(Echocardiography analysis protocol continued)
Image Measurement Result 1
21% 0 2
Ref Result 2
15% 02
Ref Result 3
12% 0 2
Ref
Pulsed TD Data
Medial mitral 
annulus
Early diastolic velocity (Ve’) 
m/s
Lateral mitral 
annulus
Early diastolic velocity (Ve’) 
m/s
Average Ve’ m/s
Lateral tricuspid 
annulus
Isovolumic relaxation time 
(IVRT) ms
Heart rate bpm
Processed TD 
Data
**Event timing from LVOT 
PWD**
FR/ HR - -
LV Lateral mitral annular systolic 
excursion/
Displacement (Ds’) mm
Peak systolic velocity 
(Vsbl) cm/s
- -
Early diastolic velocity (Vebl) 
cm/s
- -
Late diastolic velocity 
(Vabl) cm/s
- -
QRS to Peak Vs time interval 
(Q-Vs) s
- -
Isovolumic acceleration (Asbl) 
m/s2
- -
(SL= 10mm) Strain- LV lateral wall- Base 
(Ssbl)%
Strain- LV lateral wall- Apical 
(Ssal) %
Delete LV Event Timing - -
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(Echocardiography analysis protocol)
Image Measurement Result 1
21% 0 2
Ref Result 2
15% O2
Ref Result 3
12% 0 2
Ref
**Event timing from RVOT 
PWD**
FR/ HR FR/ HR FR/ HR
RV Lateral tricuspid annular 
systolic excursion/ 
Displacement (Ds’) mm
Peak systolic (S) velocity 
(Vsbl) cm/s
Early diastolic (E) velocity 
(Vebl) cm/s
Late diastolic (A) velocity 
(Vabl) cm/s
QRS to Peak Vs time interval 
(Q-Vs) s
Isovolumic acceleration 
(Asbl) m/s2
(SL= 10 mm) Strain- RV lateral wall- Base 
(Ssbl) %
Strain- RV lateral wall- 
Apical (Ssal) %
Delete RV Event Timing
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Appendix B: History proforma
Serial Number: Participant ID: Gender: M/F Age:
Birth and Neonatal History: (Case notes)
Date of birth: Gestational age at birth (in weeks): APGAR:
Multiple birth: Yes/No Twin 1 2 Triplet 1 2 3
Antenatal steroids:Y/ N Surfactant: Y/ N Postnatal steroids:Y/ N
Assisted ventilation: Y/ N
Total duration of assisted ventilation...........days
SIM V/ SIPPV........... days
HFOV........................days
CPAP.........................days
Duration of oxygen dependency:
Corrected gestational ag e  weeks
Days of life ................................... days
Maximum Fi02 at any stage after birth.........
Neonatal sepsis: Y/ N
Positive culture 1.................................... Source....................
Positive culture 2.................................... Source....................
Positive culture 2 .................................... Source....................
Persistent pulmonary hypertension of newborn (PPHN): Y/ N
Echo diagnosis □
Treatment 1.................  2 .................... 3....................
Intraventricular haemorrhage: Y/ N
Worst grade....................
Weight at birth (kg): Length at birth (cm): OFC at birth (cm):
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Feeding at birth Breast*/ formula/ mixed fed * Duration of breast feeding......... weeks
Date of discharge: Age at discharge:.................(days)..................(CGA)
Weight at discharge........................Kg
Length at discharge..........................cm
OFC at discharge............................cm
Family History in first- degree relatives: (To be filled in bv parents)
Cigarette smoking Y/N Not sure
Asthma Y/N Not sure
Eczema Y/N Not sure
Hay fever Y/N Not sure
Diabetes Y/N Not sure
High cholesterol Y/N Not sure
High blood pressure Y/N Not sure
Sudden death at under the age of 40 years Y*/ N * ............... age in years
Medical history: (To be filled in bv parents)
_Asthma: Has the child ever been diagnosed with Asthma? Y*/ N Not sure
♦Age at diagnosis.................
♦Last episode of asthmatic attack requiring treatment................... years of age
♦Last episode of asthmatic attack requiring hospital admission..... years of age
Wheeze: H/O wheeze at any time since birth: Y*/ N Not sure
♦First episode of wheeze a t  years of age
♦Last episode of wheeze at............... years of age
♦Number of attacks of wheezing in the past 1 year.................
♦Number of attacks requiring ‘rescue inhaler’ in the past 1 year............
♦Number of attacks requiring hospital admission in the past 1 year............
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Rhinitis:
Eczema:
Exercise:
Cardiac:
♦Exercise induced wheeze in the past 1 year Y/N Not sure 
♦Dry cough at night (not cold/flu) in the past 1 year: Y/N Not sure
H/O hay fever at any time since birth: Y/ N Not sure
H/O a problem with sneezing, or a runny, or a blocked nose without having 
cold or the flu: At any time since birth Y/ N Not sure
In the past 1 year Y/ N Not sure
H/O eczema at any time since birth: Y/ N Not sure
H/O itchy rash at any time in the past 1 year: Y*/ N Not sure
♦ Itchy rash affecting the folds of the elbow, behind the knees, in front of the 
ankles, under the buttocks, or around the neck, ears or eyes : Y/ N Not sure 
Periods of activity at school (~30 min=l period) i.e. walking to school, break
time, lunchtime, P E ................ (Periods per day)
After school, in the evenings or at weekends does the child play sport/or 
participate in any activities (e.g. dancing, swimming, cycling)? Y/N 
If yes, estimate of how many hours a week does he/she do this sport/activity 
fo r? ................ hours
How does the child consider his/ her daily activity compared to friends or 
siblings?
More active □ Less active □ Same as friends/ siblings □ 
H/O structural congenital heart disease Y*/ N Not sure
Diagnosis..........................
Surgical correction Y/N Not sure
Medical treatment Y/N Not sure
H/O cardiac disease any time since birth (not structural defect) Y*N Not sure 
♦Diagnosis....................................
Medical treatment Y/N Not sure
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Surgical treatment Y/ N Not sure
Cardiology follow-up in the last 1 year Y/N Not sure
Symptoms in the past 1 year
Chest pain requiring medical attention Y*/ N * At rest/ exercise
Breathlessness requiring medical attention Y*/N * At rest/ exercise
Palpitation requiring medical attention Y*/ N * At rest/ exercise
Snoring Y/ N
Undue tiredness Y/ N
Fainting episodes Y/ N
H/O treatment with oxygen in the past 1 year for any reason Y*/ N Not sure
’•‘Diagnosis.................................
Regular medication Y/N (details if yes)........................................
Any ongoing medical problem Y/ N (details if yes).........................................
Number of hospital admissions since birth ................................................................
Nutritional History: (To be filled in bv parents)
Mother’s height................  Father’s height.............
Has the child ever been a fussy eater? Y/ N
Has the child ever struggled with lumpy food? Y/ N
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Appendix C: Invitation letter to the parents
Parent/ Guardian of [Name]
Address [Date]
Dear Parent/Guardian
Re: Long term Cardio- Respiratory Outcome in Children with Chronic Lung disease of 
Prematurity
I am writing because fNamel was on the baby unit after he was bom. I hope he is keeping well. We 
are keen to learn more about how our ex-neonatal unit babies do as they grow up so that we can 
improve our care in the future. I would therefore like to invite [Name] to join the above study at 
Cardiff University. We have enclosed information leaflets which give more details of the 
study.
The study will involve spending one morning at the ‘Wales Heart Research Institute’, Cardiff 
and another morning or afternoon at the ‘University of Glamorgan’, Pontypridd. We would 
be most grateful if you could fill in the enclosed slip and send it in the enclosed envelope to 
let us know if you are or are not able to join our study. If there are any questions that we may 
answer before you can make a decision, please contact Dr Suchita Joshi on 029 2074 3438 or 
email us on Joshis3@cardiff.ac.uk.
We would very much like to thank you for taking time to consider our study.
Yours sincerely,
Dr Mark Drayton 
Consultant Neonatologist 
University Hospital of Wales 
Heath Park 
Cardiff, CF14 4XN 
(On behalf of the research team)
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Appendix D: Information sheet for parents
Information Sheet for Parents (1)
(For parents of preterm children with lung disease of infancy)
‘Long Term Cardio- Respiratory Outcome in Children with Chronic lung 
Disease of Prematurity’
Principal investigator: Professor Sailesh Kotecha
Department of Child Health 
Cardiff University 
Cardiff, CF14 4XN
Part 1
Dear Parent/Guardian
We would like to invite .............................................................. to take part in our
research study at Cardiff University. This study will be done in collaboration with the 
Wales Heart Research Institute and University of Glamorgan. Before you and your 
child decide, whether or not to participate in the study, it is important for you to 
understand why the research is being done and what it involves. Please take time to 
read the following information carefully and please feel free to ask any questions that 
you may have.
1. What is the purpose of the study?
Many babies who are bom prematurely may develop breathing problems at birth. 
Some of these babies may develop lung disease called chronic lung disease of 
prematurity or CLD. The majority of children who had CLD as a baby go on to 
participate in play, exercise and other activities without having any visible problems. 
It is unknown if there is any difference in the way the lungs work in these children 
later on in life.
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a) We are trying to find out how the blood vessel that connects the heart and the lungs 
(pulmonary artery) in these children react, when they breathe air containing less 
oxygen than natural air, as happens when travelling long distance in an aeroplane or 
when climbing a mountain or a skiing in high altitude ski resorts
b) We are also trying to find out how well their lungs can cope with exercise.
We will compare the results from children A) who were bom early and had CLD, with 
results from B) those who were bom early but did not have CLD and C) those who 
were bom at full term. A total of 90 children will take part in this study.
2. Why has my child been invited?
We have invited your child to participate in this study because he/she was bom early 
and had lung disease of infancy as a baby (group A).
3. Does my child have to take part?
No. It is up to you and your child to decide. Your child does not have to take part in 
this research if either you or your child does not wish to do so. We will describe the 
study and go through this information sheet, which we will then give to you. Your 
child will also be given his/her own information sheet. You and your child will have 
the opportunity to discuss any questions that you may have with the researcher after 
you have read the information sheets.
We will then ask you to sign a consent form if you agree your child to take part in this 
research. Your child will also be asked to sign an assent form to show that he/she is 
happy to take part.
4. What will happen to my child if he/she takes part?
We would like to invite your child to the “Physiological Assessment Suite” at the 
University of Glamorgan, Pontypridd for half a day to test how fit his/her lungs are 
after exercise. This will involve ‘breathing and blowing’ tests (spirometry) and 
pedalling on an exercise bike. On this visit, we will also ask you some questions 
regarding your child’s birth details, relevant medical history and family history. We 
will demonstrate the tests to your child and let him/her practice it until he/she 
understands how to do the tests. For one of the tests, your child will be asked to sit
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inside a cubicle with glass doors and the cubicle door will be closed for a few seconds. 
Your child will be able to see and hear us. For the exercise test, your child will be 
asked to pedal an exercise bike for as long as possible. We expect the exercise test to 
last about 15 minutes. We will be closely monitoring your child during the bicycle 
exercise test and will stop the test when your child is too tired to continue or if his/her 
heart rate goes too fast. Your child will have 15 minutes rest after the exercise test 
after which we will ask him/her to inhale a medicine called ‘Salbutamol’ (that children 
with Asthma use) which relaxes the small airways. We do not expect this inhaler 
medicine to cause any side effects to your child. We will repeat the spirometry test 
after this. This will allow us to compare the test results before and after relaxing the 
airways.
We will ensure that your child is comfortable before we allow him/her home. You 
will be able to stay with your child throughout the test and we expect that you will be 
spending 2-3 hours with us at the University of Glamorgan.
We would also like to invite you and your child to the ‘Wales Heart Research 
Institute’ at Heath Hospital site in Cardiff for another half day session. This time, 
we would like to see your child in the morning before he/she has his/her breakfast. 
This will allow us to check his/her blood sugar, cholesterol and haemoglobin levels, 
which are thought to be important in the development of heart disease in adulthood. 
This will involve a finger prick test (similar to the one that diabetic children use for 
blood sugar tests). We will provide breakfast for your child after the blood test. If you 
or your child does not wish for a blood test, we will not do one. If you do not wish 
vour child to have blood test, he/she may come after breakfast but please ensure that 
he/she does not drink tea, coffee, cola or any drink containing caffeine in the morning 
for at least 3 hours before the study. We would also like to do a urine test to check 
your child’s exposure to other people’s cigarette smoking.
On this visit, we will record your child’s details including height, weight, blood 
pressure and oxygen levels with a probe on a finger. Then, we will do a heart scan 
(similar to ultrasound scan done in pregnancy). This will take about 15-20 minutes. 
We will then ask your child to breathe decreasing levels of oxygen (15% and 12%) for 
20 minutes each. The air we breathe is about 21% oxygen, the cabin in a long distance 
aeroplane is about 15% and skiing in high mountains in Europe is about 12%. We will 
repeat the heart scans after each interval to see if any changes in heart function are 
detected with decrease in oxygen. These scans will take about 10-15 minutes each.
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On the same visit, we will also do an ultrasound scan of the blood vessel of the 
right arm before and after applying an inflated blood pressure cuff for 5 minutes 
around the right forearm of your child. This is similar to the method doctors and 
nurses use to measure blood pressure but the cuff will be inflated for longer. The 
pressure of the cuff may cause some discomfort for the child but we will use adult­
sized cuff to minimise this discomfort. This test will assess the stiffness of the blood 
vessel in the arm.
We will provide lunch for you and your child and make sure that your child is 
comfortable before letting him/her home. We expect that you and your child may have 
to spend about 3 hours at the WHRI to complete all the above tests.
5. Can I stay with my child during the tests?
You are encouraged to stay with your child throughout all the tests.
6. How long will the different tests take?
We expect the lung function tests at the University of Glamorgan, Pontypridd to last 
approximately 2-3 hours including, 30 minutes for recording history and measuring 
height, weight, heart rate and breathing rate, 15-30 minutes for demonstration of the 
breathing and blowing tests and practice sessions, 30 minutes to complete these tests, 
15-20 minutes for the exercise test and 20-30 minutes of rest periods between different 
tests.
We expect that you may have to spend about 3 hours at the WHRI, Cardiff. This 
includes, 5-10 minutes for blood tests, 5-10 minutes for urine test, 2 to 2.5 hours for 
the oxygen tests and the heart scans. After 20 minutes of oxygen challenge, each heart 
scan takes about 15 minutes.
7. Have similar studies been done in the past?
Often a similar low oxygen (15%) test is performed for 20 minutes in babies who have 
recently come off their oxygen if they are likely to travel in an aeroplane to determine 
if the baby requires oxygen during the flight. One study showed that 8 out of 20 babies 
who had pre-flight hypoxia test required additional oxygen for the flight although they 
did not normally need additional oxygen. However, we are not aware of any similar
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oxygen challenging studies 8 - 1 2  year-old children (as opposed to babies) who have 
had chronic lung disease of prematurity when they were babies.
8. What are the possible benefits of taking part?
This study may help identify whether children who are bom early and had lung 
disease of infancy are more likely to have lung and heart disease earlier in adulthood 
and therefore benefit with early monitoring and treatment.
Although we do not anticipate any major difference in children who were bom 
early compared to control population, if we find large differences, then we will firstly 
explain the findings to you and secondly, your child will be followed up in a regular 
basis by the research team (Dr DG Wilson, Paediatric Cardiologist).
9. Is my child likely to experience any discomfort or distress during this study?
The concentration of oxygen that will be used in this study is similar to that found in 
aeroplanes (15% oxygen) and in high altitude ski resorts (12% oxygen) and we do not 
anticipate any serious side effects. Some children may temporarily breathe faster, 
similar to rates after exercise in the playground. Oxygen levels using a finger probe 
will be monitored at all times and the study will be discontinued if your child is unable 
to tolerate the tests or feels any discomfort or distress by breathing reduced oxygen 
levels. The study will also be stopped if your child's oxygen level drops below 80% 
for more than 30 seconds but not below 70% at which point it would be stopped 
immediately. The study will also be stopped if your child’s oxygen level drops to 70% 
for periods of less than 30 seconds on 3 occasions.
We will have provisions for high oxygen (100%) should your child need it.
10. What if my child is harmed by the study?
Any complaint about the way your child has been dealt with during the study or any 
possible harm that your child may suffer will be addressed. The detailed information 
on this is given in Part 2.
11. Will information obtained in the study be confidential?
There will be no identifiable details of your child in any study information. All 
information about your child will be handled in confidence.
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12. Will I or my child receive out of pocket expenses for taking part in the study?
We will provide any travelling expenses that you may incur and provide breakfast for 
you and your child after the blood test and lunch for both you and your child. Your 
child will also receive two cinema vouchers with a ‘thank you’ note for helping us 
with the project.
If the information in Part 1 has interested you and you are considering participation, 
please read the additional information in Part 2 before making any decision
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Part 2
13. What happens if my child or I do not wish to participate in the study or wish to 
withdraw from the study?
If your child or you do not wish to participate in this study or if you wish to withdraw 
from the study you may do so without justifying your decision and your child’s future 
treatment will not be affected.
14. What if there is a problem?
Complains:
If you have concerns about any aspect of this study, you should ask to speak to the 
researchers who will do their best to answer your question. If you remain unhappy and 
wish to complain formally, you can do this through NHS Complaints Procedure.
Harm:
In the event that something goes wrong and your child is harmed during the research 
and this is due to someone’s negligence then you may have grounds for legal action 
for complaints against Cardiff University but you may have to pay your legal costs. 
Medical research is covered for mishaps in the same way as for patients undergoing 
treatment in the NHS i.e. compensation is only available if negligence occurs.
15. Will my child’s taking part in this study be kept confidential?
Yes. We will follow ethical and legal practice and all information about your child 
will be handled in confidence. With your permission, your GP will be informed of 
your child’s participation in this study. None of your child’s identifiable details will be 
stored or used in any publication or presentation in future.
16. What will happen to the results of the study?
The results of this study will be prepared for publication in medical journals, and for 
presentation at medical meetings.
17. Who is funding the study?
This study is being funded by the Department of Child Health, Cardiff University and 
Cardiff and Vale NHS Trust R&D Small Grants Scheme.
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18. Who has reviewed the study?
Before any research goes ahead it has to be reviewed by Research Ethics Committee. 
They make sure the research is fair. This project has been reviewed by the South East 
Wales Research Ethics Committee.
Thank you for reading this. Please feel free to ask us if there is anything that is not clear or 
if you would like more information about this study.
Dr Suchita Joshi Prof Sailesh Kotecha
Academic Clinical Fellow Professor of Paediatrics and Child Heath
University Hospital of Wales Cardiff University
Joshis3@cardiff.ac.uk kotechas@cardiff.ac.uk
• Information Sheet for Parents (2): For parents of preterm children without lung 
disease of infancy and
• Information Sheet for Parents (3): For parents of the term-born children
were also provide separately to the parents of the children in the preterm and term groups 
respectively. (Similar information sheets as above)
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Appendix E: Information sheet for children
Information Sheet (1) for Children 
(For children who were bom early and needed oxygen for a long time as babies)
‘Long Term Cardio-Respiratory Outcome for Children with Chronic Lung Disease of 
Prematurity’
Dear [child’s name],
We would like to invite you to take part in a research project on children who were bom 
early. Before you decide if you want to join in, it’s important that you understand why the 
research is being done and what you will be asked to do if you take part.
So please read this leaflet carefully with your mum or dad (or ask them to read it to you) 
and talk about it with them. If you do not understand anything that has been written here or if 
you have any questions please let us know and we will try to explain it to you.
1. What is research?
Research is a way we try to find out the answers to questions.
2. Why is this project being done?
Some babies are bom earlier than they normally should. Some of these babies need 
oxygen for a long time to help them breathe until their lungs are strong. In this research, 
we want to find out
a) How strong their lungs are now, and
b) How hard their heart has to work to pump blood to their lungs.
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To find out the answers to these questions, we will need to do different tests on children who 
were bom early and compare the test results with healthy children who were bom on time.
A total of 90 children will take part in this project.
This research project will help us understand if children who are bom early and needed 
oxygen for a long time as babies, need any special tests before they go on an aeroplane or 
skiing or if they need to have special tests when they grow older.
3. Why have I been asked to take part?
You have been asked to take part in this research because you were bom earlier than most 
babies should and you needed oxygen to help you breathe when you were a baby (Group A).
4. Did anyone else check the study is OK to do?
Before any research is allowed to happen, it has to be checked by a group of people called 
Research Ethics Committee (REC). They make sure that the research is fair. This project has 
been checked by South East Wales REC.
5. Do I have to take part?
No. It is up to you. You don’t have to take part if you don’t want to. If you do, we will ask 
you to sign a form to say that you are happy to take part in this project.
You are allowed to stop taking part at any time during the research if you do not 
wish to continue. You will not have to give us any reason.
6. What will happen to me if I take part?
If you take part in this research, you will be asked to spend one morning with us at the Wales 
Heart Research Institute (WHRI) at the Heath for about 3 hours for heart scans and another 
morning or afternoon at the University of Glamorgan in Pontypridd for about 2-3 hours for
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breathing tests. On these occasions, your mum or dad may stay with you throughout the 
tests.
Visit to WHRI (Heath):
O n th is v isit, w e w ould  like y ou  to  com e in the m orning  w ithout any breakfast to  allow  us to  
do a  blood test. I f  you  do not w ant us to  do  the blood test, you m ay com e afte r b reakfast, but 
please make sure that you do not drink tea, coffee or cola in the morning. W e will g ive 
you  breakfast after the b lood  test. W e w ill do fo llow ing d ifferen t tests to check  how  strong  
your heart has to  w ork  to  pum p blood to y ou r lungs.
(This is a  finger prick  test sim ilar to  
w hat ch ildren  w ho have d iabetes do to  
check the sugar level in the ir b lood 
every day. This m ay feel sim ilar to  a 
p in-prick  and will take only  a  few  
seconds to  co llect a  few  drops o f  blood. 
(We will not do the blood test if you 
don’t want us to do it.)
A rrive in the m orn ing  w ith  y ou r m um  or dad. 
i
B lood test
• A d a m
Y ou will then be asked to  use ou r to ilet to  co llect a urine sam ple in a  sm all bottle for us to 
test it.J,
B reakfast
i
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W e will then  listen  to  your heart w ith a  
stethoscope and record  the tracing o f  
yo u r heart beat by using special sticky 
pads on y ou r chest w hile  you  lie dow n 
com fortab ly  on a  bed.
W e w ill then ask  you  to  lie 
com fortably  on a  bed w hile w e do  a 
heart scan. F or this, w e w ill put special 
gel on y ou r chest and take p ictures o f  
you r heart. Y ou w ill be able to  see how  
the inside o f  y our heart looks like on a 
T V  screen. T his w ill take about 15-20 
m inutes. T his w ill no t cause y ou  any 
pain  or d iscom fort.
A fter th is scan, w e w ill help  you  pu t on 
a  m ask over your nose and m outh  and 
let you  breathe tw o d iffe ren t levels o f  
oxygen  for 20 m inutes each and then  
repeat the heart scans. T his m ay m ake 
you  breathe faster as i f  you  have been 
running in a  p layground. W e w ill m ake 
sure you  are alrigh t during  th is te st bu t
if  you  feel unw ell or uncom fortab le  
during th is test o r if  you  w ish  to  stop  
the test at any tim e, you  should  let us 
know .
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1A fter the heart scans, w e w ill apply a  let us know  i f  it is too  uncom fortab le
blood p ressure c u ff  around  your for you.
forearm  and inflate it fo r 5 m inutes.
T he pressure o f  the  c u ff  m ay m ake you 
feel slightly  uncom fortab le. Y ou m ay
W e w ill then  do a  scan o f  a b lood  vessel o f  your arm  w hich is sim ilar to  the heart scan  bu t th is 
is m uch quicker.
I
L unch and hom e
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V isit to  th e  U n iv ers ity  o f  G la m o rg a n  (P o n ty p r id d ) :
O n th is visit, w e w ill do  d iffe ren t tests to  see how  strong your lungs are and how  w ell they 
cope w ith  exercise. Y ou w ill be spend ing  about 2-3 hours w ith us. This v isit m ay be in the 
m orning  or in the afternoon.
A rrive w ith m um  or dad 
1
M um  or dad will be asked som e questions
i
W e w ill m easure your height and w eight and listen  to your chest
W e w ill then  show  y ou  how  to do som e 
special b reath ing and b low ing  tests called 
spirom etry . Y ou can then  practice the tests 
to m ake sure you  understand  w hat to  do. 
O nce w e are sure that you  have understood
For one o f  the tests, you w ill be asked  to 
sit inside a special box w ith  g lass doors. 
The door will be closed for about 10 
seconds. You w ill be able to hear us 
clearly  and w e w ill be able to see each 
other.
I
how  to do the special b rea th ing  and 
b low ing tests, w e w ill do the tests.
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IF or the exercise test, w e w ill ask you  to on you  throughout th is test and w ill stop
pedal an exercise bike. It w ill be easy to the test im m ediately i f  w e need to  o r i f  you
pedal to  start w ith  bu t w ill get harder and w ant us to  stop it.
harder. W e w ill stop the te st w hen you  let 
us know  tha t y ou  are too  tired to  pedal 
anym ore. W e expect th is test to  last for 
about 15 m inutes. W e will keep a  close eye
i
R est for 15 m inutes 
1
A fter the b rie f rest, w e w ill ask you  to  
inhale a special m edicine tha t w ill m ake 
the sm all b ranches o f  y ou r breath ing tube 
relax. This w ill not cause any harm  to  you  
and w ill not be painful or uncom fortable.
I
R epeat a short breathing and b low ing  test 
1
H om e
Y ou w ill receive tw o  cinem a vouchers as a  ‘thank  y o u ’ for tak ing  part in this project.
*
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7. Might anything about the research upset me?
Some children get upset about blood tests and don’t like having it. If you don’t want us to do 
the blood test, we will not do it.
When you breathe different levels of oxygen, you may breathe faster as if you have been 
running in the playground. During this test, we will keep a very close eye on you and make 
sure you are fine. If you feel uncomfortable and want us to stop the test, you have to let us 
know.
The exercise test will make you breathe faster and make your heart beat faster just as 
when you run. We will keep a close eye on you throughout this test and ask you to let us 
know when you are too tired to pedal.
8. Will joining in help me?
We cannot promise the study will help you but the information we get might help us look 
after children who were bom too early and who needed oxygen for a long time as babies.
We do not expect to find any problem with you but if we find any abnormal test results 
then we shall explain them to you and your parents and arrange for a doctor to see you soon.
9. What happens when the research stops?
We will write to your parents/ guardians to let them know the results of this research.
10. What if something goes wrong?
We do not expect anything to go wrong during this project and we will not ask you to do 
anything that maybe harmful to you. We will also keep a close eye on throughout the tests and 
will stop the test immediately if we need to or if you want us to.
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11. Will anyone else know I’m doing this?
With your mum or dad’s permission, we will let your doctor (GP) know that you are 
taking part in this project. Apart from your GP and the research team, nobody else will have 
to know that you are taking part in this project.
12. What will happen to the blood and urine samples that I give?
Once we test the blood and urine samples that you give us, we will throw it away in a special 
hospital bin.
13. Who is organising and paying for this research?
This research is being organised and paid by the Children’s Department at Cardiff University.
14. What if I don’t want to do the research anymore?
If at any time you don’t want to do the research anymore, just tell us or your mum or dad and 
you can stop taking part. You do not have to continue if you do not want to do so.
Thank you for reading this leaflet and I hope I can meet you. If you do not understand 
anything that this leaflet says or if you have any questions for us, please ask your mum or dad 
to contact me and I will try to answer your questions.
Yours sincerely 
Dr Suchita Joshi 
Department of Child Health 
Cardiff University 
02920743438 
Joshis3@cardiff.ac.uk
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• Information Sheet for Children (2): For preterm children without lung disease of 
infancy and
• Information Sheet for Children (3): For term-born children
were also provided separately to the children in the preterm and term groups respectively. 
(Similar information sheets as above).
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Appendix F: Consent form for parents
Patient Identification Number for this study:
CONSENT FORM (Version 3 .0 17th January 2008)
Title of Project: *Lona term cardio- respiratory outcome in children with chronic lung disease of prematurity*
Name of the Researchers: Professor S Kotecha, Dr S Joshi
Please initial box
1. I confirm that I have read and understand the information sheet dated 24th Sept 2007 Q  
(version 4.0) for the above study. I have had the opportunity to consider the
information, ask questions and have had these answered satisfactorily.
2. I understand that my child’s participation is voluntary and that my child is free to withdraw at any time, without 
giving any reason, without my child’s medical care or legal rights being affected.
3. I understand that relevant sections of any of my child's medical notes and data collected during 
the study, may be looked at by responsible individuals from Cardiff University, | | 
from regulatory authorities or from the NHS Trust, where it is relevant to my child’s taking
part in this research. I give permission for these individuals to have access to my child’s records.
4. I agree to my child’s GP being informed of my child’s participation in the study. Q
5 .1 agree to my child having the lung function tests as a part of the above study. Q
6 .1 agree to my child having ultrasound scans of the heart and the arm artery as a part of the above study.
□
7 .1 agree to my child having a finger prick blood test as a part of the above study. Q
8 .1 agree to my child having urine test as a part of the above study. Q
Name of Parent Date Signature
Researcher Date Signature
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Appendix G: Assent form for children
ASSENT FORM  FOR CHILDREN
(To be completed by the child in presence of their parent/ guardian)
Project title: Lone Term Cardio- Respiratory Outcome in Children with Chronic Lung Disease of Prematurity
Child (or if unable, parents on their behalf) to circle all they agree with:
1. Have you read (or had read to you) about this project?
(Child Information Sheetl Version 2.0 15th August 2007 or
Child Information Sheet 2 Version 2.0 15th August 2007 or
Child Information Sheet 3 Version 3.0 24th September) Yes/ No
2. Has somebody else explained this project to you? Yes/ No
3. Do you understand what this project is about? Yes/No
4. Have you asked all the questions you want? Yes/ No
5. Have you had your questions answered in a way you understand? Yes/ No
6. Do you understand it is OK to stop taking part at any time? Yes/ No
7. Are you happy to take part? Yes/ No
8. Are you happy to have heart scans as a part o f this project? Yes/No
9. Are you happy to have breathing and blowing tests and exercise test as a part o f this project?
Yes/No
10. Are you happy to have finger prick blood test as a part of this project? Yes/ No
11. Are you happy to have urine test as a part of this project? Yes/ No
If  any of the answers 1-9 are ‘No’ or you don’t want to take part, don’t sign your name!
If you do want to take part, you can write your name below:
Your name Date
The doctor who explained this project to you needs to sign too:
Print name 
Sign
Date
Thank you for your help.
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Appendix H: Published papers
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H1. Lung growth and development
Early Human Development (2007 ) 83 , 789-794
a v a i l a b l e  a t  w t M w .a c ie n c e d i r e c t . c o m
*•# '' ScienceDirect
ELSEVIER w w w . e l a e v i e r . c o m / l o c i
Lung growth and development
Suchita Joshi, Sailesh Kotecha*
Department o f Child Health, Cardiff University, Cardiff CF14 4XN, UK
KEYWORDS 
Fetal lung liquid;
Growth factors; 
Transcriptional factors; 
Prematurity; 
Glucocorticoids; 
Congenital diaphragmatic 
hernia;
Chronic lung disease of 
prematurity
Abstract
Homan lung growth starts as a primitive lung bud in early embryonic life and undergoes several 
morphological stages which continue into postnatal life. Each stage of lung yow th  is a result of 
complex and tightly regulated events governed by physical, environmental, hormonal and 
genetic factors. Fetal lung liquid and fetal breathing movements are by far th e  most important 
determinants of lung growth. Although timing of the stages of lung growth in animals do not 
mimic that of human, numerous art mal studies, mainly on sheep and rat, have given us a better 
understanding of the regulators of lung growth. Insight into the genetic basis of lung growth has 
helped us understand and improve management of complex life threatening congenital 
abnormalities such as congenital diaphragmatic hernia and pulmonary hypoplasia. Although 
advances in perinatal medicine have improved survival of preterm infants, premature birth is 
perhaps still the most important factor for adverse lung growth.
C  2007 Elsevier Ireland Ltd. All rights reserved.
1. Normal lung development: structural and 
vascular growth and possible developmental 
anomalies
In the  human embryo, developm ent of lung s ta r ts  as early as 
3 weeks of embryonic life and continues into postnatal life up 
to  early adulthood. The structural and vascular developm ent 
of th e  lung is closely related and progresses simultaneously in 
th e  human fetus. The events of an ten a ta l growth and 
developm ent of human lung have traditionally been divided 
into 5 stages (Table 1). Burri has recently reviewed the  role 
of mtcrovascular maturation during alveolartzation [1J. In 
each of these stages, there are possibilities of congenital 
malformations associated with abnormal lung developm ent 
(Table 2).
• Corresponding author. Tel.: *44 29 20 74 4187; fax: *44 29 20 74 
4283.
E mail address: kotechasycardlff.ac.uk (S. Kotecha).
1,1. Embryonic stage (0-7 weeks in utero)
At around 3 4 weeks of embryonic life, th e  lung develops as 
an outgrowth of the  ventral wall of the  primitive foregut, the 
laryngotracheal groove. The epithelial cells from th e  foregut 
end ode rm invade th e  surrounding mesenchyme to form the 
trachea. During the  embryonic stage, the trachea branches 
into the right and left main bronchi and subsequently into 
lobar and segm ental bronchi. Lobar and segm ental bronchi 
appear a t about the 5th week [2] and by the  end of this s tag e , 
18 m ajor lobules a re  recognisable [3J. Pulmonary arteries 
and veins develop as a single avascular bud from the  6th 
aortic arch and continue to  grow by vasculogenesis around 
th e  airway buds from 4  16 weeks [4J.
This earliest stage of lung developm ent may have a 
principle role in determ ining the  postnatal m ortality and 
morbidity of the  fetus. Structural abnormalities such as 
tracheal or pulmonary agenesis or stenosis maybe incompa­
tible w ith life whereas other forms of anomalies such as 
tracheom alacia or bronchomalacia, ectopic lobes and con­
genital lobar cysts may lead to significant respiratory
0378-3782/$ • see front m atter © 2007 Elsevier Ireland Ltd. All rights reserved, 
dot: 10.1016/J .earthumdev.2007.09.007
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Tibi* 1 States of lung growth
Stage Time
Embryonic 0 7 weeks
Canalicular 7 17 weeks
Pseudoglandular 17-27 weeks
Saccular 2ft 36we«fcs
Alveolar 36 weeks
2 years
Until 1ft
22 years
Mtcrovascular Birth to 2-
maturation 3 years
Events
Formation of trachea, nght and left main bronchi, segmental bronchi, and vasculogenesis 
around airway buds
Differentiation of epithelial cells, formation of conduction airway and terminal bronchioles, 
formation of pulmonary arteries and veins
Formation of respiratory bronchioles, alveolar ducts and primitive alveoli, differentiation of 
type I and type II pneumocytes and formation of alveolar capillary barrier 
Increment in gas exchange areas, further differentiation of type I and type II cells 
Sept at ion and multiplication of alveoli
Enlargement of terminal bronchioles and alveoli
Fusion of double alveolar capillary network into a single layer
morbidity. Arte no-venous m alform ations may also form 
during vasculogenesis.
1.2. Pseudoglandular stage (7-17 weeks in utero)
Pseudoglandular stage is m arked by fu rther branching of 
airway and vascular netw ork and progressive differentiation 
of ep ithelia l cells to form adu lt s tructu res of cartilage,
Table 2 Congenital malformations associated with abnor­
mal lung yow th
Embryonic 
Pulmonary agenesis
Tracheal or laryngeal agenesis or stenosis
7Yacheo- or broncho- motocta 
Bronchial malformation 
Ectopic lobes 
A-V malformations 
Congenital lobar cysts
Pseudo&andular
Cystic adenomatoid malformation 
Pulmonary sequestration 
Lung hypoplasia 
Lung cysts
Congenital pulmonary lymphangiectasia 
Congenital diaphragmatic hernia
Canalicular 
Lung hypoplasia 
Respiratory distress syndrome 
Acinar dysplasia
Saccular/atvtolar 
Pulmonary hypoplasia
Respiratory distress syndrome/ chronic lung disease of 
prematurity 
Acinar dysplasia
Alveolar capillary dysplasia___________________________
Reproduced with permission from Kotecha [5],
submucosal gland, bronchial smooth muscle and epithelial 
cell types. This is th e  period of fastest division of tntra- 
segm ental airways. By 14 weeks, 70% of the  to ta l airway 
generated  at b irth  is form ed (2] and by the end  of 
17 weeks, the formation of conducting airways and te rm ­
inal bronchioles is com plete [5]. Pattern  of airway branching 
and division is de te rm ined  by ep ithe lia l m esenchym al 
interactions. Bronchial m esenchym e induces branching in 
the trachea, w hereas tracheal mesenchyme inhibits b ran­
ching of th e  bronchial tre e  [6]. As th e  pseudoglandular 
stage progresses, th e  early pseudo-stratified epithelium  is 
prog-essively replaced by colum nar cells proximally and 
by cuboidal cells distally. The cuboidal cells, rich in gly­
cogen, represent th e  im m ature type II cells. Thus, during 
pseudo^andular stage, all pre-acinar structures, includ­
ing, pre-acinar airway, pulmonary arteries and veins a re  
formed.
The failure of normal division of airway structures a t this 
stage may lead to  pulmonary hypoplasia or sequestration , 
cystic adenom atoid m alform ation and crucially, failure of 
the pi euro-peritoneal m em brane to  d o s e  a t this stage may 
result in congenital diaphragm atic hernia.
1.3. Canalicular stage (17-27 weeks in utero)
The acinar structu res comprising th e  respiratory bronchioles, 
alveolar ducts and prim itive alveoli a re  form ed during the  
canalicular stage. Canalicular stage is marked by tw o  
important steps in th e  developm ent of th e  lung: d ifferen tia ­
tion of type I and type II pneum ocytes and form ation of the  
alveolar capillary barrier [3,7]. Surfactant protein is d e te c t­
able by 24 weeks of in trau terine  life. Thus, a possible 
platform for gas exchange is established. With advances in 
perinatal m edicine and ever increasing survival of extrem ely 
preterm  infants, this is an im portant landmark in lung growth 
and developm ent.
Surfactant deficiency leading to  respiratory  d istress 
syndrome is inevitable with prem ature delivery a t  this 
stage.
1.4. Saccular stage (28-36 weeks in utero)
By this stage, division of the airways is alm ost com plete  and 
further growth and developm ent of lung structures com prise
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of enlargement of the peripheral airways with dlatation of 
acinar tubules forming ‘saccules' and thinning of the airway 
walls. Thu ensures increased surface area far gas exchange. 
There Is also further differentiation of type N cells to type I 
cells and Increment in surfactant containing laminar bodies 
lining type II pneumocytes.
1.5. Alveolar stage (36 we eta In utero—2 years)
Recognition of secondary septa in the terminal airway and 
formation of definit ive a y  shaped alvcoU macks the ahmolar 
stage. Ina newborn rat lung, wfoch Is a t the saccular stage of 
lung development, the saccules are lined by a central sheet 
of connective t im e  supporting a layer of capillary network 
on either side [1]. Gradually, low ridge like project ions, also 
with double capillary network appear in the airspaces, which 
eventually dMde the airspaces into alveoli. This process of 
formation of double capilary walled secondary septa and 
multiplication of alveoli continue rapidly up to the age of at 
least 2 years in humans.
1.6. Postnatal lung growth
R has been estimated that the number of alveoli a t birth 
ranges from 20-50 mfllion [3]. Alveolar multiplication con­
tinues in the postnatal period a t least 14) to the age of 2-  
3 years and alveolar size and surface increases until after 
adolescence {5,7]. Ochs e t aL [8] have reported that the 
final number of alveoli in a fully developed adult lung reach 
300-000 million with approximately 170 alveoli per cubic 
mttimetre. Post-mortem examination of lungs of children 
who (Red as a result of trauma or after short Alnesses re­
vealed that boys had larger lungs than girls of the same 
stature which resulted in greater alveolar number and 
greater alveolar suThce area than girls for a given age and 
stature {9}. In recant yean, we have gained further insight 
into the postnatal growth of distal airways. When air space 
calibre of small airways and alveott a t their maximal natural 
dfetension was measured in 53 children of age 6-22 years and 
59 adults of age 23-80years, R was no ted that both the small 
bronchioles and alveoli ejpanded significantly in size with 
increasing age and height up to  the age of 22 years but the 
increase in size thereafter was not statistically significant 
[10].
1.7. Stage of mkrovaacular maturation (several 
months to 2-3  years)
Burrl's group has previously described that, besides the 
multiplication and enlargement of airspaces, some impor­
tant microvascular changes occur In postnatal lung develop­
ment, which he termed as the stage of microvascular 
maturation [1]. Essentially, during this period, the double 
capillary network gradually merges as a single capillary layer. 
This is an extremely Important event in the postnatal lung 
growth as angtogenesis and alveolartzation go hand in hand 
and once the capillary network fuses into a single layer; new 
alveolar septa cannot be formed. This has now been 
postulated as the major cause of premature arrest of lung 
growth following postnatal daxametharone treatment in 
premature infants with chronic lung disease.
2. Factors that regulate and modify lung 
growth: prenatal to postnatal stages
Multiple factors that govern lung growth is a topic of growing 
interest and numerous studtes have been performed on 
animal models, mainly on sheep and rat, to  explore the role 
of physical, hormonal and genetic factors in prenatal lung 
growth (Table 3).
2.1. Fetal lung volume, fatal lung fluid, amnkXIc 
fluid and fatal breathing movements
Fetal lung volume maintained by the combined mechanisms 
of fetal lung fluid secretion and fetal breathing movements is 
perhaps the most important determinant of fetal lung 
growth. Experiments on ovine fetus have proved that 
db tension of fetal lung by fetal lung fluid is related to 
hyperplasia of the lung and drainage of the fluid results in 
pulmonary hypoplasia [11]. Fetal lung fluid is mainly formed 
by the epithelial cells of the distal airways. In ovine fetus, 
lung fluid is secreted a t the rate of 2 ml/kg/h a t  mid 
gestation and gradually increases to  5 ml/kg/h a t near term 
[5]. The rate and w>tume of fluid production however 
decrease as the fetus approaches term in readiness for 
postnatal adaptation. Arginine vasopressin, catecholamines, 
corttol, prostaglandin E2 and atrial natrlureteric hormone 
ate all associated with decrease in production of fetal lung 
fluid a t  or around birth. Amniottc fluid volume also 
contributes to the fetal lung distension and hence lung 
growth. In the fetal rat, oifgohydramnious has been shown to 
retard lung powth and development of type I cells. However, 
there was no evidence of Rs effect on type A cells and 
surfactant production [12]. Another important factor con- 
trtxiting to  the maintenance of adequate lung volume is 
fetal breathing movements. In the human fetus, breathing 
movements are noted as earty as 11 weeks of gestation and 
by 30-40 weeks, R occurs 301 of the time. Various animal 
experiments on abolition of fetal breathing movements 
inducing transection of spinal cord a t the level of phrenic 
nerve [13] and ablation of phrenic nerve [14] have demon­
strated pulmonary hypoplasia and reduced lung DMA in 
affected animal fetuses. Increase in carbon dioxide and 
glucose levels, acidosis and drugs such as caffeine and 
theophylline are assodated with increased fetal breathing 
movements. Maternal smoking, alcohol and drug use are 
known to reduce fetal breathing movements. Sim tarty, 
hypoxia, hypogtycaemia, intrauterine infection and prosta­
glandin E2 may all have adverse effect on these breathing 
movements [5].
In the last decade, there have been huge advances on 
research on fetal tracheal occlusion to maintain fetal lung 
volume and stretching lung tissue to improve lung growth, 
especially infetuses with congenRal diaphragmatic hernia. A 
recent review an this topic summarises the pros and cons of 
this fetal interventional therapy [15]. Numerous studies, on 
sheep, rabbits, rats and mice, have repeated^ demon­
strated that surgical tracheal ocdusion applied during 
canalicular and saccular stages of lung development not 
only improves dry lung weigit but also increases airway 
branching, alveolization, alveolar surface area, type H 
pneumocytes and pulmonary vascular growth [15].
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2.2. Hormonal, transcriptional and growth factors
The complexity of the  role of various hormones as well as 
growth and transcriptional factors in  th e  growing lung is 
gaining more and more fascination among researchers in 
recen t years. The list of som e of th e  im portant hormones, 
grow th factors and transcriptional factors and the ir possible 
role in lung growth and developm ent is summarised in 
Table 3. Thyroid hormone has been  well recognised to  play 
an im portan t role in  ep ithe lia l and m esenchym al ceU 
d ifferentiation and airway branching in early developm ental 
period  as well as d iffe ren tia tio n  of type II cells and 
surfactant secretion  in  la te  developm ent. Pituitary and 
ad renal horm ones have also  been  im p lica ted  in lung 
m aturation. Among th e  numerous growth hormones and 
transcriptional factors, fibroblast grow th factors (FCF) and 
Sonic hedgehog (Shh) seem  to  have influential roles in 
determ ining th e  pa tte rn  of airway branching. FGFs are also
Table 3 Possible role of some growth and transcriptional 
factors in lung growth and dev el op men t
Transcriptional and growth Possible role in lung grcwth 
factors and development
FOXA1, F0XA2. GATA4 and 
GXTA6 
Tbx4
Fibroblast growth factors 
(FGFs)
Sonic hedgehog (Shh)
Bone Morphogenic FYotein 4 
(BMP4)
HQX genes
Epidermal growth factor
P latelet derived growth 
factor (POGF)
Retinotc acid (RA)
Transforming growth fa c ta
(TGF0)
Insulin like growth factor 
(IGF)
Vascular endothelial growth 
factor (VEGF)
Granulocyte macrophage 
colony stimulating factor 
(GMCSF)
• Formation and maintenance 
of foregut
• Localisation of bud site
• Localisation of organs 
derived from foregut
• Induction of budding and 
Branching 1FGF 10)
• Alveotization
• Type II cell differentiation 
and induction of Sirfactant 
Protein C ( FGF2 and FGF7)
■ Suppresses Fgf10 expression 
and prevents branching events 
a t  sites where branching is 
stereo typically determined 
not to  take place
• Formation and control of 
dorsal and ventral branches
■ Defines overall three 
dimensional orientation
• Airway proliferation , 
differentiation and branching
• Alveotization
• Induction of F$f10 and 
endodermal differentiation
• Lung repair after pulmonary 
insult and matrix production
• Inhibits cell proliferation
• Airway proliferation
• Vasculogenesis, angiogenesis 
and lymphangeogenesis
■ Macrophase differentiation
im portant in type II cell differentiation and secretion of 
Surfactant fro tein  C la ter in lung developm ent [16,17]. On 
the o ther hand, transforming growth factor (TGF (*) has an 
opposite but im portant role of inhibiting cell proliferation 
and branching morphology, promoting form ation of lung 
matrix and aiding pulmonary repair a f te r  injury. Its defi­
ciency can lead to undue lung inflammation and Its over­
expression may lead to  lung fibrosis [16,17]. Vascular 
endothelial growth facto r (VEGF) plays a cen tra l role in 
vasculogenesis and angiogenesis and  is therefore critical for 
normal lung developm ent. Beside its primary role on vascular 
developm ent. VEGF also has positive e ffec t on d ifferen tia ­
tion of type II cells and stim ulation of surfactant production. 
Furthermore, VEGF also has an im portant role o nendothelial 
function and inhibition o f VEGF in prem ature  lung has been 
known to  reduce NO bioavailability th a t may lead to  the  
development of chromic lung disease of prem aturity  (CLD)
[18].
2.3. Environmental factors
The influence of environm ental factors such as exposure of 
the developing lung to tobacco smoke both in intrauterine 
and postnatal life has long been associated with adverse 
respiratory outcom es such as reduced lung volume and 
decreased num ber of alveoli, enlarged alveolar size and 
abnormal septatkm  leading to reduction of gas exchange 
area. However, th e  precise mechanism and timing of events 
of adverse effects a re  no t clear. Some interesting effects of 
nicotine on type II cell morphology and metabolism has 
em erged from a recen t study on rats. When ra t fe tuses w ere  
exposed to  nicotine in early embryonic life from day 6 to  day 
20, it w as noted th a t nicotine could perm anently a lter lung 
y o w th  of th e  developing lung by stim ulating alveolar type II 
cells p ro lifera tion , d ifferen tiation  and m etabolism  and 
hence stim ulating  su rfac tan t synthesis [19]. In recen t 
years, th e re  has also been growing interest on the possible 
influences of o ther environm ental pollutants such as ozone 
and particu la te  m atte rs  th a t can result in impaired lung 
growth [20].
2.4. Specific diseases
2 .4 .1 . Chronic lung d isease  o f p rem atu rity  (CLO)
With advances in perinata l medicine and th e  resulting 
improved survival of extrem ely preterm  infants, CLD has 
inevitably becom e th e  most im portant specific condition 
that adversely affects postnatal lung developm ent Unlike 
term  infants, preterm  infants a re  born w ith  lungs still In 
'p ren a ta l’ stages of developm ent i. e. cannalicutar or 
saccular s tage. Surfactant deficiency leading to  mechanical 
ventilation, oxygen therapy and pulmonary inflam m ation, 
infection and p a te n t ductus arteriosus a re  some of the  
determ ining fac to rs  leading to  a cascade of events th a t result 
in CLD. Hyperoxia and barotraum a both cause lunginjury and 
inflammation th a t subsequently results in decreased  alveo- 
lization. Hyperoxia severely disrupts sep ta tio n , causes 
increased term inal sac diam eter and decreased gas exchan­
ging surface area  [3]. Intrauterine infection including w ith 
Ureaptasma Spps. may also result in disordered lung growth 
in th e fe tu s  and newborn infant [5]. An alternative theory  for 
the dysregulated lung growth seen in infants who develop
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CLD ts that their vaacular development may be abnormal 
which may lead to abnormalities of lung growth (reviewed in 
Ref. p i]) .
Postnatal glucocorticoids are widely roed in the context 
of severe respiratory dhtress syndrome (RDS) and CLD, 
mostly to wean dronkalty ventilator-dependent preterm 
intents. Although postnatal glucocorticoids have proved to 
be invaluable as a 'rescue* therapy for chronically ventftated 
preterm intents, there have been concerns over their short­
term and long-term advene effects. From animal studtes, it 
is dear, that #ucooorticoids directly affect alveolar and 
mtcrovascular growth of the lungs. Bum e t aL have studied 
the effects of high-dose, short-term as well as low-dose, 
long-term glucocorticoid administration on atvoolarlzation 
and pulmonary microvascular development on rats [22]. 
Low-dose long-term therapy was shown to produce perma­
nent impairment of lung atveolartzation, possfcly as a result 
of precoclota mtcrovascular maturation. However, when 
postnatal rats were administered short-term, high-dose 
glucocorticoids ter 4 consecutive days, although there was 
initial evidence of precocious microvascular maturation by 
capillary fusion and arrest of parenchymal septation, the 
effects were temporary, TMs initial phase of accelerated 
lung growth was arrested briefly and by day 10, normal 
alveolar growth resumed [22]. Hence, it  is dear that the 
precise dose, timing and duration of glucocorticoid therapy 
can have major implications on lung growth and develop­
ment. Besides the effects of glucocorticoids on lung 
morphology their effect on long-term pulmonary function 
has also bean investigated. The results of these studies are 
difficult to compare or to interpret because of the variations 
in the use of surfactant, severity of the chronic lung dbease, 
dose, duration and timing of the use of dexamethasone and 
because of different methods of measuring pulmonary 
function between different studies. When 145 chtUfren, 
who had participated in a double-blind, randomized con­
trolled trial (1964-1989) of dexamethasone (0.5 mg/kg/day 
for 1 week) or placebo for treatment of neonatal chronic lung 
disease werefoiowedup at 13-17 years of age, there was no 
significant dWerenoe in lung function between the two 
grot**, as assessed by spirometry [23). This study concluded 
that there is no evidence that use of dexamethasone in 
neonatal period has long-term consequences for the lung but 
beneficial effects were not demonstrated either. However, 
another recent follow-up study by Nixon e t  aL on 68, 8- 
11 year old children, who had participated in a randomized 
controlled trial (1992-1995) of a 42-day tapering course of 
postnatal dexamethasone (0.5 mg/kg/day) or placebo in the 
neonatal period to reduce the duration of ventilator 
dependency reported that the postnatal dexamethasone 
exposure was associated with higher expiratory flow but 
clinically reported asthma scores were similar between the 
two groups [24).
2.4.2. Congenital diaphragmatic hernia and pulmonary 
hypoplasia
Congenital diaphragmatic hernia (COH) affects as many as 1 / 
3000 live births. Despite extensive studies on better under­
standing of causes of CDH as well as on both prenatal and 
postnatal interventional therapies, survival stRl remains poor. 
A recent review on the genetics of COH explains in detail the 
increasing evidence of the contribution of gene mutations to
the development of COH during eerty lung development [25]. 
As summartoed in Thble 3, transcriptional and growth factors, 
such as Shh and FGF10, signal and regulate lung morphogen­
esis and defects a t  any stage may lead to lung hypoplasia 
which is an essential component of COH. In the last decade, 
radtological athancaments in 30 ultrasonography and mag­
netic resonance imaging (MRI) has made it posstele to assess 
fetal lung volume quantitotfuety in fetuses suspected to have 
pulmonary hypoplasia and COH [26]. At already described 
above, studies invohring intrauterine tracheal obstruction to 
encourage growth of hypoplastic lung in COH have been 
explored but provide many challenges before such therapy 
becomes routine in clinical practice.
3. Conclusion
The dose relationship of different stages of morphological 
and vaacular growth of human lung vtith numerous physical, 
biological and environmental factors is complex but 
fascinating. The growing knowledge of molecular biology 
and human genetics related to lung growth has not only 
enabled us to  have better understanding of this complex and 
continuous process but also contributed towards antenatal 
dtegnosb and interventional therapy ter life threatening 
congenital conditions such as congenital dtaphragmatic 
hernia and pulmonary hypoplasia. Although there are some 
important deferences in the timing and stages of lung 
growth in human and animals, numerous animal experi­
ments, mostly on sheep and rats, have greatly enhanced our 
knowledge of the important roles of various transcript ional 
and grovfth factors in lung growth and development. 
Understanding of the very basic stages of lung growth and 
recognition of development and maturation of alveoli, 
formation of functional blood alveolar barrier and produc­
tion of surfactant has made survival of extremely premature 
intents possible. The effects of glucocorticoids on postnatal 
lung maturation need to be investigated further to establish 
the appropriate dose and duration of the glucocorticoid 
therapy in severe lung disease of prematurity and to 
establish posstele long-term benefits and adverse effects. 
Advances in imaging techniques such as 30 ultrasonography 
and acVanced MRI technologies will no doubt play a major 
role in early and accurate dtegnosis of both structural and 
functional lung pathologies in fetuses with congenital 
structural defects and children with chronic lung dbease 
of prematurity However, much work stiU needs to be done 
to improve postnatal lung development in premature intents 
and to prevent chronic lung disease of prematurity
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A lm s Myocardial velocity imaging has been validated in adults for assessment of ventricular function and indirect indices of
pulmonary arterial pressure. To establish w hether it could also be used in infants, we investigated the  reproducibility 
o f myocardial velocities and deformation indices in term and preterm neonates.
M ethods and Myocardfal velocity loops acquired from 16 infants were analysed by four observers for inter-observer variability, and
resu lts re-analysed after 6 months by one observer for intra-observer variability. For myocardial velocities, the coefficients of
variation (CVs) for the left ventricle (LV) were 10-11 (intra-observer) and 14-20%  (inter-observer) and for the right 
ventricle (RV) 1 5 -1 9  and 18-24%, respectively. Reproducibility for annular displacements was <13%  (intra- 
observer) and <  18% (inter-observer). CVs for LV strain w ere 1 4 -17  (intra-observer) and 36-43%  (inter-observer) 
and for RV 1 9 -2 4  and 25 -  37%. CVs for isovolumic acceleration w ere in general >40%. In comparison, the  CVs for 
blood pool indices w ere 3 -15%
C onclusion Intra-observer reproducibility for myocardial velocity and deformation indices in neonates is adequate for these par­
am eters to  be used in clinical research. Inter-observer reproducibility is sub-optimal suggesting that these measure­
ments should be used in clinical practice with caution Myocardial acceleration, a marker of contractile function, was 
poorly reproducible.
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In tro d u ctio n
Myocardial velocity imaging o r tissue D oppler imaging has been 
validated and widely used in th e  adult population for the d a  gnosis 
of left ventricular (LV) and right ventricular (RV) dysfunction. In 
recent years, it has also been suggested as a potentially useful diag­
nostic too l for quantitative assessment of myocardial function in 
infants1 and children.1-3
Premature infants who develop respiratory distress syndrome 
are at increased risk of developing structural abnormalities in the 
pulmonary vasculature and RV hypertrophy.'4 A reliable non- 
invasive diagnostic tool to  monitor associated changes in function 
would be helpful in this population. Previously. Doppler echocar­
diography has been used to  assess the changes in pulmonary arter­
ial pressure in acute respiratory distress syndrome5 and during 
recovery6 using pulmonary arterial acceleration time. Although
this index can be highly specific for diagnosis of pulmonary arterial 
hypertension7 in patients with a heart rate of < 100bpm , this 
method may no t be as accurate in newborn infants with higher 
heart rates. The velocity of tricuspid regurgitation is another 
Doppler parameter which correlates highly with pulmonary a rter­
ial pressure,8 but it has been shown to  be measurable in only 61% 
o f children aged < 2  years w ho had chronic lung disease 9 These 
limitations can be overcome by m ore advanced tissue Doppler 
methods. Certain tissue Doppler param eters such as RV Isovolu­
mic relaxation time10,11 (IVRT) and RV systolic strain11-13 have 
been validated as usefol markers for estimation o f pulmonary arter­
ial pressure In adults. Regional myocardial strain has also been 
shown to  be feasible in healthy term  infants.14-15 This has not yet 
been tested or validated in prematurely born infants.
The feasibility and reproducibility for off-line tissue Doppler 
measurements in adults has been extensively studied by the
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MYDISE study group.16 In this present study, we have assessed the 
ntra- and inter-observer variability for off-line analysis o f longitudi­
nal systolic and diastolic myocardial velocities, myocardial strain, 
annular displacements, and isovolumic acceleration (IVA) com­
pared with conventional blood pool Doppler parameters such as 
mitral inflow velocities and pulmonary arterial acceleration time.
M ethods
Population
Thirty hedthy term infants (>38 weeks of gestational age) and 
25 preterm infants (<34 weeks of gestational age) were recruited 
from the post-natal wards and the Special Care Baby Unit of a univer­
sity hospital for a study of myocardial function in prematirity. Written 
informed consent was obtained from parents prior to  recruitment 
The South East Wales Regional Ethics Committee gave ethical 
approval for this study
All infants had their first scan within the first 72 h after birth. The 
infants were screened for congenital cardiac defects and those with 
structural cardiac defects were excluded from the study, with the 
exception of patent ductus arteriosus. A second scan was performed 
a month later.
To determine the reprodudMity of myocardid velocity and defor­
mation indices, we selected a random sample of 16 studies, by 
drawing lots—8 out of 30 studies from term  infants and 8 out of 25 
studies from preterm infants. All the data presented in the paper are 
from these 16 scans.
Echocardiographic acquisition
Images were acquired using a commercially available system (Vkrid 7, 
GE Vingmed Ultrasound AS, Horten. Norway) with a 7.0 or 
50  MHz transducer, by a cardiac sonographer (J.MJL) or a clinical 
research fella* (Sj.). Infants were kept in supine or left lateral position 
during the scan.
Pulsed wave Doppler of blood flow in the left ventricular outflow 
tract (LVOT) in the apical four-chamber view was acquired to 
measure LVOT velocity time integral Conventional pulsed wave 
Doppler of mitral and pulmonary flow was also acquired from the 
apical four-chamber and the parasternal short-axis views, respectively.
For lateral and medial mitral annular velocities and tricuspid annular 
IVRT, real-time pulsed tissue velocity profiles were acquired from the 
mitral and tricuspid annulus. respectively.
Colour tissue Doppler images were acquired separately of the LV, 
RV. and septum. The Nyquist limit was optimized to  avoid aliasing, 
and the depth of imaging and the sector angle were adjusted to 
obtain high frame rates. All images were stored as 3-beat loops an 
magneto-optical disks for post-processing.
Off-line analysis
Images were analysed using commercially available EchoPAC software 
(GE Vingmed Ultrasound EchoPAC 700. Horten. Norway). Images 
from all 16 studies were analysed independently by four observers 
(S.J, j.MiL, D.GW , and J.K.W.) for inter-observer variability. For 
intra-observer variability, one observer (5).) re-analysed the same 
images after 6 months. Observers were blinded to  the clinical status 
of the infants.
Thirteen parameters were measured from each study, hduding 
4 blood Doppler parameters and 9 tissue Doppler parameters. All par­
ameters were measured in 3 beats and averaged, except if the signal 
from an individual beat was too noisy to  be analysed in which case
1 -2  beau were measured. Each tissue Doppler parameter was 
measured at the basal segments of the LV and RV, and the base of 
the septum. The cursor was positioned within each segment, so that 
it did not encroach upon the annulus during systole 
The velocity time integral of LV outflow, the mitral E and A 
velocities, and the pulmorary artery acceleration time were measured 
conventionally from blood pool Doppler (f igure IA-C).
The mitral annular early diastolic velocity (Ve1) was measured at 
both the medial and the lateral mitral annulus (Figure 2A). Tricuspid 
annular IVRT was measured as the time interval between the end of 
systolic motion and the beginning of early diastolic motion (Figure 28).
Myocardial systolic velocity (Vs), early diastolic velocity (Ve), and 
diastolic velocity during atrial contraction (Va) were measured at the 
basal segments. When myocardial Ve and Va were fused due to  
rapid heart rate, a single diastolic velocity was recorded and noted 
as Ve. Time to  peak systolic velocity (Tq.v,) was measured as the 
time interval between the start of the QRS complex and the peak 
myocardial velocity during ejection (Figure 3, time interval 4). The 
measurement for the myocardial IVA was made by dividing the peak 
positive velocity during the I VC by time to this peak velocity from 
the onset of the sigial at the zero crossing (Figure 3. slope 5).
Annular displacement (Os') was measured using tissue tracking at 
the Lateral mitral annulus and at the lateral tncuspid annulus (Figure 4A).
F ig u re  I (A) Tracing of left ventricular outflow tract Doppler 
to calculate velocity time integral (VT1). (8) Mitral inflow 
Doppler showing early diastolic velocity (E) and diastolic velocity 
during atrial contraction (A). (Q  Pulmonary artery flow Doppler 
showing pulmonary arterial acceleration time (PA AT).
F ig u re  2 (A) Lateral mitral annular real-time (pulsed) tissue 
Doppler showing early diastolic velocity (Ve*). (8) Lateral tricus­
pid annular pulsed tissue Doppler showing measurement of 
regonal relaxation time (IVRT; between the two vertical lines).
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F ig u re  3 Processed colour tissue Doppler image of RV 
showing peak systolic velocity (point 1). early diastolic velocity 
(point 2). diastolic velocity during atrial contraction (point 3). 
QRS-Vs (time interval 4). and isovoiumic acceleration (slope 5).
F ig u re  4  (A) Processed colour tissue Doppler image of RV 
showing tricuspid annular displacement at end systole. (8) Pro­
cessed colour tissue Doppler image of RV showing basal (lower 
arrows) and apical (upper arrows) peak strain during systole. The 
vertical lines represent the timings of pulmonary valve cl os ire  
Although labelled by the machine and on these images as AVO' 
and 'AVC. the time intervals refer to  putmoncwy valve opening 
and pulmonary valve closure, obtained from the pulsed Doppler 
trace of pulmonary arterial flow.
Peak systolic strain (S) was measured within the basal and the apical 
portions of the lateral wall of the LV and the lateral wall of the RV 
(fgure 40). In the septum, peak systolic strain was measured only in 
the mid-septal segment For computation, strain length of 10 mm 
was used as recommended by Nestaas et d .1s To ensure measurement 
of mammal negative strain during systole, event timing was superim­
posed from LVOT and RV outflow tract blood Doppler recordings 
for the LV and RV. respectively.
Statistical methods
The sample size of 16 scans observed by four observers for the inter- 
observer reproduobility gave 48 degrees of freedom [number of 
studiesx (number of observers-1 )] . and the power to demonstrate 
dfferences with 95% confidence intervals estimated at 0.4 x 
standard deviation (SD).
Mean and SD were calculated for each variable. Intra- and inter­
observer reproducibility is reported as coefficients of variation (CVs, 
in %l calculated using the formula: CV =  (SD/arithmetic mean al 
measurements) x 100, where SD is the standard deviation of residuals 
(measurement 1 - measurement 2). As there were four observers, 
there were six pairs of data for comparison (each derived from 
repeated analysis of the 16 patients); the inter-observer reproducibiity 
of each variable is therefore expressed as a pooled CV, which is the 
mean value of the six comparisons
Systematic bias between repeated measurements was assessed using 
Bland-Altman analysis.17 The results from these six paired compari­
sons were also averaged and are presented as the pooled mean differ­
ence for each variable (i.e each summary statistic is the average of the 
mean difference between two observers repeated six times with differ­
ent pairs of observers).
Intra-observer variability is also presented as CV and Bland-Altman 
dfference for the paired measurements for each variable.
Results
Feasibility
Most pulsed and tissue Doppler parameters could be measured in 
>9096 of neonates. A single dastoiic velocity at the mitral valve 
was noted in 596 (1 infant), and using tissue Doppler in 3196 (5 
infants) at the LV. 2096 (3 infants) at the  RV. and 1256 (2 infants) 
a t  the septum. In these cases, a single diastolic velocity was 
measured and noted as early dastoiic velocity (E o r Ve'). The 
fusion of early and late dastoiic velocities may be due to  rapid 
heart rates in infants.
Missing values for the myocardal velocity occurred because a 
segment could no t be imaged or because the traces w ere of the 
poor quality. The feasibility for measuring LV apical strain was 
only 7596.
Reproducibility
The average frame rate for the myocardal velocity loops was 
227 ± 1 8  frames per second. The mean values for all parameters, 
and the results of Bland-Altman analysis and CV for both intra- 
and inter-observer variability, are summarized in Table 1.
Indices for assessment of LV function
Mitral annular early diastolic velocity by pulsed tissue Doppler 
(Ve') had reproducibility of 7-1396 (Intra-observer) and 996 
(inter-observer).
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Table I The mean values for all parameters, and the results of Bland-Altman analysis and CV for both intra- and 
inter-observer variability
Intra -observer Inter-observer
Mean ± SD 
(1 observer)
Bland-Altman 
(95% Cl)
CV% Mean ±  SD 
(4 observers)
Bland-Alt man, 
mean (range)
CVX, pooled 
mean ±  SD
VTI (cm) 11.6 ±  2 .4 0 »  ( - 0 5 0  to  1.1) 3j6 11.5 ± 2 .2 0.19 (002 to 034) 6-0 ±  1.9
E (m/s) 0.72 ± 0 2 3 002 ( -0 0 1  to 005) 25 073 ±0.23 002 (001 to 004) 28  ± 0 4
A (m/s) 0.66 ±  0.14 aoi ( -  007 to  0j09) 55 069 ±0.15 003 (000 to 005) 45  ± 0 8
PA AT(ma) S8.7 ±  13.8 -0.64 (-1 4 .4 to  121) 11.9 623 ±  5.3 S03 (042 to 834) 15.2 ± 2 .9
Displacement (mm)
LVDs1 3.9 ± 1 .7 -0 2 4  ( - 0 7 2  to 025) 62 41 ± 1 0 028 (012 to  032) 122 ± 2 4
RV DT 7 5  ± 1 .9 -0 1 9  ( - 2 1  to  1.7) 120 4.6 ±  12 032 (003 to  049) 18.2 ±  4.6
Septum 04 4.7 ± 1 .2 -0 1 5  ( - 0 5 8  to 028) SO 48  ±1.4 004 (002 to  009) 11.8 ±6-8
Annular velocity (cm/s)
LV Ve/ 8.0 ± 3 .0 0 0  ( - 2 0  to  20) 120 00 ± 2 0 03  (00 to  05) 9.4 ±  42
Septum Ve' 7.0 ± 2 5 0 2 ( - 1 0 t o  1.0) 6.9 7.0 ±  30 03  (02 to 0.4) 9.2 ±3 .9
Myocardial velocity (cm/s)
LV
Vi(W) 2.4 ±  09 -0 0 4  ( -0 0 5  to  0.44) 98 14 ± 1 5 0.18 (002 to  036) 143 ±  1.8
Ve(U) 4.9 ±  24 -0 1 7  ( - 1 3  to  093) 11.1 45  ± 2 0 0.12 (004 to  022) 13.5 ±  1.9
Va (bl) 
RV 
Vs(bl)
2 9  ± 1 .0 -0 1 5  ( -0 7 3  to  0.44) 9.9 10 ±1.1 024 (006 to  043) 203 ± 4 7
4.4 ±1.1 018 ( - 1 3  to  1.7) 177 4.6 ±  12 032 (0.03 to 050) 183 ±  45
Ve(bl) 6.2 ±  27 048 ( - 1 3  to  23) 150 6-3 ±  2.9 0.46 (001 to  075) 233 ± 8 4
Va (bl) 5.8 ±  1.3 034 ( -1 .7  to  24) 185 59 ± 1 2 0.48 (007 to  085) 24.1 ±  7.8
Septum
V* (bs) 2.9 ±  09 001 ( -0 5 5  to 057) 9.9 11 ±  1.1 035 (014 to  063) 21.7 ±  57
Ve(bs) 4.7 ± 2 3 015 ( -0 5 4  to 085) 77 4 7  ± 2 1 0.14 (002 to  027) 9.3 ±  08
Va (bs) 3.7 ±1.1 021 ( -0 3 6  to  0.78) 82 19 ±1.4 0.45 (010 to  084) 22.7 ±  7.3
Timing (ms)
RV relaxation time (IVRT) 501 ± 8 7 -4.1 ( -2 0 6  to  123) 16.1 347 ±  153 185 (102 to  335) 270 ±  88
T o-vs
LV 95.0 ±25.2 -0 8 9  (-25 .7  to  239) 133 980 ± 2 9 8 116 (1.8 to 26.6) 348 ±  183
RV 1045 ±  31.9 088 (-21 .6  to  213) 110 1041 ±  31.1 5.6 (09 to 108) 11.1 ± 4 2
Septum 106.8 ±  321 - 4 7  (-24 .8  to  15.3) 9.4 1126 ±37.2 18 (08 to 8.7) 222 ± 123
Isovolumic acceleration (m/s1)
LV 0.80 ± 0.41 025 ( -0 0 4  to  1.1) 625 064 ± 033 0.10 (002 to 020) 46.7 ±  7.6
RV 1.16 ± 0 3 9 016 ( -0 7 8  to  1.1) 430 1.0 ±  0.44 020 (003 to  035) 450 ± 16
Septum 0.96 ± 0.40 007 ( -0 4 5  to 059) 293 090 ± 0 5 7 0.18(000 to 028) 603 ± 133
Strain (X)
LV
Ss(bl) -1 2 2  ±4 .2 15 ( - 2 1  to  51) 140 - 1 1 1 ±  55 3.2 (1.02 to 550) 430 ± 13.9
Sa(al) -1 2 5  ± 5.4 023 ( - 4 1  t o 4.6) 17.1 -1 1 7  ± 8 4 1.3 (083 to 1.82) 36.9 ±  157
RV
S*(«) -23.9 ± 4 2 -0 4 8  ( -9 .3  to  83) 190 -21.6 ± 7.5 26(031 to  4.60) 37.1 ± 1 1 5
Ss(al) -17.4 ±6.2 40  ( - 5 2  to  133) 23.9 -22.0 ±7.8 24 (0.29 to  5.03) 253 ±  1.9
Septum
S. (ms) -1 7 7  ±4.1 043 ( - 1 0  to  18) 9.9 -19.5 ± 9.4 42  (1.21 to  870) 52.1 ±  26.4
SO. standard devauon;CI. confidence interval; CV. coafficam o f wrletion; VTI. left ventricular outflow tract velocity time kitegrat PAAT. pulmonary arterial acceleration tana: LV. 
M  ventrfcie; RV. ngtu venlncle; Va . annular early diastole velocity: Vv myocardal systole velocity. Ve. myocardal early dastoiic velocity; Va myocardial baslofcc velocity during 
an a l contraction; fVRT, tricuspid anmiarieo volume: re taxation tvne; QftS to  Vs time interval; Sa. systolic attain; bl. basal segment oflateralwalial apicd segment of hateral wal; 
bs. basal segment o f septd wait ms. mid-sepal segment
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Intra- and inter-observer variability for LV myocardal systolic 
and diastolic velocities as well as annular displacements, obtained 
by processing stored digital loops, w ere between 10 and 15% 
except for the diastolic velocity (Va) (20% inter-observer). More 
advanced parameters such as QRS to  Vs time interval (Tq .w ) 
and LV strain had intra-observer CVs o f <15% . but inter-observer 
reproducibility for these param eters was sub-optimal a t CVs 
>35%. LV IVA was not reproducible (CVs 30-60%).
In comparison, blood Doppler param eters such as LV velocity 
time integral and mitral inflow D oppler had CVs of 3-6%  for 
both intra- and inter-observer variability.
Indices for assessment of RV function
Intra-observer CVs for the RV indkes w ere generally higher com­
pared with the corresponding LV indices. Intra- and inter-observer 
CVs for the RV myocardial systolic and diastolic velocities, annular 
displacement, and (Tq .vJ .  vrere betw een 15-19%  and 18-24%. 
respectively. IVA was poorly reproducible in the RV also, with 
CV >40%
Indices for assessment of pulmonary arterial pressure
Pulmonary arterial acceleration time, which has been tradtionally 
used to estimate pulmonary arterial pressure, had CV of 1 2 - 
15% Tissue Doppler param eters that are relatively new methods 
of indirect estimation of pulmonary arterial pressure were less 
reproducible. CV for tricuspid annular IVRT was 16% 
(intra-observer) and 25% (inter-observer), and that for RV basal 
strain was 19% (intra-observer) and 25 -37%  (inter-observer).
Comparison between term  and preterm infonts
A t the time of study, preterm  infants had lower body weight and 
slower heart rate (Table 2).
Intra-observer reproducibility was marginally better in the term 
infants compared with the preterm  infonts—for the pulmonary 
arterial acceleration time (CV 9% compared with 14%) and for 
RV myocardial velocities (Vs 15% compared with 19% Ve 14% 
com pared with 18% and Va 14% compared with 20%). The CV 
for mid-septal strain was also slightly better in the term  infants 
(7% com pared with 13%). On the other hand, intra-observer varia­
bility for the tricuspid annular relaxation time had better CV in the 
preterm  infonts (7%) compared with the term  infonts (22%). None 
of these dfferences is statistically significant (P >  0.05). Analysis of 
reproducibility by body weight rather than gestational age also did 
not dem onstrate any worse reproducibility in the smallest infants.
D iscu ssion
Although numerous studies on the use of tissue D oppler have 
been published in the last decade, there have been surprisingly 
few detailed studies on the reproducibility o f  the analysis of myo­
cardial velocity and strain indices especially in children. O ur study is 
the largest and most detailed report of the intra- and inter- 
observer reproducibility of real-time and processed tissue 
D oppler parameters in infants.
Feasibility of tissue D oppler in infants
D ue to  RV dominance in newborn Infants, the acquisition of Images 
from the LV, without missing the apex and while retaining a narrow 
sector of the image and thus a high frame rate, was a challenge. 
This accounts for the fact that LV apical strain had the  most 
missing values (37%). The other tissue Doppler parameters 
measured in this study w ere no t similarly affected as they were 
all measured either a t the annulus o r  in the basal segments.
Reproducibility of off-line analysis of 
tissue D oppler m easurem ents
As anticipated, pulsed Doppler recordngs of blood flow were 
m ore reproducible than myocardal velocities. The reproducibility 
for measuring the acceleration time o f  pulmonary arterial flow in 
this study was better than previously published data in infants by 
Subhedar and Shaw18 (intra-observer CV 12 vs. 25%). This may 
be because we studed both term and preterm infants, whereas 
the previous study was restricted to  preterm infants with respirat­
ory distress syndrome.
The lateral mitral annular early diastolic velocity in this study had 
inter-observer variability of 9% which is comparable to  that 
reported  in an adult study (CV 9-17% ).19 Although there is evi­
dence that the relaxation time 'IVRT of the tricuspid annulus is 
a useful parameter for excluding pulmonary hypertension in 
adults.10 the inter-observer reproducibility for this index in 
infants was sub-optimal (CV 27%). compared with 12-13%  in 
adults.11-50 Intra-observer variability was better at CV 16%
W hen Pautiks et d. addressed myocardial velocities in children 
undergoing dosure of an atrial septal defec t21 the CVs for systolic 
(Vs) and diastolic (Ve) velocities w ere <  10% for both intra- and 
inter-observer variability, while CVs for diastolic velodty (Va) 
w ere higher (21.5% intra- and 15% inter-observer). In infants, we 
found that the reproducibility of measuring myocardial velocity 
was m ore variable in the RV (15-18%  intra- and 18-24%  inter­
observer variability) than in the septum and the lateral wall of 
the LV (CV <  15%). In adults with LV dyssynchrony, variability 
for measuring myocardial systolic velocities (Vs) has been as 
much as 1 8 -5 6 % “
There are limited data on the reproducibility of deformation 
indices or IVA in infants and children. Weidemann et a t23 
measured radial and longitudinal strain and stain rate in 33 
healthy children aged 4 -1 6  years. They reported intra-observer 
variability of 11% and inter-observer variability of 15% these 
data are pooled CVs for LV. RV. and septal strain. In our study, 
when measuring longitudinal peak systolic strain, variation 
between lowest and highest CVs varied in the LV (14-17% ) and 
RV (19-23% ). Pena et a t 14 have recently reported  a reproducibil­
ity of longitudinal peak systolic strain in infants o f  only 1 2 %  but 
this is misleadng as the figure given is a Bland-Altman difference 
presented as percentage, and not the CV between observers.
O ne of the major difficulties faced when measuring myocardial 
strain In Infants is the smal size o f the heart. W e used a computation 
length o f 10 mm, as previously recom mended15 Using smaller dis­
tances increased noise and reduced reproducibility. The strain 
length of 10 mm was therefore necessary, but in small hearts means
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Table 2 Comparison of term and preterm subjects
Number M eat (SD)
Gestational 
age a t birth 
(weekx)
Weight
(kg)
H eart
rate
(bprn)
Term nfants 8 3*4 ± 1.6 19 ± 075 153 ±26
Preterm
infants
8 306 1  24 2.0 ± 0 8 2 140 ± 10
Significance
(P-vakie)
<03X31 < 0001 0714
SO. stanched devttton
lb at it becomes difficult to  position the sample volume accurately to 
avoid influences from surroundfog structures such as the atrium.
IVA has been validated as a useful load-independent index for 
assessing myocardial contractility in animal models.2^ 25 It has 
also been used to  assess myocardal contractility in chffcfren after 
surgical closure of atrial septal defect where the variability 
reported by Pauliks et of.11 (intra-observer 10.8% and inter- 
observer 11.5%) is considerably better than was found in infants 
in our study (CV >  35%). O ne reason lor the sub-optimal repro­
ducibility of IVA may be that this index could not always be 
measured as an average of 3 beats.
Limitations
In this study, two investigators acquired all the images. Three differ­
ent GE Vivid seven machines were used. The intra- and inter­
observer variability of analysis that we have presented does not 
take into account possible inter-operator and inter-machine differ­
ences during acquisition.
Secondly, despite having experience in echocardiography, the 
four observers who analysed the images independently had differ­
ent levels of experience in tissue Doppler. A common protocol 
was developed jointly between all observers before the start of 
the study. In our study, the Intra-observer variability may represent 
the best possible reproducibility of myocardial velocity and defor­
mation in a research environment Inter-observer variability for 
both acquisition and measurement in a wider dinical context 
may be much 0 -eater.
C onclusion
W e have demonstrated that myocardial velocity imaging and its 
off-line analysis is feasible in newborn infants. Intra-observer repro­
ducibility for myocardial velocities, displacement and strain as 
demonstrated in this study are adequate and these parameters 
can be used in clinical research However, inter-observer reprodu­
cibility for more advanced indices such as LV and RV longitudinal 
strain is sub-optimal suggesting that these measurements should 
be used cautiously for clinical ct^nosis. Reproducibility for myo- 
cardial acceleration, a marker of contractile function, is currently 
unsatisfactory in infants.
Thus, myocardial velocity imaging fa a promising non-Invasive 
diagnostic tool that may be used in term and preterm  infants, 
but further technical advances are still vital to  make this a useful 
clinical diagnostic too l
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Preterm in fants have subc lin ica lly  reduced m yocard ia l function  
com pared w ith  healthy term  con tro ls
Suchita Jo sh i1. Julie M E dw ards1. Dirk G W ilson2, Orhari U zun2, M ark D rayton2. Alan G Fraser1. Sailesh K otecha1 
'C ard iff U niversity, C ard iff UK . 2University Hospital o f  W ales. Cardiff, UK
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B ackground :
□  There is a  need for a reliable, non-invasive diagnostic tool to 
a ssess  myocardial dysfunction and pulmonary arterial hypertension 
in preterm infants with Respiratory Distress Syndrome (RDS)
□  Tissue Doppler (TD) imaging has been established as a useful 
imaging modality in adults for assessm ent of myocardial function and to 
estimate pulmonary artery pressure by surrogate markers
Aim:
□  To a ssess  if TD imaging can be used to quantify regional myocardial 
function in infants VMth RDS
M ethods:
□  All Preterm (PT) of <34 weeks gestation and Term infants had 2D, 
blood pool Doppler and tissue Doppler echocardiograms within 72 hours of 
birth
□  Images were acquired with GE vivid 7, with 7MHz probe
□  TD images were post processed using GE Echopac software, to 
analyse systolic velocity (Vsbl), early diastolic velocity (Vebl), atrial 
contraction velocity (Vabl), systolic strain  at base  (Ssbl) and apex 
(Ssal) of the lateral walls of the right (RV) and left (LV) ventricles
□  Mann-Whitney U Test was used to compare differences between 
groups for each variable
Group N (Sex) G estation (wks, SD) Weight (Kg, SD)
Term(1) 23 (F=12) 39.6(1.2) 3.4 (0.3)
PT Control (2) 9(F=6) 32 (1.2) 1.8 (0.6)
PT RDS (3) 14 (F=6) 28 (3.2) 1.3 (0.5)
p<0.01 ixo.oi
p - N S
p<0.01
I
i
I
C onclusion :
□  In th is  pilot s tudy, p rem ature infants with RDS had reduced  RV systo lic and diastolic velocities, a s  well a s  reduced  longitudinal strain , com pared  with healthy  term  
con tro ls . The d ifferences in LV longitudinal function w as limited to  LV syto lic velocity
□  T issue  Doppler echocard iography  is feasib le  in th e  new born and m ay be useful to  s tudy  subclin ica l relationsh ips betw een p ers is ten t pulm onary hypertension  and  RV 
function  in preterm  infants with RDS
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Cardiovascular Response to Acute Hypoxia
Cardiff
; in 8-12 Year Old Children with Chronic Lung Disease of Prematurity
Suchita Joshi'. Julie M Edwards2, Dirk G W ilson\M ark Drayton4. Alan G Fraser2, Sailesh Kotecha' -------------------
1 Department o f  Child Health. - Department o f Cardiology. School o f Medicine, Cardiff University. l.'K . 1 Department o f Paediatric Cardiology. J Department o f Neonatology. I Iniversity Hospital o f  Wales. l 'K
B ackground :
□ Preterm children who die of chronic lung disease of prematurity (CLD) have 
been shown to have abnormal thickening of pulmonary arterioles.
□ It is unknown whether these pathological changes at an early age 
contribute to diminished right ventricular (RV) function and increased risk of 
pulmonary arterial hypertension later in life, especially in response to 
hypoxia.
Aim:
□ To assess evidence of RV dysfunction and pulmonary hypertension in 
response to acute hypoxia, in children who had CLD compared to healthy 
term and preterm controls by using Doppler echocardiography.
M ethods:
Baseline transthoradc blood and tissue Doppler echocardiography
4
Inhalation of premixed 15% oxygen for 20 minutes followed by repeat 
echocardiography (while inhaling 15% oxygen)
4
Inhalation of premixed 12% oxygen for 20 minutes followed by repeat 
echocardiography (while inhaling 12% oxygen)
> Pulse oximetry was continuously recorded during the procedure
/-Tricuspid regurgitation maximum velocity (TR), Pulmonary arterial
acceleration time (PA AT) and Tricuspid annular isovolumic relaxation time
(IVRT) were measured using GE EchoPac system
R esu lts :
Doppler indices 
that varied with 
hypoxia
p <.001 In «R groups (21%
p <.05 In •■group* (21% v
I «
JL
_^cu>
No
G esta tion Age W eight
(wks) (yrs) (kg)
Preterm CLD 20 28 10.2 32.1
Preterm control 20 30 10.4 38.6
Term control 16 39 10.1 37.5
Sa02 (%)
CLD 
Preterm Control 
Term Control
21% 15% 12%
99.2 94.9 91.8
98.7 95.7 92.9
98.9 95.6 92.4
TR (mm Hg)
CLD 
Preterm Control 
Term control
21% 15% 12%
16.1 16.9 20.2
17.0 19.1 20.0
12.7 13.0 18.2
PA AT (ms)
CLD 
Preterm Control 
Term Control
21% 15% 12%
128.4 119.0 106.0
128.9 122.4 118.0
122.0 116.4 106.7
IVRT (ms) 21% 15% 12%
CLD 73.8 98.7 98.0
Preterm Control 82.8 93.3 108.3
T erm Control 78.5 86.7 107.5
C onclusion :
□ The maximum velocity of tricuspid regurgitation (TR) was significantly higher in prematurely 
born children (p <.05), indicating that they may have higher baseline RV systolic pressure 
compared to children who are born at term.
□ Oxygen saturation and Doppler parameters in children with CLD altered in a similar manner 
to that in the control groups in response to acute hypoxia in this study with statistically 
insignificant differences between groups, suggesting that these children may not be at 
increased risk of developing pulmonary hypertension with acute hypoxia.
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Can echocardiography be used to measure right ventricular dysfunction 
and pulmonary hypertension in newborn infants?
Suchita Joshi1. Julie M Edwards2. Dirk G Wilson’, .loon k  Wong’. Alan G Fraser2. Sailesh Kotecha'
1 Departineni o f  Child Health.: Department o f  Cardiology. College o f  Medicine. Cardiff University, UK . 5 Department of Paediatric Cardiology. University Hospital of Wales. UK
B ackground and Aims:
□ Myocardial velocity imaging is a useful non-invasive diagnostic tool for 
assessing pulmonary arterial hypertension in adults. We have shown 
that this maybe a useful diagnostic tool in preterm infants with 
respiratory distress syndrome (Joshi et al ERJ 2008 Suppl. 52: 812s). 
However, reproducibility and thus dinical utility of off-line analysis of 
myocardial velocity imaging in newborns has not yet been established.
□ Our aim is to establish intra and inter-observer reproducibility for off­
line analysis of RV myocardial velocities and strain in newborn infants.
M ethods:
□ 3-beat myocardial velodty loops were acquired from newborn infants 
and were followed up at 1 month. Images from 8 term and 8 preterm 
infants were randomly selected and analysed by 4 observers for inter- 
observer variability using commercially available GE EchoPac system. 
1 observer re-analysed the images for intra-observer variability.
□ Reproducibility is presented as coeffidents of variation (CV) %. For 
inter-observer variability, CV is presented as Pooled CV for the 4 
observers.
R esults:
RV indices Mean (SD)
Intra-observer
(CV %)
Inter-observer 
(Pooled CV %)
PA acceleration time in ms (Fig. 1a) 58.7(13.8) 11.9 15.2
RV relaxation time in ms (Fig.lb) 50.1 (8.7) 16.1 27.0
RV s velocity in cm/s (Fig.2 point 1) 4.4(1.1) 17.7 18.3
RV e velocity in cm/s (Fig.2 point 2) 6.2 (2.7) 15.0 23.3
RV a velocity in cm/s (Fig.2 point 3) 5.8 (1.3) 18.5 24.1
QRS-Vs time in ms (Fig.2 point 4) 104.5(31.9) 13.3 34.6
Isovolumic Acceleration in m/s2 
(Fig.2 slope 5, Fig. 3) 1.2 (0.4) 43.6 45.0
Displacement in mm (Fig. 4) 7.5 (1.9) 12.8 18.2
Basal strain % (Fig.5 yellow) •23.9 (4.2) 19.0 37.1
Apical strain % (Fig.5 blue) -17.4 (6.2) 23.9 25.3
C onclusion:
□ Intra-observer reprodudbility for right ventricular myocardial velocities and displacement are adequate and these parameters can be used in clinical research.
□ Inter-observer reprodudbility for tissue Doppler myocardial velocity indices are sub-optimal suggesting that that these measures should be used cautiously for dinical 
diagnosis. Reprodudbility for myocardial acceleration, marker of contractile function and deformity indices were unsatisfactory.
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